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Abstract 
 
 
Background Prostate cancer is the most common cancer among men in Western countries. 
Knowledge on prostate cancer aetiology is required for identification of high-risk groups, 
optimization of treatment strategies, and development of prevention programs. The aim of this 
thesis was to obtain insight into nutritional and clinical factors relevant to different stages of 
prostate cancer.  
 
Methods and results First, an inventory of potential risk factors for prostate cancer was made by 
asking 956 patients with prostate cancer about perceived causes of their disease. Among the 
143 patients who provided self-reported causes, heredity, specific environmental factors, 
nutrition or lifestyle, and stress were most frequently reported.  
 
Second, two potential risk factors, i.e. blood lipid levels and a previous cancer diagnosis, for 
incident prostate cancer were evaluated. Higher levels of total and LDL cholesterol were 
significantly associated with an increased risk of (aggressive) prostate cancer after 6.5 years of 
follow-up in a population-based cohort of 2,118 men (43 cases). Analyses from another 
population-based cohort among 551,553 men (9,243 cases) showed that cancer survivors 
diagnosed with a first cancer (other than prostate cancer) between 1989 and 2008 had an 
overall increased risk of prostate cancer in the first year after their first cancer diagnosis. This 
increased prostate cancer risk is most likely the result of active screening or incidental detection, 
because the effects disappeared after one year of follow-up for most of the specific first cancer 
sites. 
 
Third, the effect of body mass index (BMI) on risk of biochemical recurrence was studied in two 
cohorts of 493 patients (142 cases) and 1,302 patients (297 cases) treated with radical 
prostatectomy for prostate cancer. BMI was not associated with risk of biochemical recurrence 
in these patients.  
 
Finally, the effects of selenium, a suggested candidate for prostate cancer chemoprevention, on 
gene expression profiles in the prostate were examined in a randomized and placebo-controlled 
intervention trial with 15 participants (n=8 selenium, n=7 placebo). Selenium (300 µg/day as 
selenized yeast) affected the expression of genes towards an anti-inflammatory gene expression 
profile. Furthermore, we were able to detect expression changes in genes implicated in the 
epithelial-to-mesenchymal transition.  
 
Conclusion The results of this thesis show that specific nutritional and clinical factors might 
influence risk of prostate cancer or have an effect on gene expression in the prostate. A future 
challenge is the confirmation and 'translation' of these findings into the development and 
implementation of effective treatment and prevention strategies for prostate cancer. 
 
Contents 
 
 
Chapter 1 Introduction 9 
 1.1 General introduction to prostate cancer 10 
 1.2 Risk factors and prevention of prostate cancer 16 
 1.3 Risk factors and prevention of prostate cancer progression 21 
 1.4 Risk factors and prevention of prostate cancer recurrence 23 
 1.5 Overview of this thesis 25 
 
Chapter 2 Why I got prostate cancer: an explorative study on  35 
 perceived causes of prostate cancer 
 
Chapter 3 Blood lipid levels and prostate cancer risk: a cohort study 49 
 
Chapter 4 Risk of prostate cancer among cancer survivors in the Netherlands 61 
  
Chapter 5a Body mass index is not a predictor of biochemical recurrence  73 
 after radical prostatectomy in Dutch men diagnosed  
 with prostate cancer 
 
Chapter 5b Body mass index as a prognostic marker for biochemical  85 
 recurrence in Dutch men treated with radical prostatectomy 
 
Chapter 6 Selenium affects expression of genes implicated in inflammation 95 
 and epithelial-to-mesenchymal transition in the prostate 
 
Chapter 7  Discussion 121 
 7.1 Outline 123 
 7.2 Implications for researchers 123 
 7.3 Implications for (future) patients 141 
 7.4 Implications for the urologist 144 
 7.5 Future research agenda 146 
  
Samenvatting (Summary in Dutch)   153 
Dankwoord (Acknowledgements)  159 
About the author 165
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The overall aim of this thesis is to obtain insight into nutritional and clinical aspects relevant to different 
stages of prostate cancer. In the following paragraphs, an introduction to prostate cancer will be provided. 
Basic aspects of the epidemiology, pathology, carcinogenesis, diagnosis, and treatment of prostate cancer 
will be discussed in light of the topics addressed in this thesis (paragraph 1.1). Furthermore, an overview of 
potential risk factors and targets for prevention of incident (paragraph 1.2), progressive (paragraph 1.3) and 
recurrent (paragraph 1.4) prostate cancer will be presented. As this thesis covers a relatively broad and 
extensive research area, some of the aspects discussed in this chapter will not be specifically addressed in 
the following chapters. Instead, this information can be used as background information and might be useful 
for the interpretation or discussion of the study outcomes. This chapter ends with the specific research aims 
and the outline of this thesis.  
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1.1 General introduction to prostate cancer 
 
The incidence of prostate cancer 
Prostate cancer is the most common cancer among men in Western countries1, 2. It is 
estimated that almost one out of ten Dutch men will develop prostate cancer before 
the age of 803, 4. With 21%, prostate cancer accounted for the majority of all newly 
diagnosed cancers in Dutch men in 20094. In the Netherlands, 10,166 men were newly 
diagnosed with prostate cancer in 2009, while 2,492 men died from this disease in the 
same year4. Prostate cancer is predominantly diagnosed in elderly men. In 2009, 70% 
of all newly diagnosed Dutch prostate cancer patients were men aged 65 years and 
older4. 
 
Diagnosis  
There are no characteristic symptoms for prostate cancer, because most of the 
reported local symptoms, such as lower urinary tract symptoms (LUTS), refer to benign 
prostatic disorders more specifically. The detection and diagnosis of prostate cancer is 
often based on serum levels of the prostate-specific antigen (PSA) and a digital rectal 
examination, followed by ultrasound-guided prostate biopsies. Several prostate 
cancer-specific biomarkers in urine, blood and tissue have been evaluated, but so far 
none of these biomarkers is widely used in clinical practice5.  
 
In contrast to few other cancers (i.e. cervical cancer and breast cancer in females), 
there is no national screening program for prostate cancer in the Netherlands. The 
controversy about such screening program refers to the lack of cancer specificity of 
PSA testing6. Furthermore, it has been determined that the benefits are not likely to 
balance the possible harms (i.e. complications of treatment and mental burden7) of 
early screening8-10.  
 
Pathology and staging 
Normal prostate tissue consists of glandular tissue surrounded by non-glandular 
components (e.g. fibromuscular stroma)11. The prostate ducts are lined by two layers 
of epithelial cells, with neuroendocrine cells dispersed throughout these layers12. The 
secretory luminal cells directly line the lumen of the prostate ducts, while the basal 
cells form the second layer of epithelial cells12. The vast majority of the cancers in the 
prostate arises from the epithelial cells and are therefore defined as prostatic 
adenocarcinomas13. Within the prostate, three morphological zones can be 
distinguished; the peripheral zone, the transition zone, and the central zone11, 14. The 
majority of all prostatic adenocarcinomas (~70%) occur in the peripheral zone, which is 
also highly susceptible to inflammation, while 20-25% and 5-10% arise from the 
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transition zone and central zone, respectively11, 15, 16. Benign prostate enlargement 
(benign prostate hyperplasia or BPH) typically originates from the transition zone17. 
 
Histological grading is a tool for pathologists to assess the architecture of a tumour. 
The Gleason grading system for prostatic adenocarcinomas is grouped into five 
categories18. Gleason grade 1 refers to well-differentiated tumours (resemble normal 
prostate tissue), whereas poorly-differentiated tumours (abnormal architecture) are 
assigned as Gleason grade 519, 20. The sum of the two most common Gleason grades 
provides clinical implications for treatment and prognosis20. 
 
Clinical or pathological staging is another approach to evaluate the prognostic 
characteristics of prostate cancer. Clinical staging is based on the findings during digital 
rectal examination or imaging techniques, while pathological staging is evaluated in 
surgically removed tissues. The TNM staging (Table 1.1) system refers to local tumour 
growth (T), spread to regional lymph nodes (N) and distant metastases (M)21. The 
tumour (T) classification for prostate cancer ranges from T1 (tumour present but not 
detected clinically or with imaging) to T4 (tumour invades into adjacent structures)21.  
 
Non-aggressive and aggressive prostate cancer 
In clinical practice, both Gleason grade and TNM stage are used as predictors for 
prognosis. The prognosis of prostate cancer also depends on several other factors, 
because prostate cancer is a heterogeneous disease with different levels of 
aggressiveness. As observed in autopsy studies, prostate tumours were found in 33-
65% of all men aged above 70 years22-24. In most cases, these tumours were slow-
growing, indolent tumours without clinical significance. Various criteria have been 
suggested for the classification of clinically insignificant prostate cancer25. According to 
the Epstein criteria, insignificant prostate cancer is defined as an organ-confined 
cancer with no Gleason pattern 4 or 5, PSA density <0.15 ng/mL, dominant tumour 
volume <0.5 cm3 in surgically removed specimens, or fewer than three positive 
biopsies with <50% cancer per biopsy specimen26, 27. The aim of these criteria is to 
identify low-risk patients who do not require active treatment26.  
 
Prostate cancer, however, can also be an aggressive disease which is resistant to 
therapy, shows distant metastases, and might have a fatal ending. In epidemiological 
studies, these aggressive, high-grade or advanced forms of prostate cancer usually 
refer to tumours with stage T3 or worse, Gleason scores ≥7, and involvement of 
regional lymph nodes (N1) or distant metastases (M1) (e.g. Platz et al.28). Many studies 
aimed to determine biomarkers that can distinguish between insignificant, indolent 
and aggressive types of cancer29-31. So far, none of the suggested biomarkers is 
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implemented in clinical practice, mostly because they were not able to provide more 
information than Gleason score alone32.  
 
Table 1.1 Grading and staging system for prostate cancer 
System Category Description 
Gleason Gradinga Gleason 1 Well-differentiated, closely packed, uniform, medium-sized glands 
 Gleason 2 Glands somewhat loosely arranged, there may be minimal infiltration 
 
Gleason 3 
Smaller, discrete glands, marked variation in size and shape of the 
glands with some infiltration 
 Gleason 4 Fused glands with an irregular border 
 Gleason 5 Poorly-differentiated, no glandular differentiation 
TNM Stagingb Tumour (T) T1 
Clinically inapparent tumour  
(neither palpable nor visible by imaging) 
   T1a Tumour in ≤5% of resected tissue 
   T1b Tumour in >5% of resected tissue 
   T1c Tumour identified by needle biopsy 
  T2 Tumour confined within prostate 
   T2a Unilateral, ≤one-half of one lobe 
   T2b Unilateral, >one-half of one lobe 
   T2c Bilateral 
  T3 Tumour extends through the prostate capsule 
   T3a Extracapsular extension 
   T3b Invasion into seminal vesicle(s) 
  T4 Tumour invades adjacent structures other than seminal vesicles 
 Node (N) N0 No regional lymph node metastases 
  N1 Regional lymph node metastases 
 Metastasis (M) M0 No distant metastases 
  M1 Distant metastases 
   M1a Nonregional lymph node(s) 
   M1b Bone(s) 
   M1c Other site(s) 
 
a International Society of Urological Pathology Consensus Conference19; b American Joint Committee on 
Cancer Staging Manual, 7th edition21 
 
Treatment 
The treatment of prostate cancer depends on the stage of the disease, presence of co-
morbidities, and the age, condition and preference of the patient. For patients with 
insignificant or low-risk prostate cancer, conservative management (“active 
surveillance”) is often indicated25, 33. Active treatment regimens for prostate cancer 
include surgical removal of the prostate (radical prostatectomy), and radiation 
therapy34. Androgen-deprivation therapy and chemotherapy are mostly used to 
control and relieve the symptoms of advanced prostate cancer and to improve quality 
of life35.   
I n t r o d u c t i o n | 
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Prostate carcinogenesis  
Prostate cancer is a complex disease, with a number of molecular events and pathways 
involved in its development and progression. The process of development and 
progression of cancer is defined as ‘carcinogenesis’. Carcinogenesis is mostly driven by 
changes in the sequence, structure or stability of the genetic material. A brief overview 
of some of these changes is provided below (Figure 1.1). 
 
Genetic changes 
Genetic changes usually refer to changes or variants in the sequence of the DNA. These 
changes can either be inherited or acquired, the latter for instance as a consequence 
of prolonged exposure to harmful substances or oxidative stress. Mutations in relevant 
parts of the DNA (i.e. genes) can result in loss or aberrant function of these genes. In 
particular, mutations in genes that are involved in control of cell growth (e.g. proto-
oncogenes, tumour suppressor genes) and DNA repair (DNA repair genes) might 
substantially contribute to the carcinogenic process. Family-based studies identified 
several variations (single nucleotide polymorphisms, SNP’s) in genes that are 
associated with an increased risk of developing prostate cancer (e.g. the ribonuclease L 
gene, RNASEL)37. In the past years, the efforts of the so-called genome-wide 
association (GWAS) studies, which compare DNA sequences of prostate cancer 
patients with a control population, also revealed several prostate cancer susceptibility 
loci38, 39. 
 
More extensive alterations in the DNA sequence are associated with prostate 
carcinogenesis as well. Duplication or deletion of substantial parts of the DNA (defined 
as chromosomes) is referred to as chromosomal gain and loss, respectively32. With 
some exceptions, chromosomal loss is often observed during early stages of 
carcinogenesis, whereas chromosomal gain occurs mainly during later stages40, 41. 
Deletions in the 8p region are often accompanied by a reduced expression of the gene 
NKX3.142, which is located at 8p2143. As NKX3.1 is considered a tumour suppressor 
gene with a critical function in response to DNA damage44, the deletion of this gene 
might explain its relevance with respect to prostate cancer. In parallel with the effects 
for NKX3.1, deletions in the 10q region often result in a loss of PTEN45, another gene 
implicated in prostate carcinogenesis. PTEN is also considered a tumour suppressor 
gene with a regulatory role in a survival (PI3K/AKT) signalling pathway46.  
 
Epigenetic changes 
Epigenetic changes refer to changes in the genetic material that occur without altering 
the sequence of the DNA. Several epigenetic processes have been described47-49. It is 
beyond the scope of this thesis to review all of these phenomena, however, epigenetic 
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processes which might be of special relevance to prostate cancer will be shortly 
highlighted. DNA methylation primarily refers to the binding of methyl groups to 
cytosine nucleotides of the DNA. DNA methylation plays an essential role in the 
regulation of gene expression49. Excessive methylation or hypermethylation, which 
often occurs in specific regions rich of cytosine and guanine nucleotides (CpG islands), 
might result in a detrimental blocking or silencing of the genes and thereby contribute 
to the development of cancer49. For prostate cancer, over fifty genes have been 
identified that are frequently hypermethylated during carcinogenesis50. One of the 
best studied genes which is often hypermethylated in prostate tumours is involved in 
DNA repair and encodes for the glutathione S-transferase P1 (GSTP1)51.  
 
Other phenomena, which are more recently associated with prostate cancer 
development and progression, are the small, non-coding RNA fragments52, 53. These so-
called microRNA’s (miRNA) are able to regulate gene expression via binding to the 
coding RNA (messenger RNA or mRNA)53, 54. Alterations in the expression of several 
microRNA’s might affect cell cycle control, cellular migration and invasion, apoptosis, 
and androgen signalling in prostate tissue53, and thereby explain its possible relevance 
with respect to prostate cancer. 
Normal 
prostate 
epithelium
Prostatic 
intraepithelial 
neoplasia
(PIN)
Localized 
prostate 
cancer
Metastatic 
prostate 
cancer
Hormone-
refractory 
prostate 
cancer
GSTP1 hypermethylation
Mutations (e.g. RNASEL)
Chromosomal loss (e.g. NKX3.1 )
Chromosomal loss (e.g. PTEN )
Chromosomal gain (e.g. MYC    )
? Epithelial-to-mesenchymal transition ?
? Mechanisms affecting function of 
the androgen receptor ?
 
Figure 1.1 Schematic overview of suggested molecular processes occurring during 
prostate carcinogenesis (based on Nelson et al, 200336)  
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Androgen receptor 
Most of the molecular processes implicated in prostate carcinogenesis directly result 
from the genetic or epigenetic changes described above. One process that deserves 
some special attention is the androgen signalling pathway. Androgens are, through 
their interaction with the androgen receptor (AR), involved in growth and 
development of both normal and cancerous prostate tissue55. After binding of 
androgens, the androgen receptor is subjected to conformational changes and is 
transported to the nucleus55. In the nucleus, the activated androgen receptor binds to 
specific regions (androgen-response elements) and thereby regulates the expression of 
target genes involved in cellular growth and survival55, 56. Initially, prostate tumours 
require androgens for their growth, which explains the efficiency of androgen-
deprivation therapy for advanced prostate cancer57. Sooner or later, most tumour cells 
gain the ability to grow in the absence or at minimal levels of androgens, which result 
in the androgen-independent or hormone-refractory stage of the disease55, 58. Several 
mechanisms may lead to the development of hormone-refractory prostate cancer, 
including58 mutations in the androgen receptor59, overexpression of the androgen 
receptor60, changes in expression of factors that collaborate with the androgen 
receptor61, activation of the androgen receptor by alternative factors or pathways62, 63, 
or the production of androgens by the tumour itself64. As reviewed by others, more 
recent studies suggest that alternative mechanisms, independent of the androgen 
receptor, might also contribute to the development of hormone-refractory prostate 
cancer32, 58. 
 
Epithelial-to-mesenchymal transition 
Progression of prostate cancer is not only characterized by the development of 
hormone-refractory disease, but also by the formation of metastases. The molecular 
mechanisms underlying metastatic prostate cancer are poorly defined. Given its 
important role in cellular invasion and migration, it is suggested that epithelial-to-
mesenchymal transition (EMT) might facilitate the spread of prostate cancer cells65. 
During the epithelial-to-mesenchymal transition, the unique characteristics of 
epithelial cells are replaced by mesenchymal properties66. Epithelial cells typically form 
structured layers of cells and have close contacts with their neighbouring cells, 
whereas cells with a mesenchymal phenotype do not form cell layers and might have 
the ability to migrate66. Important molecular events that come along with the 
epithelial-to-mesenchymal transition are loss of markers for epithelial cells (e.g. E-
cadherin)67 and aberrant expression of markers for mesenchymal cells (e.g. vimentin 
and N-cadherin)66. Although the exact mechanisms remain unclear, it has been clearly 
demonstrated that processes related to the epithelial-mesenchymal transition might 
play a role in development of metastatic prostate cancer65. 
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1.2 Risk factors and prevention of prostate cancer  
 
Relatively little is known about the aetiology of prostate cancer. Knowledge on 
aetiology and risk factors is required for the identification of high-risk groups, 
development of new treatment strategies, and optimization of effective prevention 
programs. In the following sections, an overview of established and some suggested 
risk factors for prostate cancer will be presented. Furthermore, examples of potential 
prevention strategies will be described. 
 
Established risk factors for prostate cancer 
So far, old age, black race, a positive family history, and a few dozen of low-penetrance 
genetic markers have been established as risk factors for prostate cancer68, 69. Previous 
studies, however, suggested that a considerable part (~60%) of all prostate cancer 
diagnoses is most likely attributable to clinical or environmental factors70. Apparently, 
these factors have not yet been identified or confirmed and further research is 
therefore needed to elucidate the role of these factors in the aetiology of prostate 
cancer. 
 
Clinical factors 
High-grade prostatic intraepithelial neoplasia (HGPIN) refers to the presence of 
atypical epithelial cells in the prostate71. In contrast to prostatic adenocarcinomas, the 
basal epithelial cell layer of HGPIN foci is disrupted, but not absent71. Currently, HGPIN 
is considered as a premalignant stage of prostate cancer72. If HGPIN is found in an 
initial diagnostic biopsy, the chance of detecting prostate cancer in subsequent 
biopsies ranges from 30-75% and seems to depend on the number of previous biopsies 
with HGPIN73.  
 
Inflammation is very common in prostate tissue74-76, however, its role in prostate 
cancer aetiology remains controversial77. Based on the estimation that up to 15-20% of 
all cancers is caused by either infections or inflammation78-80, it is suggested that 
inflammation might be involved in prostate carcinogenesis as well16, 80. Prostatitis and 
sexually-transmitted diseases have been associated with increased risks of prostate 
cancer81, 82. However, the role of detection bias should be considered, because men 
with prostate-related symptoms might have relatively intensive screening for prostate 
cancer75.  
 
It has been suggested that a previous cancer diagnosis might influence the subsequent 
risk of developing prostate cancer. The incidence of prostate cancer, for instance, is 
relatively high in bladder cancer patients83, 84.  
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The co-occurrence of bladder cancer and prostate cancer can be explained by 
incidental detection in surgical specimens or active medical surveillance. Also previous 
cancer treatments might influence prostate cancer risk. It has been suggested that 
pelvic radiotherapy reduces the risk of developing prostate cancer85, 86. Finally, the 
association between prostate cancer and other malignancies might be explained by 
common aetiological factors, such as genetic susceptibility or shared exogenous 
factors as nutrition and lifestyle factors. In order to explore the aetiology of prostate 
cancer, more insight into the co-occurrence of prostate cancer and other malignancies 
is warranted. 
 
Nutrition and lifestyle factors 
There has been considerable interest in the role of nutrition and lifestyle factors in 
prostate cancer development and progression. In 2007, the World Cancer Research 
Fund (WCRF) and the American Institute for Cancer Research presented an extensive 
report on food, nutrition, and physical activity in relation to cancer87. The aim of this 
report was to evaluate and judge factors that can modify the risk of cancer. For 
prostate cancer, an extensive systematic literature review (558 publications) was 
performed and several factors were judged according to the strength of evidence87. 
For the majority of the nutritional and lifestyle factors, there was no or limited 
evidence that these factors modify the risk of prostate cancer87. Only diets high in 
calcium are reported as a probable cause of prostate cancer according to this report87.  
 
Overweight and obesity have also been suggested as risk factors for prostate cancer88. 
Body mass index (weight in kilograms divided by height in meters squared, kg/m2) is 
often used to define overweight (BMI 25-30 kg/m2) and obesity (BMI ≥30 kg/m2). 
Although results are fairly inconsistent, several prospective studies demonstrated that 
a high body mass index (BMI) is associated with an increased risk of prostate cancer, 
particularly for advanced prostate cancer89-91. Most of these studies, however, were 
conducted in the United States, where a rapidly growing epidemic of overweight and 
obesity is reported with over 68% of adult Americans being overweight or obese92. So 
far, most European studies were not able to confirm these results, although some 
prospective studies did find an association between measures of overweight, obesity 
and fat distribution (e.g. BMI and waist circumference) and prostate cancer 
incidence93-95.  
 
According to the WCRF report, foods containing lycopene and selenium, and dietary 
supplements with selenium are probably protective against prostate cancer87. In 
theory, intervention strategies with these nutrients might provide relatively simple and 
straightforward possibilities for the prevention of prostate cancer.  
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At this moment, however, the long-term effects of these factors on cancer biology and 
other health outcomes need to be explored. 
 
Prevention of prostate cancer  
Prevention is a strategy to reduce the development and progression of cancer. It is 
suggested that at least 40% of all cancer cases is preventable96, 97. Avoidance or 
reduction of risk factors, and pharmacological, dietary or lifestyle interventions can be 
effective prevention strategies. Chemoprevention is defined as an intervention with 
synthetic or naturally occurring substances in order to prevent, reverse, or inhibit the 
development of cancer in any of its stages98, 99. 
 
Prostate cancer is considered as an important target for chemoprevention, because of 
the high prevalence, the long latency period, and the roles of hormones100 and possible 
modifiable risk factors in prostate cancer development and progression. Currently, the 
most studied strategies for prostate cancer chemoprevention could be classified either 
as hormonal interventions or dietary interventions. 
 
Hormonal interventions  
An intervention targeting a hormonal pathway is a reasonable possibility for prostate 
cancer chemoprevention, because hormones play an important role in the prostate100. 
The enzyme 5α-reductase facilitates the conversion from testosterone to 
dihydrotestosterone (DHT), which is the main androgen responsible for prostate 
development and growth101, 102. The 5α-reductase inhibitors decrease the levels of DHT 
and are therefore used in the treatment of symptomatic benign prostate hyperplasia 
(BPH)101, 103. Finasteride and dutasteride are 5α-reductase inhibitors that are also 
evaluated as candidates for prostate cancer chemoprevention.  
 
Finasteride specifically inhibits the activity of the 5α-reductase isoenzyme type 2. The 
Prostate Cancer Prevention Trial (PCPT) showed that finasteride reduced the risk of 
prostate cancer by 25%104. Stratified analyses, however, suggested that high-grade 
tumours (Gleason score ≥7) were more frequently detected among finasteride-
users104. Dutasteride is also considered as a potential chemopreventive agent for 
prostate cancer, because it is a dual inhibitor of the 5α-reductase isoenzymes type 1 
and 2105. The Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial was 
initiated to examine the effects of dutasteride on the risk of incident prostate cancer in 
high-risk men106. First results of the REDUCE trial showed that dutasteride reduced the 
risk of incident prostate cancer detected on biopsy by 23%107. Stratified analyses 
showed that the preventive effects were confined to the low-grade prostate cancers 
(Gleason grade 5 or 6)107. 
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Dietary interventions 
Lycopene, a carotenoid and major constituent of tomatoes and other red fruit and 
vegetables, is classified as ‘probably protective against prostate cancer’ by the WCRF 
report87. Small intervention studies with lycopene supplements or tomato-based 
products examined the effects of lycopene on PSA levels108, 109, pathological 
outcomes108 and DNA damage109. The overall evidence that lycopene influences the 
prostate in a beneficial way, however, is inconsistent110, 111. 
 
Based on their roles as antioxidants, several vitamins have also been suggested as 
candidates for prostate cancer chemoprevention. For vitamin A, D, and C, there is no 
conclusive evidence that these vitamins prevent the development of prostate cancer87, 
112. Although vitamin E intake and status were associated with a significantly decreased 
risk of prostate cancer in some prospective cohort studies113-115 and a randomized 
trial116, two large chemoprevention trials with incident prostate cancer as primary 
outcome did not confirm these results112, 117, or even suggest an increased risk of 
developing prostate cancer118.  
 
Selenium is an essential trace element and has been considered as a promising 
candidate for prostate cancer chemoprevention. This hypothesis is supported by 
several observations that selenium deficiencies increased the risk of prostate cancer, 
whereas high selenium status or selenium supplementation decreased the risk of 
prostate cancer 87, 119-122. Recent observational and intervention studies, however, did 
not consistently confirm a preventive effect of selenium for prostate cancer117, 123. The 
Selenium and Vitamin E Cancer Prevention Trial (SELECT) is a randomized, controlled 
intervention trial that was initiated in order to determine the effects of selenium, 
vitamin E or a combination on prostate cancer incidence in a large sample of the 
general population124. The planned follow-up for the SELECT trial was seven to twelve 
years, however, the trial was discontinued after five and half years, because no 
preventive effects of selenium or vitamin E were found for prostate cancer, or were 
expected with additional exposure117, 118. The inconsistent findings of prospective 
studies and intervention trials highlight the need for extensive research on the possible 
mechanisms of selenium in the prostate, as well as the role different doses, 
formulations and baseline status of selenium.  
 
Other interventions 
Several other chemopreventive strategies for prostate cancer have been suggested. 
The use of cholesterol-lowering drugs is consistently associated with decreased risk of 
(advanced) prostate cancer125. This observation provides leads for research on the role 
of cholesterol in the aetiology of prostate cancer. Use of aspirin and non-steroidal anti-
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inflammatory medications might lower prostate cancer risk through anti-inflammatory 
mechanisms126. Oestrogen receptor modulators have been implicated in the 
prevention of prostate cancer through mechanisms that have not been elucidated127, 
128. Most of these agents, however, have not been validated in randomized, controlled 
intervention trials primarily designed for prostate cancer outcomes. 
 
Implementation of chemopreventive strategies 
So far, none of the chemopreventive strategies described above is recommended or 
implemented in clinical practice or in the general population. It is beyond the scope of 
this thesis to address all aspects involved in decision-making related to 
chemoprevention. However, few aspects will be addressed below. Overall, the cost-
effectiveness of chemoprevention depends on the balance between costs, desired 
effects, and manifestation of adverse effects129. Depending on the aim and design of 
the chemopreventive strategy, the target population should be carefully defined. For 
chemoprevention aimed at the entire, lower-risk population (e.g. SELECT117 and 
PCPT104), the expected effects should be relatively strong in order to achieve a cost-
effective intervention130. Furthermore, the acute and long-term effects of the 
intervention are extremely important; every minor adverse effect should be taken into 
consideration. From this perspective, dietary and lifestyle interventions are frequently 
suggested as appropriate and safe candidates for widespread chemoprevention. 
However, also dietary and lifestyle interventions, especially at supranutritional or 
supraphysiological levels, might be accompanied by adverse health effects118, 131, 132. A 
high-risk population for prostate cancer (e.g. REDUCE107) is an effective target 
population for chemoprevention, however, this population might have more 
aggressive forms of cancer that are not susceptible to the suggested prevention 
strategies133. Extensive research on the biological mechanisms and the long-term 
effects on cancer biology and other health outcomes is therefore required before any 
prostate cancer prevention program should be implemented or recommended.  
 
In conclusion 
The aetiology of prostate cancer remains poorly understood. Only few non-modifiable 
risk factors for prostate cancer have been established. For other factors, evidence is 
missing or inconsistent. Identification of risk factors involved in prostate carcinogenesis 
is important in order to understand the aetiology, to identify high-risk groups for early 
detection and to develop effective prevention strategies. Several chemopreventive 
agents for prostate cancer have been suggested. Before any of these chemoprevention 
strategies can be implemented, the balance between desired effects, adverse effects 
and costs should be carefully considered. Extensive research on the biological 
mechanisms and the long-term effects on cancer biology and other health outcomes is 
therefore required. 
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1.3 Risk factors and prevention of prostate cancer progression   
 
From non-aggressive to aggressive prostate cancer 
Progression of prostate cancer refers to the transformation from HGPIN and 
insignificant or indolent tumours to more advanced, aggressive or fatal forms of 
prostate cancer. Although numerous studies revealed that different factors are 
involved in the development of non-aggressive and aggressive prostate cancer, there is 
relatively little known about what exactly drives prostate cancer towards an aggressive 
form.  
 
Risk factors for prostate cancer progression 
Several clinical, nutritional and lifestyle factors, such as calcium intake134, body mass 
index88, use of cholesterol-lowering drugs135, and blood lipid profiles28, 136 have been 
linked to aggressive prostate cancer in particular. These findings suggest that these 
factors might play a substantial role in prostate cancer progression. At present, few 
observational studies examined the effects of post-diagnostic variables on risk of 
prostate cancer progression (defined as prostate cancer death, metastases, rising PSA 
levels or start of secondary treatment) as primary outcome137-139. Intake of eggs and 
poultry with skin137, as well as whole milk (but not total milk or dairy intake)139, were 
significantly associated with higher risk of progression, whereas intake of fish and 
tomato sauce protected against progression in these studies138. Furthermore, it was 
demonstrated that men with moderate to high levels of physical activity after their 
diagnosis had lower risk of prostate cancer-specific mortality or progression in some 
prospective studies140, 141. Also, several genetic (e.g. single nucleotide polymorphisms) 
and epigenetic (e.g. DNA hypermethylation) variations have been associated with 
prostate cancer progression142-145.  
 
Prevention of prostate cancer progression 
Stopping or delaying prostate cancer progression and recurrence, sometimes referred 
to as tertiary prevention, might result in a reduction of treatment-related 
complications and prostate cancer-related mortality133. Previous studies demonstrated 
that cancer patients are relatively motivated to change their diet and lifestyle146, 147. 
This starting point provides good opportunities for adherence to tertiary prevention 
programs. Several studies addressed the effects of dietary and lifestyle interventions in 
relation to prostate cancer progression148-150. The primary outcomes in most of these 
studies were indicators of disease progression (e.g. start of primary treatment, rising 
PSA levels) among men with HGPIN or low-risk prostate cancer undergoing active 
surveillance.  
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Prescription of an intensive lifestyle program, including a vegan diet (supplemented 
with selenium, vitamin E and C, soy, and fish oil), moderate aerobic exercise, stress 
management techniques, and participation in a support group seemed to reduce 
serum PSA levels149, and delay the start of a conventional therapy for prostate 
cancer148, suggesting that disease progression was attenuated in these patients with 
low-risk prostate cancer. Supplementation with selenium alone did not influence 
changes in PSA levels over time (PSA velocity) in men with low-risk prostate cancer150. 
 
As can be concluded from above, mixed results were found for the effects of dietary 
and lifestyle interventions on risk of prostate cancer progression. Before considering 
the development and implementation of prevention programs, further research is 
warranted. First, it is important to identify factors that are responsible for the potential 
protective effects. The advantage of comprehensive dietary and lifestyle interventions 
is that they mimic daily life situation, however, the disadvantage is that the role of 
individual factors or specific combinations of factors cannot be evaluated. Second, 
feasibility and adherence to such comprehensive intervention programs should be 
evaluated. Third, long-term effects on cancer outcome, other health outcomes, and 
prognosis should be carefully assessed. Of special importance is the clinical relevance 
of indicators for progression; preventive effects on indicators of progression (e.g. start 
of primary treatment or rising PSA levels) should also reflect protection against clinical 
or pathological progression and, in the end, improve survival. Finally, biological effects 
should be studied in order to understand the mechanisms of prevention.  
 
At present, some studies examined the molecular effects of dietary and lifestyle 
interventions in prostate tissue151-155. Results of these studies showed that dietary and 
lifestyle interventions are able to induce pronounced effects on gene expression in 
either non-malignant or malignant prostate tissue. The relevance of the changes in 
gene expression with respect to prostate cancer progression, however, warrants 
further investigation.   
 
In conclusion 
The progression to aggressive or fatal prostate cancer reveals important implications 
for prognosis and survival. There is little known about what exactly drives prostate 
cancer towards an aggressive form. In order to obtain more insight into prostate 
cancer progression, observational studies should stratify their analyses for aggressive 
and non-aggressive prostate cancer whenever possible. Furthermore, extensive 
research on the molecular events occurring during progression, and the possible 
mechanisms underlying prevention of progression is warranted. 
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1.4 Risk factors and prevention of prostate cancer recurrence   
 
Indicators for prostate cancer recurrence 
Recurrence of prostate cancer is defined as the return of the disease after a curative 
treatment. Confirmation of recurrence is often based on PSA levels or imaging 
techniques156. Biochemical recurrence (BCR) is widely used as a measure of recurrence 
in patients treated with radical prostatectomy157. Ideally, PSA levels should become 
undetectable after a radical prostatectomy, because the entire prostate is removed. 
Persistently detectable, post-operative PSA levels usually indicate residual disease, 
while rising PSA levels after an undetectable PSA refer to biochemical recurrence156, 157. 
For other forms of therapy (e.g. radiotherapy) alternative definitions for biochemical 
recurrence have been suggested157, 158, however, recognizing biochemical recurrence is 
often more complicated because PSA levels do not necessarily become 
undetectable158. Therefore, the majority of studies on prostate cancer recurrence 
focused on patients treated with radical prostatectomy157. This paragraph will highlight 
the main predictors and role of preventive strategies for (biochemical) recurrence after 
radical prostatectomy. 
 
Risk factors for recurrence  
Following radical prostatectomy, up to 35% of the patients develop biochemical 
recurrence159-164. Although some suggest that a rising PSA does not perfectly predict 
prognosis or prostate cancer-specific mortality165, 166, it is an important ‘tool’ for the 
identification of recurrent prostate cancer. Many studies evaluated clinical or 
pathological factors that predict risk of biochemical recurrence after radical 
prostatectomy. Several prognostic factors for biochemical recurrence have been 
established; i.e. advanced stage, high Gleason grade, positive surgical margins, 
invasion into seminal vesicles, extracapsular extension, lymph node involvement, and 
pre-operative PSA levels167.  
 
Except from positive surgical margins, which may sometimes depend on the 
experience of the urologist168, none of the prognostic factors described above can be 
easily controlled. Identification of modifiable risk factors, such as nutritional and 
lifestyle factors, allows development of prevention strategies for recurrent prostate 
cancer. So far, obesity is the main modifiable risk factor studied in relation to risk of 
prostate cancer recurrence. Several studies examined whether body mass index, as a 
measure of obesity, was associated with biochemical recurrence after radical 
prostatectomy169. Prospective studies from the USA almost consistently demonstrated 
that a higher body mass index was associated with an increased risk of biochemical 
| C h a p t e r  1  
P a g e | 24 
recurrence or mortality169. Also a recent weight gain is associated with an increased 
risk of biochemical recurrence after radical prostatectomy170. Only few European 
studies examined the effects of body mass index on risk of prostate cancer recurrence 
after radical prostatectomy and these studies demonstrated inconsistent results171, 172. 
Since the incidence of obesity increases substantially173, additional research on the 
effects of obesity on recurrent prostate cancer in Europe is needed. 
 
Prevention of prostate cancer recurrence 
Adequate strategies for the prevention of recurrent prostate cancer may ultimately 
contribute to the reduction of prostate cancer-specific mortality. Also from the 
patients’ perspective, an active preventive strategy may help to deal with the difficult 
and anxious period of frequent PSA testing and thereby improve quality of life174. In 
line with the results for progressive prostate cancer, relatively few studies evaluated 
preventive strategies for recurrent prostate cancer133. 
 
A number of dietary interventions have been evaluated in the light of the prevention 
of prostate cancer recurrence. A diet rich in plant-based foods and fish, together with a 
mindfulness program, increased the PSA doubling time in prostate cancer patients 
with rising PSA levels after primary treatment175. The PSA doubling time is the time 
needed for the PSA levels to double, and is considered as a predictor of recurrence and 
mortality after radical prostatectomy176. Also, different dietary supplements containing 
isoflavones, carotenoids, phytosterols, trace-elements and vitamins did influence PSA 
doubling time177 or levels of specific subclasses of PSA (free PSA)178, however, risk of 
biochemical recurrence itself was not examined as outcome in any of these studies 
because participants already had rising PSA levels175, 177, 178.  
 
In conclusion 
Recurrence of prostate cancer after a radical therapy is often characterised by rising 
PSA levels. Several clinical and pathological factors can predict risk of biochemical 
recurrence after radical prostatectomy. A number of modifiable factors, such as high 
body mass index, have been suggested as risk factors for prostate cancer recurrence, 
however, current evidence is inconclusive.  
I n t r o d u c t i o n | 
25 | P a g e  
1.5  Overview of this thesis 
 
Gaps of knowledge  
As can be concluded from the previous paragraphs, there is extensive knowledge on 
various aspects of prostate cancer; however, a number of other important aspects 
remain poorly understood. Prostate cancer is still the most common cancer among 
men, and an important cause of cancer death. As already suggested for years, 
prevention of prostate cancer is the ultimate strategy to stop this alarming 
development179. For the design of effective prevention programs, better 
understanding of the aetiology of prostate cancer is required. Moreover, insight into 
risk factors allows identification of high-risk groups for early detection. Focusing on 
high-risk groups reduces the detection of insignificant tumours and overtreatment in 
low-risk men.  
 
Important issues that need to be addressed: 
 
1. Understand the biology of prostate cancer 
2. Identify risk factors for prostate cancer development, progression, or recurrence 
3. Identify targets for effective prevention and/or treatment 
 
Extended knowledge on these issues might subsequently shed a new light on other 
research areas, such as the finding of prostate cancer-specific biomarkers, 
identification of methods to distinguish between insignificant and aggressive tumours, 
and development of new treatment strategies. 
  
Aims 
The overall aim of this thesis is to obtain insight into nutritional and clinical factors 
relevant to different stages of prostate cancer. Insight into these factors allows 
identification and evaluation of risk factors for prostate cancer as well as potential 
candidates for chemoprevention.  
 
For this purpose, randomized, controlled intervention trials usually provide the highest 
level of evidence and are therefore considered as the gold standard. However, these 
trials are often time-consuming, expensive and characterized by rather complicated 
logistics. Therefore, we sought to initiate one randomized, controlled intervention trial 
with molecular endpoints, while other studies and comprehensive datasets were 
added in order to address our main research aims.  
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The specific research aims addressed in this thesis are: 
 
1. Identification of leads for research on potential risk factors (Chapter 2) 
2. Evaluation of risk factors for incident prostate cancer (Chapter 3 and 4) 
3. Evaluation of factors that might influence risk of recurrent disease (Chapter 5) 
4. Studying the molecular mechanisms of chemoprevention (Chapter 6) 
 
Outline of this thesis 
Chapter 1 provides a general introduction to prostate cancer and highlights the need 
for research on potential risk factors. Identification of risk factors is often based on 
agnostic or biology-driven observational studies. Unexpected and useful leads for 
research on risk factors may also come from patients themselves. In Chapter 2, self-
reported causes and patients’ perceptions of prostate cancer are presented.  
 
In chapter 3 and 4, potential risk factors for incident prostate cancer are examined. 
Chapter 3 presents the results from a population-based cohort study on the 
association between serum levels of cholesterol and triglycerides and the risk of 
incident prostate cancer. Chapter 4 evaluates whether a previous cancer diagnosis 
influences the risk of prostate cancer as a second primary cancer.  
 
In Chapter 5, the focus shifts from incident to recurrent prostate cancer. In chapter 5a 
and chapter 5b, body mass index is examined as prognostic factor for biochemical 
recurrence after a radical prostatectomy. Chapter 5a is based on a cohort of patients 
identified through the population-based cancer registry, while Chapter 5b refers to a 
study with patients from two tertiary referral hospitals.  
 
In Chapter 6, the results of a short-term, randomized, controlled intervention trial with 
selenium are presented. Selenium is considered a chemopreventive agent for prostate 
cancer, however, the possible mechanisms by which selenium might lower prostate 
cancer risk have not been elucidated. The aim of this study was to examine the 
molecular effects, as determined by gene expression profiles, in prostate tissue before 
and after a five-week intervention with selenium in patients suspected for prostate 
cancer.  
 
In Chapter 7, the main findings of our studies are summarized and the methodology 
and relevance of each of the chapters are discussed. Finally, implications for clinical 
practice and areas of interest for future research are suggested.   
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Purpose The aim of this study was to evaluate self-reported causes of prostate cancer among patients 
recently diagnosed with this disease in order to identify potential leads for aetiological research and to 
obtain insight into patients’ perceptions of causes.  
Subjects and methods A total of 956 patients, who were identified from a population-based cancer registry 
and provided written informed consent, completed a questionnaire on sociodemographic characteristics, 
lifestyle, medical history and family history of cancer. The final open-ended question: “You have been 
diagnosed with prostate cancer. Do you have any idea what may have been the cause of your cancer?” was 
evaluated for this study.  
Results In total, 143 patients (15%) reported that they were aware of any factors that might have caused 
their prostate cancer. Reported causes reflect a wide range of different factors that are often highly specific. 
Patients reported factors related to heredity (37%), specific environmental factors (17%), nutrition and 
physical activity (13%), and stress (13%) as most likely causes. Interestingly, although a positive family history 
is established as a risk factor for prostate cancer, only 19% of the patients with an affected first-degree 
relative reported this as possible cause.   
Conclusion Established risk factors for prostate cancer were not commonly perceived, not even among 
patients with these risk factors. This finding might be taken into account while developing future cancer 
education programs. Some suggestions given by the patients, such as psychological stress, infections, and a 
sedentary lifestyle may warrant further investigation, because current evidence is missing or inconclusive. 
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Introduction 
Prostate cancer is the most common cancer among men in Western countries1, 2. As for 
many other types of cancer, little is known about causes of prostate cancer. So far, old 
age, black race, a positive family history, and a few dozen of low-penetrance genetic 
markers have been established as risk factors for prostate cancer3, 4. The identification 
of new risk factors for prostate cancer is important in order to understand the 
aetiology, to identify high-risk groups for early detection and to develop effective 
prevention strategies. 
 
Searching for associations in agnostic (such as genome-wide association studies) or 
biology-driven observational studies might reveal new factors that modify prostate 
cancer risk. A limitation of this approach, however, is that unexpected associations 
may be missed. Leads for new risk factors may sometimes come from unexpected 
sources such as patients themselves. For example, maternal exposure to 
diethylstilbestrol (DES) was identified as a cause of vaginal clear-cell adenocarcinomas 
after the mother of one of the patients reported that she had taken DES during early 
pregnancy5. Although prostate cancer seems to be a multifactorial disease with a 
complex aetiology and different factors involved in non-aggressive and aggressive 
tumours, asking patients about perceived causes of their prostate cancer might give 
leads regarding potential risk factors.  
 
Furthermore, understanding of what patients think and to what extent they are aware 
of potential risk factors might provide valuable information for education and 
prevention programs. Previous studies showed a low awareness of risk factors for 
prostate cancer among the general population6-8. Data on patients’ perceptions of 
individual risk factors for prostate cancer, however, is scarce9-11. The aim of the 
present study was to evaluate self-reported causes of prostate cancer among patients 
diagnosed with this disease in order to identify potential leads for aetiological research 
and to obtain insight into patients’ perceptions of causes. 
 
Subjects and methods 
Self-reported possible causes of prostate cancer were evaluated in this study among 
Dutch men with prostate cancer. Recruitment and characteristics of the study 
population have been described in detail previously12, 13. Briefly, patients diagnosed 
with prostate cancer between 2003 and 2006 (n=1668) were identified from the 
population-based cancer registry held by the Comprehensive Cancer Centre East 
(CCCE) in the Netherlands. Patients diagnosed with prostate cancer before the age of 
76 years were invited between September 2006 and June 2007 to participate in a 
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European study named Polygene (www.polygene.eu) which aimed to identify common 
genetic variants that influence the risk of developing breast or prostate cancer13.  
 
All eligible patients with prostate cancer (n=1330) received an invitation letter and an 
information brochure. The information brochure explained the aim of the study and 
highlighted the need for aetiological research into risk factors for prostate cancer and 
breast cancer. Lifestyle factors (“nutrition and physical activity”) and genetic factors 
were mentioned as established risk factors for prostate cancer in this information 
brochure. Overall, 956 men agreed to participate and filled out a baseline postal 
questionnaire on sociodemographic and lifestyle characteristics, physical activity, 
occupational history, sun exposure, medical history, use of medicines, and family 
history of cancer. The final open-ended question: “You have been diagnosed with 
prostate cancer. Do you have any idea what may have been the cause of your cancer?” 
(No / Yes, namely…) was evaluated for this study.  
 
Categories of perceived causes were based on answers given by the patients and were 
presented as clusters of risk factors (environment / heredity / stress / nutrition and 
physical activity / clinical interventions / voiding problems / vasectomy / infections / 
other physical problems / cycling / smoking / screening / other). Patients were divided 
into subgroups in order to search for patterns among reported causes and shared 
patients’ characteristics. For these subgroup analyses, patients were stratified based 
on their age, family history of prostate cancer, educational level, body mass index 
(BMI), and reasons for PSA testing. Strata of age were defined as below and equal or 
above 68 years of age, which was the median age of the study population. A positive 
family history of prostate cancer was defined as at least one reported first-degree 
family member (father, brother, son) with prostate cancer. Educational level was 
classified as low (primary school, secondary school, vocational education) or high 
(college and university), based on the seven response options in the questionnaire. 
BMI (kg/m2) was calculated using self-reported weight (kg) and height (cm). Strata of 
BMI were below 25 kg/m2 (normal weight) and equal or above 25 kg/m2 (overweight 
and obesity). Initial reasons for PSA testing were either based on screening and routine 
check-ups or to complaints and symptoms.  
 
The institutional review board approved the Polygene study and all participants 
provided written informed consent. The Statistical Package for Social Sciences (SPSS, 
version 16.0, Chicago, Illinois), was used for all analyses. 
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Results 
Patients’ characteristics, stratified for patients who did and did not report a causal 
explanation, are presented in Table 2.1. The median (interquartile range (IQR)) age at 
completion of the questionnaire was 68 (63-73) years. Median (IQR) time between 
diagnosis of prostate cancer and completion of the questionnaire was 26.9 (17.7-36.8) 
months. The majority of the participants indicated that they were not aware of any 
causal factor that might have contributed to the development of their prostate cancer 
(n=809; 85%) or did not answer this question (n=4; <1%).  
 
Table 2.1 Sociodemographic and clinical characteristics of the study population 
 All patients 
with prostate 
cancer 
Patients with causal 
explanation for their 
prostate cancer 
Patients without 
causal explanation for 
their prostate cancer 
Number of patients 956 143 (15%) 813 (85%) 
Age at completion of questionnaire (years) 68.2 (63.2-72.8) 
66.1 
(60.7-70.7) 
68.8 
(63.6-73.1) 
Time between diagnosis and completion of 
questionnaire (months) 
26.9 
(17.7-36.8) 
26.9 
(18.7-34.9) 
26.9 
(17.4-37.0) 
Body mass index (kg/m2) 25.2 (23.8-26.9) 
24.8 
(23.6-26.1) 
25.2 
(23.9-27.0) 
Marital status (%) 
   Married / cohabiting 
   Single 
   Divorced / widowed 
 
858 (90%) 
46 (5%) 
52 (5%) 
 
126 (88%) 
8 (6%) 
9 (6%) 
 
732 (90%) 
38 (5%) 
43 (5%) 
Educational level (%)a 
   Low 
   High   
 
664 (70%) 
286 (30%) 
 
93 (65%) 
50 (35%) 
 
571 (70%) 
236 (29%) 
Currently employed (%) 
   Yes 
   No 
 
181 (19%) 
775 (81%) 
 
40 (28%) 
103 (72%) 
 
141 (17%) 
672 (83%) 
Positive family history of prostate cancer (%) 211 (22%) 55 (39%) 156 (19%) 
Reason for PSA screening (%) 
    Complaints 
    Routine check-up 
    Screening 
    Otherb 
 
484 (51%) 
324 (34%) 
27 (3%) 
118 (12%) 
 
71 (50%) 
50 (35%) 
3 (2%) 
19 (13%) 
 
413 (51%) 
274 (34%) 
24 (3%) 
99 (12%) 
Data are presented as median (interquartile range) or numbers (%). Percentages may not add up to 100% 
because of missing values. a Educational level is defined as low (primary school, secondary school, vocational 
education) or high (college and university). b The category ‘Other’ consisted of explanations given by the patients 
and includes for example: “prostate cancer diagnosis among family or friends”, “article in newspaper”, “other 
physical complaints or diseases”. 
 
In total, 143 (15%) patients suggested a possible cause. These patients were younger, 
were more likely to have a positive family history of prostate cancer and were more 
frequently currently employed compared to patients who did not report any cause. 
Patients with causal explanations had the same reasons for initial PSA testing 
compared to patients without causal explanations (i.e. complaints and symptoms 51%, 
routine check-up 34%, screening 3%, and other 12%). 
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The perceived causes as mentioned by the prostate cancer patients are summarized in 
Table 2.2. Results were stratified by age, family history, educational level, BMI, and 
reasons for PSA testing.  
 
Heredity is most commonly reported (n=53; 37%) by the 143 patients who mentioned 
at least one possible cause. Patients with a positive family history were more likely to 
mention heredity (n=41; 75%) compared to patients without prostate cancer in their 
family (n=12; 14%). However, of all patients with a positive family history in the first 
degree (n=211), only 41 patients (19%) reported this positive family history as one of 
the potential causes of their disease, while 14 patients (7%) only mentioned other 
causes and 156 patients (74%) indicated that they were not aware of any causes of 
their prostate cancer. By contrast, 12 out of 745 patients without a positive first-
degree family history  indicated that heredity might have caused their prostate cancer. 
Some of these patients reported second or third-degree affected family members (“a 
grandfather with prostate cancer”, “cousins from my mother”), referred to other types 
of cancer in the first-degree (“father had testis and lymphatic cancer”) or mentioned 
heredity in general (“my father also was a prostate-person, he got several surgeries 
since he was 55 years of age”).  
 
Environmental factors like pesticides and other chemicals, electromagnetic radiation, 
and air pollution were frequently mentioned as well (n=25; 17%). Most environmental 
factors were linked to current or previous occupations (“occupational-disease for 
painters”, “chemicals in rubber industry”, “cold or sun exposure during work”) although 
incidental or accidental exposures were also reported (“defect fridge”, “Chernobyl 
disaster”). Most patients reported highly specific causes (“DDT intoxication at young 
age”, “mobile phone in right trouser pocket”, “use of felt-tip pens”) rather than general 
environmental factors (e.g. “air pollution” and “car exhaust”). Environmental factors 
were more frequently reported among patients with lower education (n=22; 24%) 
compared to patients with a high educational level (n=3; 6%).  
 
For factors related to nutrition and physical activity an opposite pattern was found; 
patients with a low educational level were less likely (n=7; 8%) to report these factors 
compared to patients with higher education (n=11; 22%). Nutrition and related factors 
comprise both abundant intake (“abundant alcohol intake”, “salt”, “tomatoes” “dairy”) 
and deficient intake of foods (“low fruit intake”), as well as specific food patterns 
(“irregular”, “monotonous diet”, “Mediterranean lifestyle with meat and wine”). Also 
additives (“chemicals in food”, “hormones in meat industry”) and a sedentary lifestyle 
(“sedentary occupation”, “traveling by train”) belong to this category. 
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Table 2.2 Categories of perceived causes of prostate cancer among Dutch patients 
recently diagnosed with this disease  
 All patients Age Family history 
 - < 68 
years 
≥ 68 
years 
Negative Positive 
Number of patients 956 462a 492 745 211 
Number of patients giving a  
causal explanation 143 (15%) 85 (18%) 58 (12%) 88 (12%) 55 (26%) 
Causal explanations      
Heredity 
  “Heredity, DNA, mutations” 53 (37%) 31 (36%) 22 (38%) 12 (14%) 41 (75%) 
Environmental 
  “Pesticides,  air pollution”  25 (17%) 18 (21%) 7 (12%) 18 (20%) 7 (13%) 
Nutrition / physical activity 
  “Food additives, meat, alcohol,    
  sedentary lifestyle” 
18 (13%) 12 (14%) 6 (10%) 13 (15%) 5 (9%) 
Stress / psychological 
  “Stress, burnout, workaholic,  
  depression” 
18 (13%) 15 (18%) 3 (5%) 16 (18%) 2 (4%) 
Voiding problems 
  “Urgent, frequent” 8 (6%) 4 (5%) 4 (7%) 7 (8%) 1 (2%) 
Vasectomy 7 (5%) 5 (6%) 2 (3%) 7 (8%) 0 (0%) 
Infection 
  “Prostatitis, virus infection” 7 (5%) 5 (6%) 2 (3%) 7 (8%) 0 (0%) 
Other physical problems 
  “Immune system, thrombosis, digestion” 7 (5%) 3 (4%) 4 (7%) 5 (6%) 2 (4%) 
Cycling 7 (5%) 4 (5%) 3 (5%) 7 (8%) 0 (0%) 
Smoking 6 (4%) 3 (4%) 3 (5%) 4 (5%) 2 (4%) 
Clinical interventions 
  “X-ray, light therapy for eczema” 6 (4%) 3 (4%) 3 (4%) 5 (6%) 1 (2%) 
Age 5 (3%) 1 (1%) 4 (7%) 4 (5%) 1 (2%) 
Other 
  “Use of drugs,  high testosterone” 4 (3%) 3 (4%) 1 (2%) 3 (3%) 1 (2%) 
Screening 2 (1%) 0 (0%) 2 (3%) 2 (2%) 0 (0%) 
Data are presented as numbers (%). Numbers might exceed the total number of patients in our study as 
some patients provided more than one answer to the question. a For two patients, age at completion of the 
questionnaire is missing. 
  
Six patients mentioned drinking alcohol as the potential cause of their prostate cancer. 
One patient suggested overweight, together with other causes, as a possible cause of 
his prostate cancer; “Somewhat abundant weight? Eaten too much fat? Deficient fruit 
intake during adolescence? Too little physical activity?”.  
 
Patients with overweight or obesity (BMI ≥ 25kg/m2) did not clearly report causes 
related to nutrition or physical activity more frequently (n=9; 13%) than patients with 
normal weight (n=9; 12%). Patients with overweight and obesity reported other 
physical problems relatively frequently in comparison to patients with normal weight. 
Their explanations seem not to be specifically related to overweight; “hypertension”, 
“thrombosis”, “polyp”, “cyst in prostate”, “auto-immune system” and “deficient auto-
immune system, neuropathy, thyroid”.  
P e r c e i v e d  c a u s e s  o f  p r o s t a t e  c a n c e r | 
41 | P a g e  
Table 2.2 Continued  
 Educational levelb Body mass index Detectionc 
 Low High  < 25 kg/m2 ≥ 25 kg/m2 Screening Complaint 
Number of patients 664 286 449 499 351 484 
Number of patients giving a causal 
explanation 93 (14%) 50 (17%) 74 (16%) 69 (14%) 53 (15%) 71 (15%) 
Causal explanations       
Heredity 
  “Heredity, DNA, mutations” 35 (38%) 18 (36%) 26 (35%) 27 (39%) 23 (43%) 19 (27%) 
Environmental 
  “Pesticides,  air pollution”  22 (24%) 3 (6%) 13 (18%) 12 (17%) 8 (15%) 16 (23%) 
Nutrition / physical activity 
  “Food additives, meat, alcohol,    
  sedentary lifestyle” 
7 (8%) 11 (22%) 9 (12%) 9 (13%) 7 (13%) 7 (10%) 
Stress / psychological 
  “Stress, burnout, workaholic,  
  depression” 
10 (11%) 8 (16%) 11 (15%) 7 (10%) 3 (6%) 13 (18%) 
Voiding problems 
  “Urgent, frequent” 5 (5%) 3 (6%) 5 (7%) 3 (4%) 1 (2%) 5 (7%) 
Vasectomy 3 (3%) 4 (8%) 6 (8%) 1 (1%) 2 (4%) 5 (7%) 
Infection 
  “Prostatitis, virus infection” 3 (3%) 4 (8%) 3 (4%) 4 (6%) 2 (4%) 4 (6%) 
Other physical problems 
  “Immune system, thrombosis,digestion” 2 (2%) 5 (10%) 0 (0%) 7 (10%) 2 (4%) 5 (7%) 
Cycling 4 (4%) 3 (6%) 3 (4%) 4 (6%) 3 (6%) 4 (6%) 
Smoking 6 (6%) 0 (0%) 4 (5%) 2 (3%) 3 (6%) 2 (3%) 
Clinical interventions 
  “X-ray, light therapy for eczema” 5 (5%) 1 (2%) 3 (4%) 3 (4%) 1 (2%) 4 (6%) 
Age 2 (2%) 3 (6%) 2 (3%) 3 (4%) 2 (4%) 3 (4%) 
Other 
  “Use of drugs,  high testosterone” 4 (4%) 0 (0%) 2 (3%) 2 (3%) 3 (6%) 1 (1%) 
Screening 1 (1%) 1 (2%) 2 (3%) 0 (0%) 2 (4%) 0 (0%) 
Data are presented as numbers (%). Numbers might exceed the total number of patients in our study as some 
patients provided more than one answer to the question. b Educational level is defined as low (primary school, 
secondary school, vocational education) or high (college and university).  c Reasons for initial PSA testing are either 
related to complaints / symptoms (n=484) or to screening / routine check-up (n=351). Another, minor category in 
the questionnaire was ‘other’ (n=118) and includes for example “prostate cancer diagnosis among family or 
friends”, “article in newspaper”, “other physical complaints or diseases”. 
 
Stress was reported relatively frequently (n=18; 13%) as a possible cause of prostate 
cancer. Patients gave causal explanations such as “Fatigue and stress caused prostate 
enlargement and subsequently cancer”,” busy lifestyle”, “high workload”, “depression”, 
and “burnouts”. Stress-related explanations were somewhat more common among 
young men with a high educational level, which may suggest that stress is mainly 
related to current occupation.  
 
Patients (n=7; 5%) who mentioned infections as a possible cause of their prostate 
cancer either specified infections related to the prostate (n=3) or urinary tract (n=3). 
One patient reported a theory about an unknown retrovirus that is suggested to cause 
prostate cancer. All three patients who mentioned prostatitis, gave a clear cause of the 
infection (“prostatitis in adolescence because of cycling”, “frequent episodes of 
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prostatitis because of poorly performed vasectomy”, and “chronic prostatitis during 2 
years because of catheterization after a serious accident”). From the questionnaire, we 
identified 93 patients with self-reported prostatitis. Only four of them mentioned 
infections or prostatitis as a possible cause of their prostate cancer, suggesting that 
most patients do not consider prostatitis as a main risk factor.  
 
Other causes that were mentioned are related to voiding problems (n=8; 6%), other 
physical problems (n=7; 5%), vasectomy (n=7; 5%), cycling (n=7; 5%), smoking (n=6; 
4%), clinical interventions (n=6; 4%), age (n=5; 4%), screening (n=2; 1%), and others 
(n=4; 3%). The last category comprised a variety of causal explanations; “it is a man-
thing?”, “use of prednisone and azathioprine”, ”an accident as testing engineer”, and 
“high levels of testosterone”. These and other examples of reported causes are 
presented in Table 2.3.  
 
Table 2.3 Selection of perceived causes of prostate cancer reported by Dutch patients 
diagnosed with this disease.  
Perceived causes … Examples of perceived causes given by the patients 
…established as risk 
factors for prostate 
cancer 
“Heredity”, “Conform age incidence”, “My father; he was diagnosed with 
prostate cancer when he was 70 years”, “It is in my genes”, “It is a man-thing?”, 
“My father also was a prostate-person, he got several surgeries since he was 55 
years of age”, “Hereditary mutation (father) could not be excluded”, “DNA”, 
“Heredity, therefore I asked for a screening”, “Because my father also had 
prostate cancer, I think that it is hereditary” 
…with an unknown or 
unidentified effect on 
prostate cancer risk 
“Sweeteners”, “Abundant intake of tomatoes”, “Little physical activity during 
the last 25 years”, “Fluid from defect fridge”, “Air pollution from the Ruhr 
district”, “Television switched on for 6 h/day”, “I assume because I was exposed 
to chemicals in rubber industry”, “Traffic jam during rush hours“, “DDT 
intoxication at  young age”, “Electromagnetic radiation”, “Unknown retrovirus”, 
“Chronic voiding problems”, “Polyps in the rectum”, “Stress” “Completely 
overtired because of family problems”, “Work-related stress and traveling by 
car”, “Sadness”, “Depression”, “Maybe stress and depression in the past”, 
“Fatigue and stress for years caused prostate enlargement and subsequent 
cancer”, “Many X-rays lower part of the body”, “Disorder of the autoimmune 
system?”, “Association with neuropathy and thyroid”, “Outdoor profession 
(cold)”, “Sun exposure during work”, “Light therapy for eczema in 1999/2000”, 
“Chronic prostatitis”, “Frequent episodes of prostatitis because of poorly 
performed vasectomy”, “Ignorance of voiding problems by general 
practitioner”, “Air pollution in Nijmegen-West” 
…unlikely to have an 
effect on prostate 
cancer risk 
“Vasectomy”, “Cycling”, “Smoking”, “Cyst in the prostate”, “Is there any 
relationship between vasectomy and prostate cancer?”, “Increased risk because 
of vasectomy, I have read that somewhere”, “A lot of cycling 5 years before 
diagnosis, pressure on prostate because of problems with saddle”, “Smoking 
and moderate alcohol intake”, “Cycled 65.141 km between 1993-2003”, 
“Smoking!!!” 
This table is provided in order to give insight into the types of perceived causes reported by the patients. The 
classification of perceived causes into the different categories is based on a rather arbitrary selection. Future 
research and new insights might result in a shift of perceived causes among the different categories. Some of 
the perceived causes reported by the patients may be proxies for other underlying risk factors.  
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Many patients reported possible causal explanations to which they apparently have 
been exposed during a long period (“Thirty-seven years of unhealthy and dirty work”, “I 
have been a workaholic during my whole life”, “Too little physical activity and sports 
during the last 25 years”) or that has occurred during the past (“Monotonous diet 
during the war”, “Not much fruit during childhood”, “Prostatitis in adolescence due to 
frequent cycling”, “Frequent X-rays in the sixties and seventies”). Only few patients 
reported more acute or recent events that might have contributed to the development 
of their prostate cancer (“A defect fridge” and “Serious infection in bladder and 
prostate during the past 9 months”).  
 
If a causal explanation was given, this was frequently coupled with a measure of 
uncertainty. “If I knew that! Perhaps a monotonous diet during the war in 1940-1945 
or during my stay abroad in 1964-1995?” Almost one third of the patients provided a 
causal explanation followed by a question mark, or mentioned words as “possibly” and 
“perhaps”. These measures of uncertainty may suggest that many patients did not 
recognize one clear, outstanding responsible cause of their prostate cancer. 
 
Discussion 
In this study among patients diagnosed with prostate cancer, we evaluated self-
reported potential causes of prostate cancer. Only 15% of the patients reported at 
least one causal explanation, whereas the majority of the patients (85%) indicated that 
they were not aware of any cause that might have contributed to the development of 
their prostate cancer.  
 
A few studies examined perceived causes of prostate cancer among patients recently 
diagnosed with this disease9-11. It was demonstrated that patients with prostate cancer 
were least likely (41%) to report perceived causes, as compared to other cancer 
patients (47-74%), which was explained by the authors by the lack of scientific 
evidence available for factors involved in prostate carcinogenesis11. Fitzpatrick and 
colleagues reported on awareness of risk factors and perceived levels of risk among 
prostate cancer patients and the general population9. Participants were asked to 
identify risk factors for prostate cancer from a prompted list. In addition to this, the 
participants were requested to explain why they did perceive their risk of getting 
prostate cancer as low or high9. Similar studies with patients were performed for 
prostate cancer10, breast cancer14 and other chronic diseases, like heartburn15, and 
gastro-oesophageal reflux16. Most of these studies9, 10, 14, 15, however, used multiple-
answer questions from a prompted list. The prompted question format is considered 
to reflect recognition and usually indicates higher levels of knowledge compared to 
open-ended questions17.  
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Furthermore, the prompted question format does not allow unique, unexpected or 
new responses and is strongly directed by views of the health professionals. Because 
the aim of our study was to evaluate self-reported causes of prostate cancer in order 
to identify leads for aetiological research and to obtain insight into patients’ thoughts 
about causes, we used the open-ended question format.  
 
In our study, we expected to find three categories of answers; factors that have been 
established as risk factors for prostate cancer, factors that are unlikely to have an 
effect on prostate cancer risk, and factors with an inconsistent or unidentified effect 
that might provide potential leads for aetiological research.   
 
Factors that have been established as risk factors for prostate cancer 
Black race, old age, a positive family history, and several low-penetrance genetic 
markers have been established as risk factors for prostate cancer3, 4. Race was not 
mentioned by any of the patients, which is expected because 99% of the population in 
our study was Caucasian. Although age is established as a main risk factor for prostate 
cancer, this was mentioned by only few patients (n=5; 4%) in our study, which is 
consistent with previous studies11. Reasons for the small number of patients reporting 
age may be related to lack of knowledge, the open-ended question format, or to the 
perception of ‘old age’. Median age of our population was 68 years and many of the 
patients may not perceive themselves as ’old’. The patients (n=5) who did report age 
were indeed somewhat older than 68 years (namely 74-75 years), except for one 
patient of 62 years who was working in a medical profession.  
 
A positive family history is another main risk factor for prostate cancer18. Although 
causes related to heredity were the most frequently reported aetiological factors in 
our study (n=53, 37%), only 19% of the patients with a positive family history in the 
first degree reported this as a possible cause of their prostate cancer. This finding 
highlights the modest prostate cancer awareness. Patient education might 
theoretically stimulate adherence to screening programs and thus lead to early 
detection, improvement of prognosis and reduction of mortality. However, before 
such education programs can be implemented and optimized, it should be carefully 
considered whether these benefits balance the possible harms (i.e. complications of 
treatment, mental burden) of early detection and treatment, especially in the field of 
prostate cancer.   
 
Factors that are unlikely to have an effect on prostate cancer risk 
For several causes mentioned in our study there is no or only limited evidence that 
these factors increase prostate cancer risk3. Vasectomy, for example, was perceived as 
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a cause of prostate cancer among several patients. Although early studies suggested 
vasectomy as a risk factor for prostate cancer19, 20, other studies refuted this21, 22. We 
assume that patients remember the ‘old rumours’ (“Increased risk because of 
vasectomy, I have read that somewhere”) or that they associate prostate cancer with 
other disorders or procedures in the genitourinary system (“When I was 44 years of 
age, I had a vasectomy. Since then I had pain in that area during ejaculations”). From 
that perspective, it is reasonable that several patients also reported voiding problems 
(which might refer to benign prostate hyperplasia), prostatitis, or cycling as possible 
causes of their prostate cancer. However, for none of these factors there is consistent 
evidence that they increase the risk of prostate cancer3. Also smoking and alcohol 
intake were sometimes perceived as potential causes of prostate cancer. Since 
smoking and alcohol are common risk factors for other types of cancer and a variety of 
other diseases and conditions, it seems reasonable that patients link these factors to 
prostate cancer as well. 
 
Factors with an unknown or unidentified effect on prostate cancer risk  
Many of the suggested causes have not yet been extensively studied in relation to 
prostate cancer, or have shown inconsistent results in previous studies. In parallel with 
the study of Willcox et al.11, stress and stress-related causes such as burnouts, 
depression, and fatigue were reported by relatively many patients in our study. From 
either an epidemiological or biological perspective, the role of psychological stress in 
prostate cancer development has not been uniformly confirmed. The common 
hypothesis states that stress impairs immune function, which in turn may increase 
susceptibility to malignancies23. In-vitro studies showed that glucocorticoids, such as 
cortisone and cortisol, might activate a mutated androgen receptor and thereby 
stimulate androgen-independent growth of prostate cancer cells24. Whether 
physiological levels of glucocorticoids can promote growth of prostate cancer cells in-
vivo, and to what extent the mutated androgen receptors occur in prostate cancer 
patients need further investigation. Although psychological stress has been previously 
associated with risk of cervical cancer,25 lung cancer,26 and breast cancer,27 only few 
studies examined the relationship between stress and prostate cancer risk28, 29. 
Perceived stress was not associated with risk of prostate cancer in a case-control study 
among older men (65-79 years) from the United States29. A major limitation of this 
study, however, was the timing of exposure, which reflected only a one-year period 
before the reference date. A prospective cohort study from Denmark, did not find an 
association between self-reported stress level and prostate cancer risk either28. 
Although the prospective design was a major strength of this study, the measure of 
exposure was only based on two questions concerning stress intensity and frequency, 
rather than the more detailed Global Perceived Stress (GPS) scale30.  
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Concluding, psychological stress is perceived as a major cause of prostate cancer in 
patients recently diagnosed with this disease. We cannot rule out the possibility that 
patients perceived and reported high levels of stress as a consequence of their recent 
cancer diagnosis or treatment. Future prospective studies may include a psychological 
stress measurement in order to further evaluate the effects of stress on prostate 
cancer risk. Measures of stress should include both stressful life events and chronic 
stress as measured by an adequate method, wherever possible supported by reliable 
biomarkers, and reflecting a relevant timing of exposure.  
 
Limitations and strengths 
Prostate cancer is a multifactorial disease with a complex aetiology and different 
factors involved in development of non-aggressive and aggressive tumours. 
Identification of new risk factors for prostate cancer is therefore complicated. We 
realize that asking patients for perceived causes of their prostate cancer is not the 
most conventional strategy for aetiological research. However, the unique and 
individual responses of patients allow an explorative and creative way of thinking, 
which can provide directions for future research. The relatively small number of 
patients who provided a causal explanation should be considered in the interpretation 
of our findings. This small number, however, also indicates the current state of 
awareness among prostate cancer patients. Furthermore, causal explanations of 
patients might be somewhat biased by the design of the provided questionnaire. Since 
the open-ended question on the causes of the prostate cancer was the final question, 
previous questions on exposures to chemicals, smoking, physical activity, sun 
exposure, baldness, medical history or family history might have influenced thoughts 
of the patients. However, we assume that addressing these topics in the questionnaire 
did not discourage the patients from reporting new and unique causes. In addition, we 
did not observe a striking overrepresentation of the topics addressed in the 
questionnaire. The median time between diagnosis of prostate cancer and completion 
of the questionnaire was 26.9 months. We cannot rule out the possibility that patients 
changed their perception during this period of time. Strengths of our study are the 
population-based design and the open-ended question format, which gave the 
patients the opportunity to provide their own answers, without being led by suggested 
causal relationships from a prompted list.  
 
In conclusion, the results of this study show that only few patients were aware of any 
causal factors that might have contributed to the development of their prostate 
cancer. Established risk factors for prostate cancer were not commonly perceived, not 
even among patients with these risk factors. This finding might reflect the current state 
of knowledge on risk factors for prostate cancer and stresses the need for 
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development of effective education and prevention programs. Few unexpected or 
unidentified causes that could provide leads for further research were reported by the 
patients in this study. Nevertheless, some of the suggestions given by the patients, 
such as psychological stress, infections, a sedentary lifestyle, and specific 
environmental factors may warrant special attention, as there is still insufficient 
scientific evidence available for the possible role of these and many other factors in 
prostate carcinogenesis. Or as stated by one of the patients: “I can mention some 
things here, but science does not know the answer itself”. 
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Purpose It has been hypothesized that blood lipid levels might be associated with prostate cancer risk. The 
aim of the present study was to evaluate the association between serum total cholesterol, high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides and prostate cancer risk 
in a cohort study among 2842 Dutch men. 
Subjects and methods By the end of follow-up, 64 incident cases of prostate cancer were identified. Serum 
total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were evaluated as potential risk factors 
for prostate cancer using multivariable Cox proportional hazards regression models. These analyses were 
restricted to men who never used cholesterol-lowering drugs (2118 men, 43 cases). 
Results Higher total and higher LDL cholesterol were significantly associated with an increased risk of 
prostate cancer (hazards ratios (HR) and 95% confidence interval (CI) per mmol/L were 1.39 (95% CI 1.03–
1.88) and 1.42 (95% CI 1.00-2.02), respectively). Similar results were observed for aggressive prostate 
cancer, whereas for non-aggressive prostate cancer a significant association with HDL cholesterol was found 
(HR 4.28, 95% CI 1.17-15.67). 
Conclusion The results of this study suggest that blood lipid levels may influence risk of prostate cancer. 
However, the exact roles of different cholesterol fractions on prostate cancer aggressiveness should be 
further evaluated. 
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Introduction 
Epidemiological studies suggest that lipid profiles in blood are associated with risk of 
prostate cancer. Although some studies indicated that high serum triglycerides1, 2, low 
or high serum high-density lipoprotein (HDL) cholesterol3, 4, and high total3-8 or low-
density lipoprotein (LDL) cholesterol3, 4 might contribute to the development or 
progression of prostate cancer, overall results are relatively scarce and inconclusive. So 
far, few studies have assessed the relation between serum triglycerides and prostate 
cancer risk2, 9. A case-control study among 504 cases with prostate cancer and 565 
controls with benign prostatic hyperplasia (BPH) found a positive association between 
serum triglycerides and prostate cancer risk (odds ratio (OR) 1.15, 95% CI 1.00-1.32)2. A 
recent, prospective study based on 29,364 Norwegian men (687 incident cases), 
however, did not confirm an association between serum triglycerides and risk of 
incident or fatal prostate cancer9. 
 
Cholesterol has also been regarded as a potential risk factor for prostate cancer. 
Although two case-control studies have suggested that hypercholesterolemia increases 
the risk of prostate cancer3, 5, most prospective studies did not find any association9-15 
or suggested that risk of prostate cancer decreases with increasing cholesterol levels16, 
17. Recent studies were able to examine risk of clinical subtypes of prostate cancer in 
relation to cholesterol levels4, 6-8. An association between total cholesterol levels and 
risk of high-grade prostate cancer was consistently reported, whereas for total or low-
grade prostate cancer risk results were inconsistent4, 6-8. Supportive evidence for the 
potential role of cholesterol in prostate cancer development has been provided by 
observations that cholesterol-lowering drugs (3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors, commonly known as statins) might be inversely associated with 
risk of (advanced) prostate cancer4, 18-21. A meta-analysis by Bonovas et al.22 confirmed 
that use of statins lowers the risk of advanced prostate cancer (relative risk (RR) 0.77, 
95% CI 0.64-0.93); however, no effect for total prostate cancer risk was found (RR 0.95, 
95% CI 0.73-1.23). Others proposed that the cholesterol-lowering effects of statins 
might not be the only reason why these drugs are associated with a reduced risk of 
advanced prostate cancer22. Direct pro-apoptotic and anti-inflammatory effects of 
statins are suggested to inhibit the development or progression of prostate cancer 
independent of cholesterol23, 24. Furthermore, differences in PSA screening patterns 
between statin users and non-users might be responsible for the observed 
associations18, 22. As results are conflicting and underlying mechanisms have to be 
elucidated, further research is needed to evaluate the effects of cholesterol-lowering 
drugs on prostate cancer prevention, whereas studies on serum cholesterol and other 
blood lipids should confirm whether these blood lipids itself are potential risk factors 
for prostate cancer. 
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As described above, the relation between blood lipid profiles and prostate cancer risk 
has been previously investigated, but only few recent, prospective and population-
based studies have been reported4, 6-9. The aim of the present study was to address the 
association between serum cholesterol, triglycerides and prostate cancer risk in a 
prospective, population-based study from the Netherlands.  
 
Subjects and methods 
The Nijmegen Biomedical Study is a survey of the general population in which a 
random, age- and sex-stratified sample was recruited among adult inhabitants of 
Nijmegen, Lent and Oosterhout (eastern part of the Netherlands) between 2001 and 
2003. The study was approved by the Institutional Review Board, and all participants 
provided written informed consent. In total, 21,756 inhabitants received an invitation 
to participate in this study. Of these, 9350 (43%) subjects agreed to participate, and 
filled out a postal questionnaire on lifestyle and medical history at baseline. Majority of 
the participants (90%) were Caucasian. Furthermore, 6468 (69%) participants donated 
two non-fasting blood samples, which were collected in tubes containing heparin (8.5 
mL) or EDTA (8.5 mL). Blood samples were processed within two hours after 
withdrawal and aliquots of serum were stored at -40°C. All analyses of blood lipid 
profiles were performed between October 2004 and April 2005. Levels of serum total 
cholesterol, HDL cholesterol and triglycerides were analysed enzymatically using an 
Abbott Aeroset autoanalyser (Abbott Diagnostics, Hoofddorp, the Netherlands). Levels 
of LDL cholesterol were estimated using the Friedewald formula25. As the Friedewald 
formula appears to be accurate only up to triglyceride levels of 4.52 mmol/L25, we did 
not calculate LDL levels for participants with triglyceride levels above 4.52 mmol/L 
(n=132). 
 
All 3050 male participants of the Nijmegen Biomedical Study who provided blood 
samples were initially included in our analyses. Of these, 36 participants were excluded 
because they had a diagnosis of prostate cancer before blood withdrawal, 160 
participants were excluded because no blood lipid measurements were available, and 
another 12 participants were excluded because of incomplete follow-up data, leaving 
2842 cohort members for final analyses. Cases of incident prostate cancer (n=64) were 
identified through record linkage with the Dutch population-based cancer registry. 
Follow-up duration was defined as the day of blood withdrawal until date of death, 
emigration, prostate cancer diagnosis, or the end of follow-up (31 December, 2009), 
whichever came first. 
 
Information on age, height, weight, smoking status (current, former, never), history of 
hypertension (yes, no), history of diabetes mellitus (yes, no), and use of cholesterol-
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lowering drugs (current, former, never) were obtained from the self-reported 
questionnaires. For the prostate cancer cases, date of diagnosis, clinical and 
pathological stage (TNM based on the 2002 American Joint Committee on Cancer 
guidelines26), Gleason score (from biopsy or radical prostatectomy specimen) and PSA 
levels were obtained through the cancer registry, whenever available.  
 
Cox proportional hazards regression analysis was used to calculate hazard ratios (HR) 
and 95% confidence intervals (CI) for prostate cancer risk. In order to attenuate any 
distorting effect of cholesterol-lowering drugs, these analyses were restricted to men 
who never used cholesterol-lowering drugs (cohort n=2118, cases n=43). Age 
(continuous), body mass index (BMI) (continuous), and self-reported history of 
diabetes mellitus were included in the multivariable Cox model, because these factors 
were previously shown to be associated with prostate cancer risk27, 28 and substantially 
(>10%) affected the effect estimates in our analyses. Each blood lipid was evaluated 
individually as a continuous parameter (per mmol/L). Although the number of cases is 
relatively small, we aimed to repeat the analyses for non-aggressive and aggressive 
prostate cancer separately. Non-aggressive prostate cancer is defined as a clinical or 
pathological stage T1 or T2, no evidence of positive lymph nodes (N0, NX) or 
metastases (M0, MX), Gleason score <7 and prediagnostic PSA levels <20 ng/mL. 
Aggressive prostate cancer is defined as a clinical or pathological stage T3 or T4, N1, 
M1, Gleason score ≥7, or prediagnostic PSA levels ≥20 ng/mL. The Statistical Package 
of Social Sciences (SPSS, version 17.0, Chicago, Illinois) was used for all statistical 
analyses. 
 
Results 
Baseline characteristics of the participants are presented in Table 3.1. Among 2842 
participants, 64 incident prostate cancer cases were identified during a median 
(interquartile range) follow-up of 79.5 (IQR: 74.0-83.1) months. The median time 
between blood withdrawal and diagnosis of prostate cancer was 43.7 (IQR: 20.0-66.8) 
months. Cases were slightly older compared with cohort members. Median serum 
levels of total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides appear to 
be fairly similar among the cohort members and the prostate cancer cases. After 
exclusion of participants who reported former or current use of cholesterol-lowering 
drugs (n=416) or with missing data on use of cholesterol-lowering drugs (n=308), 2118 
cohort members and 43 cases were available for analyses. The participants who were 
excluded because of former or current use of cholesterol-lowering drugs (n=416) 
tended to be somewhat older, had a slightly higher BMI and lower total and LDL 
cholesterol levels and were more likely to have a history of smoking, diabetes or 
hypertension compared with the participants included in the analyses (data not 
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shown). Of the 43 cases included in the analyses, 15 had a tumour with Gleason score 
<7, 20 cases had a Gleason score ≥7 and 8 cases had no data available for Gleason 
score. Tumour stage T1 or T2 was diagnosed in 27 cases, while T3 or T4 was found in 
12 cases, and 4 cases had an unknown tumour stage. Furthermore, 6 cases had 
positive lymph nodes (N1), 7 patients had distant metastasis (M1), and 15 patients had 
PSA levels ≥20 ng/mL (data not shown).   
 
Table 3.1 Baseline characteristics of all cohort members and members with incident 
prostate cancer in a Dutch, population-based cohort study 
Median (interquartile range) or numbers (%) Total cohort Prostate cancer cases 
Number 2842 64 
Follow-up (months) 79.5 (74.0-83.1) 43.7 (20.0-66.8) 
Age (years) 62.0 (47.3-73.1) 70.8 (65.1-75.7) 
Height (cm) 178 (173-183) 175 (170-178) 
Weight (kg) 80 (73-88) 80 (71-84) 
BMI (kg/m2) 25.2 (23.4-27.5) 26.1 (24.0-27.7) 
Smoking (ever, %a) 2214 (78%) 54 (89%) 
Diabetes (yes, %a) 189 (8%) 6 (11%) 
Hypertension (yes, %a) 667 (26%) 20 (33%) 
Use of cholesterol-lowering drugs (ever, %a)    416 (16%) 14 (25%) 
Serum total cholesterol (mmol/L) 5.6 (4.9-6.3) 5.7 (5.0-6.8) 
Serum HDL cholesterol (mmol/L) 1.2 (1.0-1.4) 1.2 (1.0-1.4) 
Serum LDL cholesterol (mmol/L) 3.5 (2.9-4.1) 3.6 (2.9-4.5) 
Serum triglycerides (mmol/L)  2.0 (1.4-2.7) 1.8 (1.4-2.4) 
Abbreviations: BMI body mass index, HDL high-density lipoprotein, LDL low-density lipoprotein 
a Percentages are based on the number of cohort members and cases without missing values for these 
variables. Cohort members with missing values for smoking n=8, history of diabetes mellitus n=309, history 
of hypertension n=245, use of cholesterol lowering drugs n=308. 
 
As shown in Table 3.2, serum levels of total cholesterol (HR 1.39 per mmol/L, 95% CI 
1.03-1.88) and LDL cholesterol (HR 1.42 per mmol/L, 95% CI 1.00-2.02) were associated 
with an increased risk of total prostate cancer in the model adjusted for age, BMI and 
history of diabetes mellitus. Similar results were found for aggressive prostate cancer, 
which was positively associated with total cholesterol (HR 1.65 per mmol/L, 95% CI 
1.10-2.47) and LDL cholesterol (HR 1.83 per mmol/L, 95% CI 1.15-2.90). In contrast, 
non-aggressive prostate cancer risk seemed to be associated predominantly with HDL 
cholesterol (HR 4.28 per mmol/L, 95% CI 1.17-15.67) in this cohort. Levels of 
triglycerides did not statistically significantly influence prostate cancer risk. Inclusion of 
men who reported former, current or unknown use of cholesterol-lowering drugs 
resulted in lower effect estimates; none of the previously reported associations 
remained statistically significant. In order to exclude any possible reverse causal effect, 
we also excluded cohort members and cases with a follow-up less than 12 months.  
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Although HDL cholesterol was no longer statistically significantly associated with non-
aggressive prostate cancer risk (HR 3.03, 95% CI 0.73-12.51), this restriction did not 
substantially influence results for total cholesterol (HR for aggressive prostate cancer 
1.58, 95% CI 1.04-2.39) and LDL cholesterol (HR for aggressive prostate cancer 1.72, 
95% CI 1.06-2.77). 
 
Table 3.2 Cox proportional hazards regression models for prostate cancer incidence 
associated with blood lipid levels in a Dutch, population-based cohort study 
Modela  Age-adjusted  Multiple-adjustedc 
No. of 
cases 
HRb 95% CI  No. of 
cases 
HRb 95% CI 
Prostate cancer Cholesterol  
HDL cholesterol  
LDL cholesterold 
Triglycerides 
43 
43 
42 
43 
1.34 
1.82 
1.40 
0.87 
1.00-1.80 
0.79-4.23 
1.00-1.97 
0.65-1.18 
 41 
41 
40 
41 
1.39 
2.16 
1.42 
0.88 
1.03-1.88 
0.92-5.05 
1.00-2.02 
0.65-1.20 
Aggressive 
prostate cancere  
Cholesterol  
HDL cholesterol  
LDL cholesterold 
Triglycerides 
23 
23 
22 
23 
1.54 
1.41 
1.72 
0.89 
1.04-2.29 
0.43-4.68 
1.09-2.71 
0.59-1.33 
 22 
22 
21 
22 
1.65 
1.65 
1.83 
0.90 
1.10-2.47 
0.49-5.60 
1.15-2.90 
0.59-1.36 
Non-aggressive 
prostate cancerf 
Cholesterol  
HDL cholesterol  
LDL cholesterold 
Triglycerides 
16 
16 
16 
16 
1.32 
3.37 
1.31 
0.82 
0.82-2.13 
0.94-12.16 
0.76-2.27 
0.49-1.37 
 15 
15 
15 
15 
1.34 
4.28 
1.26 
0.84 
0.82-2.20 
1.17-15.67 
0.71-2.24 
0.50-1.42 
Abbreviations: CI confidence interval, HDL high-density lipoprotein, HR Hazard Ratio, LDL low-density lipoprotein 
a Restricted to men who never used cholesterol-lowering drugs (n=2118); b Hazards ratios per mmol/L; c Adjusted 
for age (continuous), BMI (continuous), and history of diabetes mellitus; d Restricted to men with triglyceride 
levels ≤ 4.52 mmol/L, n=2033; e Aggressive prostate cancer is defined as: clinical or pathological stage T3, T4, or 
N1, M1, or Gleason ≥7 or PSA ≥20 ng/mL; f Non-aggressive prostate cancer is defined as: clinical or pathological 
stage T1, T2, N0, M0, Gleason<7, and PSA <20 ng/mL. 
 
Discussion 
In this prospective, population-based study, we evaluated the association between 
blood lipid profiles and prostate cancer risk. We found that high levels of both total 
cholesterol and LDL cholesterol were associated with an increased risk of total and 
aggressive prostate cancer. In contrast, high levels of HDL cholesterol were associated 
with an increased risk of non-aggressive prostate cancer, while triglycerides were not 
statistically significantly associated with prostate cancer risk.  
 
It has previously been suggested that associations between blood lipid profiles and 
prostate cancer risk depend on the aggressiveness of the disease4, 6-8. Platz et al.6 
evaluated the association between plasma total cholesterol and prostate cancer risk in 
a case-control study nested in the Health Professionals Follow-Up Study. Low total 
cholesterol levels (in the bottom quartile) were not associated with total prostate 
cancer risk (OR 0.93, 95% CI 0.72-1.20), however, those participants with low total 
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cholesterol levels had a lower risk of high-grade prostate cancer (OR 0.61, 95% CI 0.39-
0.98)6. Subsequent prospective studies confirmed an association between levels of 
cholesterol and high-grade prostate cancer7, 8. Consistent with these results, we found 
a positive association between total cholesterol and aggressive prostate cancer risk. 
Next to aggressive disease, however, we also observed a modest association for total 
prostate cancer risk. Farwell et al.4 presented similar findings from a retrospective 
cohort study in which total cholesterol was associated with total and high-grade 
prostate cancer risk. 
 
The findings from our study suggest that increased levels of serum LDL cholesterol 
might be positively associated with total or aggressive prostate cancer risk. Studies 
focussing on the association between levels of LDL cholesterol and prostate cancer risk 
are relatively scarce. A hospital-based, case-control study suggested that high levels of 
LDL cholesterol (OR 1.60, 95% CI 1.09-2.34), but also total cholesterol (OR 1.58, 95% CI 
1.11-2.24) and low levels of HDL cholesterol (OR 1.57, 95% CI 1.04-2.36), increase the 
risk of prostate cancer3. In the cohort of Farwell et al., LDL cholesterol in the highest 
quartiles was statistically significantly associated with total and high-grade prostate 
cancer4. Our results with respect to LDL cholesterol need to be interpreted with some 
caution, as non-fasting blood samples were used. The Friedewald formula for 
calculating levels of LDL cholesterol is based on the assumption that total cholesterol 
minus HDL and very-low-density lipoprotein (VLDL) cholesterol equals LDL 
cholesterol25. This method requires measurements of total cholesterol, HDL 
cholesterol and triglycerides (as a proxy for VLDL cholesterol) levels25. Using non-
fasting samples might result in high levels of triglycerides, a subsequent 
overestimation of VLDL cholesterol and therefore might underestimate levels of LDL 
cholesterol29. In our cohort, 132 cohort members had non-fasting triglyceride levels 
above 4.52 mmol/L, which is suggested as the upper level for accurate Friedewald 
calculations25. For these 132 cohort members, we did not calculate levels of LDL 
cholesterol. Nevertheless, use of the Friedewald formula for non-fasting blood samples 
remains controversial30, 31. Although we assume that the non-fasting state is not 
different between men who later develop prostate cancer and men who do not, its 
possible role as source of bias should be considered when interpreting the results. 
Most likely, a non-differential underestimation of LDL cholesterol might result in a bias 
towards the null, i.e. an underestimation of the hazards ratios for LDL cholesterol. 
 
In contrast to total cholesterol and LDL cholesterol, the effects of HDL cholesterol were 
most pronounced for non-aggressive prostate cancer, that is, the results suggest that 
men with high levels of HDL cholesterol are at increased risk of developing non-
aggressive prostate cancer. Similar findings were presented by Farwell et al., who 
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described a statistically significant association between HDL cholesterol (as continuous 
measure) and total and low-grade prostate cancer, whereas for high-grade prostate 
cancer the association did not reach statistical significance. However, detailed analyses 
with quartiles of HDL cholesterol did show statistically significant associations with 
high-grade prostate cancer risk4. Other studies on HDL cholesterol and prostate cancer 
risk are inconclusive. Hammersten et al.1 evaluated features of the metabolic 
syndrome among 299 patients recently diagnosed with prostate cancer. Subjects with 
poorly differentiated prostate cancer had lower HDL cholesterol levels and higher 
triglyceride levels compared with those with well differentiated disease1. A hospital-
based, case-control study found a statistically significant association between low 
levels of HDL cholesterol and total prostate cancer risk3. Large prospective studies, 
however, did not consistently confirm an association between HDL cholesterol and 
localized, advanced, or total prostate cancer risk9, 15. Our findings might be explained 
by several factors. First, high levels of HDL cholesterol may be associated with a 
healthy lifestyle32. In theory, participants with a healthy lifestyle, and consequently 
high HDL levels, may on average be more health conscious and may have consulted 
their physicians for periodic PSA testing. As a result, more early-stage prostate cancers 
might have been diagnosed among these men compared with other men in the cohort. 
Second, the positive association between HDL cholesterol and non-aggressive prostate 
cancer may be a chance finding, resulting from the relatively small number of cases.  
 
The mechanisms underlying the possible association between blood lipid profiles and 
prostate cancer risk are poorly understood, but are possibly related to signalling 
functions of cholesterol. Cholesterol is incorporated into moving platforms in the fluid 
bilayer of cellular membranes, which are referred to as lipid rafts33. As reviewed by 
others34-36, these lipid rafts might have an important role in cell signalling (such as the 
EGFR/Akt137 or IL6/STAT338 pathways) and could thereby act on growth and survival of 
prostate cancer cells37, 38. Future experiments focusing on lipid rafts should elucidate 
these and other signalling networks and their effects with respect to prostate cancer 
development or progression. Another hypothesis is based on the theory of 
steroidogenesis, which postulates that prostate cancer cells itself might be able to 
produce androgens which can bind to the androgen receptor and stimulate growth 
and survival39. It has recently been shown that prostate cancer cells in advanced stages 
can synthesize androgens directly from cholesterol40. These findings might explain the 
suggested association between serum cholesterol levels and risk of aggressive forms of 
prostate cancer. Future studies are needed to confirm the exact role of cholesterol and 
other blood lipids in the development and progression of prostate cancer.  
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Unfortunately, because of the relatively small number of cases in our cohort, we were 
not able to perform extensive analyses based on different tumour characteristics such 
as Gleason grade or tumour stage. Instead we used a rather arbitrary, combined 
definition of prostate cancer aggressiveness. It should be noted that only 69% of the 
participants of the Nijmegen Biomedical Study was willing to provide blood samples. 
Although we aimed at recruiting a random, population-based sample, we cannot 
exclude the possibility that only specific subgroups of participants agreed to provide 
blood samples. Although this selection is not an issue for the validity of the study, in 
theory, it may be so for the generalizability. Other potential limitations of the present 
study were the non-fasting blood samples as discussed previously, the relatively short 
follow-up (median 79.5 months) and the incapability to adjust for other potential 
confounders such as family history or socioeconomic status. Strengths of this study are 
the prospective design and the analyses of several blood lipid fractions in blood 
samples from a population-based cohort. 
 
In conclusion, this study provides further evidence that blood lipid levels are 
associated with prostate cancer risk. Furthermore, our results suggest that different 
fractions of cholesterol are involved in aggressive and non-aggressive prostate cancer. 
The associations between the different fractions of cholesterol and clinical sub-types 
of prostate cancer warrant confirmation in larger, prospective studies.   
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Purpose In parallel with increasing numbers of cancer patients and improving cancer survival, the occurrence 
of second primary cancers becomes a relevant issue. The aim of our study was to evaluate risk of prostate 
cancer as second primary cancer in a population-based setting.  
Subjects and methods Data from the Netherlands Cancer Registry were used to estimate standardized 
incidence ratios (SIRs) and 95% confidence intervals (CIs) for prostate cancer as second primary cancer. The 
effect of time since first cancer diagnosis, specific first cancer sites, age, and pelvic radiotherapy was taken 
into account.  
Results Out of 551,553 male patients diagnosed with a first primary cancer between 1989-2008, 9,243 
patients were subsequently diagnosed with prostate cancer. Overall, cancer survivors showed an increased 
risk (SIR 1.3, 95% CI 1.2-1.3) of prostate cancer. The increased prostate cancer risk was limited to the first 
year of follow-up for the majority of the specific first cancer sites. More than ten years after the first cancer 
diagnosis, only melanoma patients were at increased risk (SIR 1.5, 95% CI 1.2-1.9), while patients with head 
or neck cancers were at decreased risk (SIR 0.7, 95% CI 0.5-0.9) of being diagnosed with prostate cancer. 
Patients treated with primary pelvic radiotherapy for their first cancer had a decreased risk of prostate 
cancer in the long term (SIR 0.5, 95% CI 0.4-0.6).  
Conclusion Our data showed that cancer survivors have an increased prostate cancer risk in the first year 
following a first cancer diagnosis, which is most likely the result of active screening or incidental detection. 
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Introduction 
The number of patients newly diagnosed with cancer increased substantially during 
the past decades and this trend is expected to continue in the coming years1, 2. At the 
same time, survival for most cancer sites improved by early detection and more 
effective treatment strategies3, 4. As a growing number of patients survive their first 
cancer, the occurrence of second primary cancers becomes a relevant issue5. Prostate 
cancer is the most common cancer among elderly men in Western countries2, 6. The 
incidence of prostate cancer as second primary cancer is likely to increase as a 
consequence of demographic aging and increased diagnostic activities, combined with 
the improved cancer survival7. Risk of prostate cancer among cancer survivors might 
also depend on various clinical as well as biological factors. It has been suggested that 
initial cancer treatment might influence subsequent cancer risk. As such, pelvic 
radiotherapy for a first cancer has been associated with a reduced prostate cancer risk 
as compared to non-irradiated patients or the general population8-11. Furthermore, 
incidental detection in surgical specimens or intensive screening after a previous 
cancer diagnosis might also influence prostate cancer risk. Likewise, the detection of 
prostate tumours in cystoprostatectomy specimens12 is therefore a plausible 
explanation for the reported co-occurrence of bladder cancer and prostate cancer13, 14. 
Finally, common aetiological factors, such as genetic susceptibility or shared 
environmental factors, might explain an association between prostate cancer and 
other malignancies. 
 
Insight into the occurrence of prostate cancer as second primary cancer may yield 
important implications for aetiological research. Several studies have addressed the 
relevance of prostate cancer as a second cancer. Most of these studies, however, were 
limited to specific first cancer sites13, 15-17 or focussed on treatment effects8, 9, 11 or 
family history of the first cancer18 in particular. The aim of the present study was to 
evaluate the risk of prostate cancer as second primary cancer in a population-based 
setting while taking into account the first cancer sites and time since first cancer 
diagnosis. This approach allowed us to compare prostate cancer risk among different 
first cancer sites and to evaluate the possible effects of detection and treatment.  
 
Subjects and methods 
Male patients diagnosed with a first primary cancer between 1989 and 2008 were 
identified through the nationwide, population-based Netherlands Cancer Registry19. 
The analyses were restricted to primary cancers as defined by the International Agency 
for Research on Cancer (IARC)20. Non-invasive cancers, except from bladder cancer 
because of its common non-invasive character, were excluded from all analyses. 
Patients with a first and second primary cancer diagnosed on the same day, and 
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patients diagnosed with cancer found during autopsy were not included in the 
analyses. Furthermore, patients with a first primary prostate cancer were excluded, 
resulting in a study population of 551,553 male cancer patients.  
 
Follow-up duration was defined as the time between date of first primary cancer 
diagnosis until date of death, emigration, diagnosis of prostate cancer as second 
primary cancer, diagnosis of any (other than prostate cancer) second primary cancer, 
or end of follow-up (1st of January 2009), whichever came first. Information on death 
and emigration were obtained from the municipal registries and since 1995 from the 
Dutch Municipal Personal Records Database which keeps information about vital 
status of all inhabitants in the Netherlands. Information on primary cancer treatment 
was recorded from the medical charts. Clinical tumour stages were grouped into six 
categories (0, I, II, III, IV and other/unknown) according to the fourth (tumours 
diagnosed before 1999), fifth (tumours diagnosed between 1999 and 2002) or sixth 
(tumours diagnosed after 2002) edition of the American Joint Committee on Cancer 
guidelines (AJCC).  
 
Standardized incidence ratios (SIRs) were estimated to compare incidence rates of 
prostate cancer as a second cancer in the study population versus incidence rates of 
prostate cancer in the general Dutch population. The SIR was calculated as the number 
of observed patients with prostate cancer as a second cancer divided by the number of 
expected patients. The number of expected patients with prostate cancer was 
estimated by multiplying age- and calendar period-specific incidence rates (5-year age 
and 1-calendar year groups, respectively) in the general Dutch population by the 
number of person-years at risk. The 95% confidence intervals (CIs) were calculated 
assuming a Poisson distribution for the observed number of prostate cancers. Absolute 
excess risks (AERs) were calculated to estimate the excess burden of the prostate 
cancers occurring as second cancer. The AER (expressed per 10,000 person-years) was 
calculated by subtracting the number of expected patients from the number of 
observed patients in the study population and subsequently divided by the person-
years at risk. Analyses were presented according to the time since first cancer 
diagnosis, the first cancer site or age of the patients at first cancer diagnosis. In 
addition to estimates for all cancer sites together, results were provided for all sites 
excluding bladder cancer in order to take into account possible distorting effects of 
early and incidental detection of prostate tumours in cystoprostatectomy specimens.  
 
In order to assess the effect of radiotherapy on the subsequent prostate cancer risk, 
we computed SIRs for patients treated with or without pelvic radiotherapy. Pelvic 
radiotherapy was defined as primary radiotherapy for one of the following first 
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primary cancers: sigmoid colon, rectum, anus and anal canal, penis, testis, other male 
genital organs, renal pelvis, ureter, and other urinary tract. Patients with bladder 
cancer were not included in this analysis, because most patients who were not treated 
with pelvic radiotherapy were likely to undergo radical cystoprostatectomy and were 
therefore not at risk of developing prostate cancer in the long term. The subgroup 
analysis for patients treated without pelvic radiotherapy comprised all patients 
diagnosed with the aforementioned tumours located in the pelvic area (without 
bladder cancer), who were not treated with primary radiotherapy. SAS software 
(version 9.3, SAS Institute, Cary, North Carolina) was used for all analyses.  
 
Results 
The study population includes 551,553 male cancer patients diagnosed with a first 
primary cancer between 1989 and 2008. Of these, 9,243 patients subsequently 
developed prostate cancer after a median follow-up of 2.3 years (range: 1 day to 19 
years). The median age (interquartile range (IQR)) of these patients was 70 years (64-
76) at the time of first cancer diagnosis (Table 4.1). Clinical tumour stages of the 
prostate cancers occurring as second cancer were compared to clinical stages of first 
prostate cancers diagnosed in the general Dutch population in the same period (Figure 
4.1). Overall, stage III and IV tumours were somewhat less common for subsequent 
prostate cancers (especially in the period 1989-1998) as compared to first prostate 
cancers, while the opposite was observed for unknown tumour stages. Also for 
subsequent prostate cancers diagnosed more recently (2004-2008), a larger 
percentage of unknown tumour stages was found, while especially stage II tumours 
tended to be less common in comparison to first prostate cancers.  
 
The risk of prostate cancer as second primary cancer according to first cancer site and 
years since first cancer diagnosis is presented in Table 4.2. Overall, cancer survivors 
showed an increased risk (SIR 1.3, 95% CI 1.2-1.3) of being diagnosed with prostate 
cancer as compared to the general Dutch population. This effect was mainly observed 
shortly (0-1 year) after the first cancer diagnosis (SIR 2.1, 95% CI 2.0-2.2). The 
increased prostate cancer risk in the first year following the first cancer diagnosis was 
also shown for several specific cancer sites. The corresponding SIRs ranged from 1.3 
(95% CI 1.1-1.5) for cancers in the digestive tract (without colorectal cancer) up to 9.2 
(95% CI 8.7-9.8) for invasive bladder cancer. These effects disappeared after one year 
of follow-up for most of the specific cancer sites. Contrary, for patients with skin 
cancer as first primary cancer, an increased prostate cancer risk was mainly observed 
after one year since first cancer diagnosis. These effects were most pronounced for 
melanoma skin cancer. Prostate cancer risk was reduced in patients diagnosed with 
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head or neck cancer. This effect was observed ten years since first cancer diagnosis in 
particular (SIR 0.7, 95% CI 0.5-0.9).  
 
Table 4.1 Characteristics of patients diagnosed with or without prostate cancer as second 
primary cancer after a first primary cancer diagnosis between 1989 and 2008 in the Netherlands 
 Patients who were not 
diagnosed with prostate 
cancer as second primary 
cancer (n=542,310) 
Patients who were 
diagnosed with prostate 
cancer as second primary 
cancer (n=9,243) 
Age at first cancer diagnosis  
      Median (interquartile range, in years) 
      < 50 years 
      50-74 years 
      75+ years 
 
68 (58-75) 
71,116 (13%) 
327,929 (60%) 
143,265 (26%) 
 
70 (64-76) 
167 (2%) 
6338 (69%) 
2738 (30%) 
Period of first cancer diagnosis  
      1989-1993 
      1994-1998 
      1999-2003 
      2004-2008 
 
124,057 (23%) 
128,434 (24%) 
135,556 (25%) 
154,263 (28%) 
 
2717 (29%) 
2694 (29%) 
2316 (25%) 
1516 (16%) 
Time at riska  
      Median (interquartile range, in years) 
      < 1 year 
      1-10 years 
      10+ years 
 
1.3 (0.3-4.5) 
241,149 (44%) 
248,943 (46%) 
52,218 (10%) 
 
2.3 (0.3-5.9) 
3386 (37%) 
4946 (54%) 
911 (10%) 
Pelvic radiotherapy for first primary cancerb  
      Yes 
      No    
 
18,218 (27%) 
49,823 (73%) 
 
202 (16%) 
1096 (84%) 
a Time at risk is defined as the time between date of first primary cancer diagnosis until date of death, 
emigration diagnosis of any (other than prostate cancer) second primary cancer, or end of follow-up (1st of 
January 2009), whichever came first. For patients with prostate cancer as a second primary cancer, time at 
risk is defined as the time between their first and second primary cancer diagnosis. b Restricted to patients 
with first primary cancers of the: sigmoid colon, rectum, anus and anal canal, penis, testis, other male genital 
organs, renal pelvis, ureter, and other urinary tract (without bladder cancer). 
 
The analyses stratified by age at first cancer diagnosis further confirmed that cancer 
survivors had an increased prostate cancer risk mainly during the first year following 
first cancer diagnosis (Table 4.3). This finding applies to all age groups, although a 
more pronounced effect was found for patients who were diagnosed with a first 
cancer at a relatively young (<50 years) age (SIR 12, 95% CI 8.0-17).  
 
As shown in Table 4.3, both patients treated with or without pelvic radiotherapy for 
their first primary cancer had an increased risk of prostate cancer during the first year 
following first cancer diagnosis. Patients treated with pelvic radiotherapy, however, 
showed a decreased prostate cancer risk in the long term (SIR 0.5, 95% CI 0.4-0.6 and 
SIR 0.6, 95% CI 0.3-0.98, for 1-10 and 10+ years after first cancer diagnosis, 
respectively). 
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Figure 4.1 Clinical stage distribution of prostate cancer diagnosed as a first primary cancer (from 
the general population) and as a second primary cancer (among previously diagnosed cancer 
patients) in the Netherlands between 1989 and 2008 according to period of prostate cancer 
diagnosis. 
 
Discussion 
Overall, our study showed a 30% increased risk of prostate cancer among Dutch cancer 
survivors in the first year of follow-up, whereas in the long term prostate cancer risk 
did not differ from risk in the general Dutch population.  
 
An increased prostate cancer risk shortly after a first cancer diagnosis strongly suggests 
an effect of active screening or incidental detection, resulting from either an increased 
awareness or anxiety of the patient, or active medical surveillance indicated by the 
supervising specialist. It has been shown that incidental prostate cancers are 
frequently detected in cystoprostatectomy specimens12, 21. Furthermore, urological 
patients in particular might request their urologists for PSA testing as a consequence of 
anxiety or persisting urological complaints. In these situations, the prostate cancer 
stage distribution would presumably be more favourable in comparison to prostate 
cancer detected among the general Dutch population. Concurrently, our data showed 
that unfavourable tumour stages (III and IV) were less common in patients with 
prostate cancer diagnosed as a second rather than a first primary cancer. The larger 
percentage of prostate cancers with an unknown tumour stage might indicate that 
staging is considered less important or is less accurate in patients with prostate cancer 
diagnosed as a second cancer.   
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As expected, the risk of prostate cancer was reduced 1-10 years after an invasive 
bladder cancer diagnosis, probably because the patients who underwent a 
cystoprostatectomy were no longer at risk of developing prostate cancer. Notably, this 
finding was not applicable to patients with non-invasive bladder cancer, whose 
increased prostate cancer risk persisted up to ten years following diagnosis. The more 
expectant treatment strategy which is often applied to these patients may have 
resulted in prolonged detection effects.  
 
For patients with a previous diagnosis of melanoma as well as non-melanoma skin 
cancer, an increased prostate cancer risk was mainly found during later years of follow-
up. Contrary to our findings, a previous study with data from one of the regional 
cancer registries in the Netherlands showed that patients with (non-melanoma) skin 
cancer had a reduced risk of prostate cancer22. It was hypothesized that patients with 
skin cancer might have relatively high levels of vitamin D as a consequence of sun 
exposure, which may protect them against the development of prostate cancer22. 
Several other studies, however, did not confirm these findings23, or showed an 
increased prostate cancer risk following  a skin cancer diagnosis17, 24. Focusing on 
melanoma, data from the Surveillance, Epidemiology, and End Results (SEER) program 
showed an increased prostate cancer risk up to ten years following melanoma 
diagnosis25, 26, which is consistent with our findings. Possible explanations for the 
increased prostate cancer risk in melanoma patients might refer to shared 
environmental or genetic aspects. A recent study demonstrated that at least two 
prostate cancer risk alleles were associated with an increased risk of melanoma in 
prostate cancer patients (rs1512268, odds ratio (OR) 3.9, 95% CI 1.4-10.9 and 
rs5759167 OR 2.6, 95% CI 1.2-5.6)27. We cannot fully exclude the possibility that 
increased awareness and screening also contributed to the excess of prostate cancer in 
melanoma patients, although the lack of an effect during the first year of follow-up 
argues against this.  
 
We observed a reduced risk of prostate cancer, especially after a follow-up period of 
more than ten years, among patients who were diagnosed with a head or neck cancer. 
The possible mechanisms for the reduced prostate cancer risk in these patients are 
unclear. So far, there is no indication that the main established risk factors for head 
and neck cancers, such as smoking, alcohol intake, and infections with the human 
papillomavirus28 are likely to protect against the development of prostate cancer. 
Future studies should focus on the possible associations between prostate cancer and 
different specific tumours in the head and neck region as well as the possible 
underlying mechanisms. 
 
  
 Table 4.2 Risk of prostate cancer as a second primary cancer according to first cancer site and time since first cancer diagnosis 
Abbreviations: AER absolute excess risk per 10,000 person-years, CI confidence intervals, Obs. number of observed cases, PY person-years, SIR standardized incidence ratio.   
a All invasive primary cancer sites, excluding prostate cancer and including non-invasive bladder cancer. b All primary cancer sites, excluding prostate cancer, invasive bladder cancer and non-
invasive bladder cancer. c Basal cell carcinomas were not included. d Restricted to patients with first primary cancers of the: sigmoid colon, rectum, anus and anal canal, penis, testis, other male 
genital organs, renal pelvis, ureter, and other urinary tract (without bladder cancer). 
Time since first cancer diagnosis (years) 
   0-1     1-10     10+  
First cancer site PY at risk Obs. SIR (95% CI) AER  PY at risk Obs. SIR (95% CI) AER  PY at risk Obs. SIR (95% CI) AER 
All sitesa 392,642 3388 2.1 (2.0-2.2) 45  1200,526 4945 1.0 (0.98-1.0) 0.2  203,319 910 1.1 (0.99-1.1) 2 
All sites without bladder cancerb 342,395 2003 1.5 (1.4-1.5) 19  998,673 3872 1.0 (0.96-1.0) -0.2  169,079 713 1.1 (0.99-1.1) 3 
Invasive bladder 23,166 1090 9.2 (8.7-9.8) 419  76,628 361 0.9 (0.8-0.98) -6  12,156 64 0.9 (0.7-1.1) -6 
Non-invasive bladder 27,078 295 2.4 (2.1-2.6) 63  125,226 712 1.2 (1.1-1.2) 8  22,084 133 1.1 (0.9-1.3) 6 
Renal pelvis & ureter 1921 16 1.8 (1.0-2.9) 36  4785 28 1.2 (0.8-1.7) 9  727 5 1.3 (0.4-2.9) 14 
Other urinary tract 207 8 7.3 (3.1-14) 333  536 2 0.7 (0.08-2.5) -16  106 0 0 (0-5.8) -60 
Penis, testis & other male genital organs 10,872 11 1.2 (0.6-2.1) 1  59,997 51 1.1 (0.8-1.4) 1  16,640 18 1.1 (0.7-1.8) 1 
Kidney 11,904 124 3.0 (2.5-3.5) 69  41,997 232 1.4 (1.3-1.6) 17  7555 39 1.1 (0.8-1.5) 6 
Colorectal 66,093 521 1.7 (1.6-1.8) 32  221,187 1053 0.9 (0.9-1.01) -3  33,453 196 1.1 (0.9-1.2) 3 
Digestive tract without colorectal 34,328 195 1.3 (1.1-1.5) 13  50,522 203 0.9 (0.8-1.05) -4  6969 40 1.1 (0.8-1.5) 6 
Male Breast 1021 11 2.6 (1.3-4.6) 66  4113 17 0.9 (0.5-1.5) -4  606 3 1.0 (0.2-2.8) -2 
Skin (non-melanoma)c 33,254 175 0.9 (0.8-1.1) -3  132,240 792 1.1 (1.003-1.2) 4  19,510 126 1.2 (0.97-1.4) 9 
Melanoma 18,160 49 1.2 (0.9-1.6) 5  78,968 256 1.4 (1.3-1.6) 10  16,455 69 1.5 (1.2-1.9) 14 
Lung, bronchus & trachea 71,739 458 1.4 (1.3-1.5) 18  96,178 390 0.8 (0.8-0.9) -8  11,289 70 1.1 (0.8-1.4) 5 
Head or neck 25,069 73 0.9 (0.7-1.1) -5  93,491 332 0.9 (0.8-1.001) -4  16,062 53 0.7 (0.5-0.9) -17 
Eye & adnexa 1450 8 1.9 (0.8-3.8) 26  6194 19 1.1 (0.6-1.7) 2  1397 5 1.2 (0.4-2.7) 5 
Haematolymphopoetic 43,146 229 1.6 (1.4-1.8) 20  149,260 399 0.9 (0.8-1.004) -3  25,296 62 1.0 (0.8-1.3) -0.3 
Bone, joint & soft tissue 6637 18 1.5 (0.9-2.3) 9  25,862 55 1.1 (0.9-1.5) 3  6365 14 1.1 (0.6-1.8) 1 
Central nervous system 6772 13 1.2 (0.6-2.1) 3  15,532 10 0.9 (0.4-1.6) -1  3139 1 0.3 (0.004-1.7) -7 
Endocrine glands 2096 6 1.7 (0.6-3.7) 11  9954 11 0.7 (0.3-1.2) -5  2611 8 1.6 (0.7-3.2) 12 
Primary site unknown 7247 88 2.8 (2.3-3.5) 78  6426 17 0.7 (0.4-1.1) -12  659 3 1.0 (0.2-3.0) 1 
Other (e.g. thymus) 472 0 0 (0-2.5) -31  1396 5 1.3 (0.4-3.1) 9  224 1 1.3 (0.02-7.0) 9 
  
Table 4.3 Risk of prostate cancer as a second primary cancer according to age at first cancer diagnosis, treatment  
and time since first cancer diagnosis 
 
Time since first cancer diagnosis (years) 
   0-1     1-10     10+  
 PY at risk Obs. SIR (95% CI) AER  PY at risk Obs. SIR (95% CI) AER  PY at risk Obs. SIR (95% CI) AER 
               
Age at first cancer diagnosis (years)             
   < 50 61,121 27 12 (8.0-17) 4  280,993 54 1.2 (0.9-1.6) 0.4  79,658 86 1.2 (0.9-1.5) 2 
   50-74 241,611 1989 2.2 (2.1-2.3) 45  732,833 3584 1.0 (0.998-1.07) 1  115,057 765 1.0 (0.96-1.1) 2 
   75+ 89,910 1372 1.9 (1.8-2.0) 73  186,701 1307 0.9 (0.9-0.98) -5  8604 59 1.3 (0.97-1.6) 15 
Pelvic radiotherapy for first primary cancera              
   Yes 16,294 104 1.9 (1.6-2.3) 31  56,558 82 0.5 (0.4-0.6) -17  9381 16 0.6 (0.3-0.98) -11 
   No 41,460 305 1.8 (1.6-2.0) 33  159,662 653 1.0 (0.9-1.1) 0  30,045 138 1.2 (0.97-1.4) 6 
 
Abbreviations: AER absolute excess risk per 10,000 person-years, CI confidence intervals, Obs. number of observed cases, PY person-years, SIR standardized incidence ratio. a Restricted to patients 
with first primary cancers of the: sigmoid colon, rectum, anus and anal canal, penis, testis, other male genital organs, renal pelvis, ureter, and other urinary tract (without bladder cancer). 
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Consistent with previous literature8-11, we showed an overall reduced prostate cancer 
risk following primary pelvic radiotherapy. Nevertheless, for the first year of follow-up, 
the subsequent prostate cancer risk was increased among patients who received pelvic 
radiotherapy. Similar findings were observed for patients who did not receive pelvic 
radiotherapy, suggesting once more the effects of detection. A possible explanation for 
the consistently reported reduced prostate cancer risk following pelvic radiotherapy 
might be that early and indolent prostate tumours are suppressed by the irradiation 
exposure. Another hypothesis9, 10 refers to the possibility that radiotherapy initially 
increases, but in the long term lowers PSA production29, 30. In theory, the incidence of 
screen-detected prostate cancers would then, due to masked PSA levels, be lower as 
compared to non-irradiated patients. As a consequence, the prostate tumours in 
irradiated patients are detected later, and hence are more advanced or high-grade as 
compared to tumours in non-irradiated patients9. Others, however, did not find an 
effect of previous pelvic radiotherapy on prostate cancer stage or grade10, neither on 
the decline in PSA levels after irradiation of the non-malignant prostate31. We did not 
compare clinical tumour stages for patients treated with or without pelvic 
radiotherapy, because we cannot exclude the possibility that period-specific changes in 
treatment regimens during our extended follow-up period (1989-2008) will account for 
possible differences between these two groups.  
 
Strengths of our study include the comprehensive approach, which allows a 
simultaneous evaluation of all specific first cancers sites in relation to subsequent 
prostate cancer risk during a long follow-up period. Furthermore, we used population-
based data of a high-quality cancer registry with a large number of first and second 
cancer patients. Possible limitations of our study are the relatively small number of 
patients in some of the subgroup analyses and the limited data on delayed or 
secondary cancer treatment. As a consequence, patients who were classified as ‘not 
having pelvic radiotherapy’ in the subgroup analyses, might still have undergone pelvic 
radiotherapy as secondary therapy32. Although this limitation might have influenced 
the risk estimates for this subgroup, it is not likely to bias the findings for the subgroup 
of patients who were classified as ‘having pelvic radiotherapy’.       
 
In conclusion, our data showed that cancer survivors have an increased risk of being 
diagnosed with prostate cancer as a second primary cancer. The effects were mostly 
restricted to the first year following the first cancer diagnosis, which might implicate 
an effect of active screening or incidental detection.  
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Purpose To determine the effect of body mass index (BMI) on clinical and pathological characteristics at time 
of diagnosis and on risk of biochemical recurrence after radical prostatectomy among Dutch men diagnosed 
with prostate cancer.  
Subjects and methods In total, 1,116 prostate cancer patients with known BMI, diagnosed between 2003 
and 2006, were identified from the population-based cancer registry held by the Comprehensive Cancer 
Centre East, The Netherlands. Of these, 504 patients underwent a radical prostatectomy. Patients were 
categorized as normal weight (BMI < 25 kg/m2), overweight (BMI 25–30 kg/m2), or obese (BMI ≥ 30 kg/m2). 
Multivariable proportional hazards regression models, adjusted for age, prediagnostic PSA levels, and 
pathological characteristics were used to evaluate BMI as a prognostic factor for biochemical recurrence 
after radical prostatectomy.  
Results Overall, clinical and biopsy characteristics did not significantly differ among BMI groups. Pathological 
characteristics after radical prostatectomy did not significantly differ among BMI groups, except for tumor 
stage, which was highest in obese patients (P = 0.017). For patients treated with radical prostatectomy, 5-
year risk (95% confidence intervals) of biochemical recurrence was 30% (23–37%) for normal weight, 32% 
(25–39%) for overweight, and 25% (9–41%) for obese patients (log rank P = 0.810). BMI was not an 
independent prognostic factor for biochemical recurrence in multivariable proportional hazards regression 
analyses (hazard ratio 0.99 per kg/m2, 95% CI: 0.93–1.06).  
Conclusion Compared with non-obese men, pathological tumor stage tended to be higher in obese men. 
Clinical relevance of this finding is unclear, because BMI was not an independent predictor of biochemical 
recurrence after radical prostatectomy.  
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Introduction 
It has been hypothesized that obesity is a risk factor for the development and 
progression of prostate cancer (PC), although results are inconsistent. Most studies 
focusing on body size and PC were conducted in the United States, where a rapidly 
growing epidemic of obesity is reported with over 66% of adult Americans being 
overweight or obese1. In Europe, incidence of overweight and obesity is also increasing 
substantially2. Whether body size predisposes to adverse PC characteristics or 
outcome in European men is a matter of debate. Only few European studies examined 
effects of body mass index (BMI) on adverse pathological findings after biopsy or 
radical prostatectomy (RP)3-6. Gallina and colleagues suggested that high-grade PC at 
RP might be more prevalent among obese men; however, adding BMI to the 
multivariable model failed to increase predictive accuracy for high-grade PC6. Other 
studies did not find an association for BMI and tumor grade or stage, extracapsular 
extension, seminal vesicle invasion, lymph node involvement or positive surgical 
margins either3-5. Results for PC outcome are inconclusive as well. One study from 
Germany reported BMI as independent predictor of biochemical recurrence (BCR) 
after RP, although it did not improve predictive accuracy7, while we and others did not 
find any effect of BMI on BCR rates after RP5, 8 or brachytherapy9.  
 
Since results are conflicting and the epidemic of obesity is growing, additional evidence 
on the effects of body size on PC risk and prognosis in Europe are needed. Aim of the 
present study was to determine effects of BMI on clinical and pathological findings at 
time of diagnosis and on risk of BCR after RP among Dutch men with PC.  
 
Subjects and methods 
Patients diagnosed with PC were identified from the population-based cancer registry 
held by the Comprehensive Cancer Centre East, The Netherlands. From 2003 to 2006, 
1,668 patients with PC were identified in this region. Only patients with known BMI 
data were included in our analyses (n=1,116). For all patients, clinical data were 
collected retrospectively by review of the clinical charts. Part of the patients (n=951), 
who were diagnosed before the age of 76, participated in the POLYGENE project10 and 
filled out a postal questionnaires as part of it. Self-reported weight and length were 
collected either from the POLYGENE questionnaire (n=943) or from the clinical charts 
(n=173) and were used to calculate BMI. For 278 patients, BMI was available from the 
questionnaire as well as from the charts (Spearman r=0.81, P <0.001). For these 
patients, BMI from the questionnaire was used in the analyses. BMI categories were 
defined according to the WHO criteria: BMI <25 kg/m2 (normal weight), BMI 25-
30 kg/m2 (overweight), and BMI ≥30 kg/m2 (obesity). The institutional review board 
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approved the study, and all participants of the POLYGENE project provided written 
informed consent.  
Primary treatments were categorized as radical prostatectomy (RP) with or without 
neoadjuvant androgen-deprivation therapy (ADT), radiotherapy (RT, including external 
beam radiation and brachytherapy) with or without ADT, active surveillance (AS), 
androgen-deprivation therapy (ADT), and others (such as cryotherapy and 
chemotherapy). In total, 517 patients who underwent RP as primary therapy were 
identified. Patients treated with neoadjuvant ADT (n=13) were excluded, leaving 504 
patients for analysis. BMI was evaluated as prognostic factor for BCR, which is defined 
as two consecutive PSA levels ≥0.2 ng/ml. For these analyses, 11 patients were 
excluded, because data on post-operative PSA levels or BCR status were missing. After 
RP, patients were generally seen after 6 weeks, 3, 6, 9, and 12 months and then every 
6 months, according to the national guidelines for PC follow-up11. RP specimens were 
processed according to protocols from the institutes where patients were submitted 
to. Gleason grade was presented as the sum of two main Gleason scores. Clinical and 
pathological stages were classified according to the 2002 TNM classification based on 
the American Joint Committee on Cancer guidelines (AJCC)12.  
We used Kruskal-Wallis tests to assess the association between BMI categories and 
continuous clinical and pathological variables, while Chi-square tests were applied to 
categorical variables. Risk of BCR was calculated with the Kaplan-Meier method, using 
the log-rank test to compare BMI groups. Univariable and multivariable proportional 
hazards regression analyses adjusted for age, prediagnostic PSA levels, and 
pathological variables (Gleason score at RP, pathological stage, surgical margin status, 
and lymph node status) were performed to evaluate whether BMI is a prognostic 
factor for BCR after RP. The significance level was set at P <0.05, and all P values were 
two-tailed. Statistical Package of Social Sciences (SPSS, version 16.0, Chicago, Illinois) 
was used for all analyses.  
Results 
Patient characteristics are shown in Table 5a.1. Among all PC patients included in the 
analyses (n=1,116), median age at diagnosis was 66.3 (inter-quartile range: 61.2-70.5) 
years. Median BMI was 25.3 (IQR: 23.9-27.0) kg/m2, with 47% of this population being 
overweight and 7% obese. Overall, no statistically significant differences for clinical or 
pathological findings were observed among the BMI groups. Although not statistically 
significant, obese patients were somewhat less likely to be referred for RP compared 
to normal weight and overweight patients (38% versus 46% and 48%, respectively).  
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Table 5a.1 Demographic, clinical, and pathological characteristics of Dutch patients 
diagnosed with prostate cancer according to BMI categories  
  Total group BMI <25 kg/m2   BMI 25-30 kg/m2  BMI ≥30 kg/m2  P value  
Number of patients (%) 1,116 (100%) 510 (46%) 530 (47%) 76 (7%) – 
Age at diagnosis (years) 66.3 (61.2-70.5) 66.1 (61.5-71.0) 66.2 (61.0–70.2) 65.1 (61.1-69.6) 0.753 
BMI (kg/m2)  25.3 (23.9-27.0) 23.7 (22.9-24.4) 26.6 (25.8–27.8) 31.6 (30.7-33.6) – 
BMI at age 18 (kg/m2)a  22.2 (21.0-23.7) 21.5 (20.2-22.6) 23.0 (21.8–24.2) 24.4 (23.1-28.1) – 
Height (cm) 177 (172-182) 178 (173-183) 176 (172–180) 175 (172-179) – 
Weight (kg) 80 (74-85) 75 (70-80) 83 (80–90) 100 (92-104) – 
Smoking (%) 
    Never 170 (15%) 86 (17%) 74 (14%) 10 (13%) 0.035 
    Former 641 (57%) 285 (56%) 321 (61%) 35 (46%)   
    Current 136 (12%) 80 (16%) 50 (9%) 6 (8%)   
Family history of prostate cancer (%) 
    Yes 228 (20%) 101 (20%) 117 (22%) 10 (13%) 0.285 
    No 736 (66%) 357 (70%) 336 (63%) 43 (57%)   
Prediagnostic PSA level 
(ng/ml)b  10 (6–20) 9 (6–20) 10 (7–21) 10 (7–27) 0.187 
Gleason score biopsy (%) 
    <7 689 (62%) 331 (65%) 316 (60%) 42 (55%) 0.128 
    7 226 (20%) 88 (17%) 120 (23%) 18 (24%)   
    >7 120 (11%) 49 (10%) 61 (12%) 10 (13%)   
Clinical stage (cTNM) (%) 
    cT1 447 (40%) 200 (39%) 224 (42%) 23 (30%) 0.229 
    cT2 418 (38%) 196 (38%) 194 (37%) 28 (37%)   
    cT3 or cT4 233 (21%) 107 (21%) 104 (20%) 22 (29%)   
Primary treatment (%) 
    Active surveillance (AS) 121 (11%) 58 (11%) 57 (11%) 6 (8%) 0.585 
    RP without ADT 504 (45%) 230 (45%) 245 (46%) 29 (38%)   
    RP with ADT 13 (1%) 4 (1%) 9 (2%) –   
    RT without ADT 115 (10%) 60 (12%) 46 (9%) 9 (12%)   
    RT with ADT 210 (19%) 94 (19%) 100 (18%) 16 (21%)   
    ADT 138 (12%) 58 (11%) 66 (12%) 14 (18%)   
    Others 10 (1%) 5 (1%) 4 (1%) 1 (1%)   
Data presented as median (IQR) or number (%). Percentages may not add up to 100% because of missing 
values. Abbreviations: ADT androgen-deprivation therapy, AS active surveillance, BMI body mass index, 
cTNM clinical tumor-node-metastasis, PSA prostate specific antigen, RP radical prostatectomy,  
RT radiotherapy. aMissing n=243; bMissing n=12.  
 
Characteristics of patients with PC who underwent RP are shown in Table 5a.2. Median 
age and BMI of patients treated with RP were 63.3 (IQR: 58.8-67.1) years and 25.3 
(IQR: 23.7-26.9) kg/m2. Pathological characteristics after RP did not significantly differ 
between BMI groups, except for tumor (pT) stage which was somewhat higher in 
obese patients (P=0.017).  
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Table 5a.2 Demographic, clinical, and pathological characteristics of Dutch patients 
with prostate cancer treated with radical prostatectomy (RP)  
  Total group BMI <25 kg/m2  BMI 25-30 kg/m2  BMI ≥30 kg/m2  P value  
Number of patients (%) 504 (100%) 230 (46%) 245 (49%) 29 (6%) – 
Age at RP (years) 63.3 (58.8-67.1) 63.4 (58.7-66.7) 63.2 (58.8-67.4) 63.0 (59.3-67.8) 0.961 
BMI (kg/m2)  25.3 (23.7-26.9) 23.7 (22.9-24.4) 26.6 (25.8-27.7) 31.3 (30.5-34.3) – 
Prediagnostic PSA (ng/ml)a  8 (6-12) 7 (5-10) 8 (6-13) 8 (5-12) 0.004 
Follow-up (months) 40.3 (19.5-53.1) 40.9 (24.7-53.8) 39.4 (17.0-52.4) 40.6 (17.1-57.0) 0.502 
Surgery (%) 
    Open 284 (56%) 123 (53%) 145 (59%) 16 (55%) 0.251 
    Laparoscopic 195 (39%) 99 (43%) 88 (36%) 8 (28%)   
    Missing 25 (5%) 8 (3%) 12 (5%) 5 (17%)   
PSA nadir < 0.2 ng/ml (%) 
    Yes 461 (91%) 213 (93%) 221 (90%) 27 (93%) 0.853 
    No 36 (7%) 15 (7%) 19 (8%) 2 (7%)   
    Missing 7 (1%) 2 (1%) 5 (2%) 0   
Biochemical recurrence (%) 
    Yesb  142 (28%) 65 (28%) 70 (29%) 7 (24%) 0.874 
    No 351 (70%) 163 (71%) 167 (68%) 21 (72%)   
    Missing 11 (2%) 2 (1%) 8 (3%) 1 (3%)   
Gleason score RP (%) 
    <7 348 (69%) 165 (72%) 162 (66%) 21 (72%) 0.148 
    7 111 (22%) 44 (19%) 60 (24%) 7 (24%)   
    >7 30 (6%) 10 (4%) 20 (8%) 0   
    Missing 15 (3%) 11 (5%) 3 (1%) 1 (3%)   
To be continued on the next page 
 
Furthermore, obese patients tended to have higher prediagnostic PSA levels compared 
to overweight and normal weight patients (P=0.004). BMI presented as a continuous 
variable, however, was only weakly correlated with prediagnostic PSA levels 
(Spearman r=0.13, P=0.004).  
 
Median follow-up of patients treated with RP was 40.3 (IQR: 19.5-53.1) months. In 
total, 142 patients developed BCR after RP. The 5-year risk (95% CI) of BCR was 30% 
(23-37%), 32% (25-39%), and 25% (9-41%) for normal weight, overweight, and obese 
patients, respectively (log rank P=0.810) (Figure 5a.1).  
 
As presented in Table 5a.3, BMI was not a significant prognostic factor for BCR after RP 
in univariable (HR 1.02 per kg/m2, 95% CI: 0.97-1.07) or multivariable (HR 0.99 per 
kg/m2, 95% CI: 0.93-1.06) analyses after adjustment for age, prediagnostic PSA, 
Gleason score at RP, positive surgical margins, positive lymph nodes, and pathological 
stage. Higher Gleason score, pathological stage, and positive surgical margins were all 
statistically significant predictors of risk of BCR after RP.  
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Table 5a.2 Continued 
  Total group BMI <25 kg/m2  BMI 25-30 kg/m2  BMI ≥30 kg/m2  P value  
Pathological stage (pTNM) (%) 
    pT2 349 (69%) 170 (74%) 165 (67%) 14 (48%) 0.017 
    pT3 or pT4 143 (28%) 54 (23%) 76 (31%) 13 (45%)   
    Missing 12 (2%) 6 (3%) 4 (2%) 2 (7%)   
Surgical margins (%) 
    Positive 211 (42%) 93 (40%) 102 (42%) 16 (55%) 0.341 
    Negative 270 (54%) 125 (54%) 133 (54%) 12 (41%)   
    Missing 23 (5%) 12 (5%) 10 (4%) 1 (3%)   
Extracapsular extension (%) 
    Yes 175 (35%) 72 (31%) 89 (36%) 14 (48%) 0.204 
    No 221 (44%) 102 (44%) 110 (45%) 9 (31%)   
    Missing 108 (21%) 56 (24%) 46 (19%) 6 (21%)   
Invasion seminal vesicles (%) 
    Yes 45 (9%) 15 (7%) 25 (10%) 5 (17%) 0.068 
    No 446 (88%) 211 (92%) 214 (87%) 21 (72%)   
    Missing 13 (3%) 4 (2%) 6 (2%) 3 (10%)   
Lymph node dissection (%) 230 (46%) 83 (36%) 131 (53%) 16 (55%) 0.001 
Positive lymph nodes (%) 17 (3%) 6 (3%) 9 (4%) 2 (7%) 0.726 
Data presented as median (IQR) or numbers (%). Abbreviations: BMI body mass index, PSA prostate specific 
antigen, pTNM pathological tumor-node-metastasis staging criteria, RP radical prostatectomy.  
aMissing n=5,  bIncluding 36 patients who did not reach post-operative PSA levels <0.2 ng/ml.  
 
Discussion 
In the present study among Dutch men diagnosed with PC, BMI was weakly associated 
with higher pathological tumor (pT) stage and higher prediagnostic PSA levels in 
patients treated with RP. Gleason score, pathological stage, and positive surgical 
margins were independent predictors of BCR, whereas BMI did not add any prognostic 
value in multivariable proportional hazards regression analyses. Our findings are 
consistent with other European studies which did not find a prognostic effect of BMI in 
patients treated with RP5, 8. Only one study reported a trend toward statistical 
significance for BMI as independent prognostic factor for BCR7. Addition of BMI to a 
multivariable model, however, did not significantly increase predictive accuracy7. 
Whereas most European studies so far were not able to find an association between 
BMI and any clinical or pathological characteristics, several studies from the United 
States did report BMI as predictor of BCR and adverse pathological findings after RP13-
15. These inconsistent results might be explained by the lower rates of obesity and 
severe obesity in Europe compared to the United States1, 2.  
A remarkable observation in this study is the weak positive association between BMI 
and prediagnostic PSA levels among RP patients, which was not observed in the overall 
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study population. Several studies observed an inverse association between BMI and 
prediagnostic PSA levels16, 17. Based on the theory of haemodilution, it has been 
hypothesized that obese patients have larger plasma or serum volumes, which may 
lead to lower PSA concentrations16. It has also been suggested that lower PSA levels in 
obese patients might result from decreased androgenic activity18. Our results indicated 
a weak correlation between BMI and PSA levels and were limited to a small 
subpopulation of patients treated with RP; therefore, we cannot rule out that our 
result was a chance finding.  
 
Figure 5a.1 The 5-year risk of biochemical recurrence in normal weight, overweight, and obese 
prostate cancer patients treated with radical prostatectomy (n=493). Log rank P=0.810.  
 
Another finding of our study was the association between BMI and pathological tumor 
(pT) stage among RP patients, suggesting that advanced-staged tumors were more 
common among obese patients. As reviewed by others, obesity might indeed play a 
role in PC aggressiveness, i.e. high stage, high grade, and increased risk of recurrence 
or mortality19. It has been hypothesized that both non-biological and biological 
mechanisms can be responsible for the association between tumor aggressiveness and 
body size. Firstly, it might be more difficult to detect (early) PC in obese men, due to 
lower PSA levels16, 17 and difficult digital rectal examinations19. Secondly, difficulties 
related to treatment might be responsible for an aggressive type of PC in obese men. 
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Pathological findings related to technical aspects of surgery like positive surgical 
margins, however, would be more likely to be affected than tumor grade or stage. 
Finally, alterations in levels of steroid hormones, adipokines, and inflammatory 
mediators might also drive PC towards a more aggressive form in obese men19, 20.  
Table 5a.3 Univariable and multivariable proportional hazards regression models 
predicting biochemical recurrence after radical prostatectomy (RP)  
   Univariable  Multivariable (n = 444)a,b 
n HR 95% CI P value   Adjusted HR 95% CI P value  
BMI (kg/m2)  493 1.02 0.97–1.07 0.525  0.99 0.93–1.06 0.732 
BMI 493              
    <25 kg/m2    1.00 – –        
    25–30 kg/m2    1.08 0.77–1.51 0.658        
    ≥30 kg/m2    0.90 0.41–1.96 0.789        
Age at RP (years) 493 1.05 1.02–1.08 0.003  1.02 0.98–1.05 0.396 
Surgery 472              
    Open   1.00 – –        
    Laparoscopic   1.15 0.81–1.62 0.429        
Year of RP 493 1.07 0.90–1.27 0.441        
Prediagnostic PSA level (ng/mL) 489 1.03 1.01–1.05 0.002  1.00 0.98–1.02 0.866 
Prediagnostic PSA level 489              
    <4 ng/ml   1.00 – –        
    4–10 ng/ml   3.02 0.95–9.58 0.061        
    ≥10 ng/ml   4.99 1.57–15.89 0.006        
Gleason score at RP 478              
    <7   1.00 – –  1.00 – – 
    7   2.55 1.77–3.68 <0.001  1.71 1.13–2.60 0.012 
    >7   4.39 2.64–7.31 <0.001  2.55 1.43–4.52 0.001 
Pathological stage (pTNM) 483              
    pT2   1.00 – –  1.00 1.00 – 
    pT3 or pT4   2.50 1.79–3.50 <0.001  1.68 1.13–2.49 0.010 
Extracapsular extension 386 2.41 1.62–3.58 <0.001        
Positive surgical margins 470 4.33 2.94–6.38 <0.001  2.85 1.87–4.35 <0.001 
Invasion seminal vesicles 480 2.58 1.64–4.04 <0.001        
Positive lymph nodesc  489 2.93 1.54–5.58 0.001  1.57 0.80–3.07 0.186 
Abbreviations: BMI body mass index, PSA prostate specific antigen, pTNM pathological tumor-node-
metastasis staging criteria, RP radical prostatectomy. aVariables in the multivariable model are adjusted for 
each other; bReplacing pathological stage by extracapsular extension and seminal vesicles invasion in the 
multivariable model resulted in adjusted hazards ratios (95% CI) of 1.45 (0.92-2.28, P=0.106) for 
extracapsular extension and 1.06 (0.59-1.91, P=0.845) for seminal vesicles invasion, while the adjusted 
hazards ratios for the remaining variables hardly changed; cThe reference category is: no lymph node 
dissection performed or no positive lymph nodes.  
Evidence is growing that differentiation between total adiposity and distribution of 
adipose tissue is relevant in the studies related to obesity and PC. Recent studies 
suggested that measures of body fat distribution might be better predictors of PC risk 
B o d y  m a s s  i n d e x  a n d  b i o c h e m i c a l  r e c u r r e n c e | 
81 | P a g e  
and prognosis when compared to BMI21, 22. Fat distribution measurements usually 
distinct subcutaneous fat from visceral fat depots or simply indicate the location of 
adipose tissue. Skin fold measurements, waist circumference, and waist-to-hip ratios 
are frequently used estimates for the amount and location of adipose tissue. Magnetic 
resonance imaging (MRI) and computed tomography (CT) are considered more reliable 
methods for assessing subcutaneous and visceral fat content23. Von Hafe et al.22 
examined the relation between abdominal visceral fat accumulation, as measured by 
CT, and PC incidence within a case-control study. They found that visceral fat area and 
visceral to subcutaneous fat ratio were strongly associated with increased PC risk 
(crude OR 4.6, 95% CI: 2.6-8.2 and OR 6.0, 95% CI: 2.3-11.0, respectively).  
Unfortunately, we did not have data on any measures of fat distribution. Other 
potential limitations of our study might be its retrospective data collection, self-
reported BMI, relatively short follow-up (median 40.3 months), and small number of 
patients, especially in the obese group. Results therefore need to be interpreted with 
some caution. We cannot exclude the possibility that the relatively large number of 
missing values for BMI might have been a source of selection bias, although the 
observation that patients with missing BMI did not have more advanced tumor 
characteristics compared to the patients with evaluable BMI in our RP cohort (data not 
shown) argues against this. The absence of an association between BMI and BCR might 
also be explained by treatment-related selection. If obese patients tend to have more 
advanced tumor characteristics at diagnosis, and therefore have other types of 
treatment (e.g. ADT), while mainly normal weight, low-risk patients will have surgery, a 
possible association between BMI and BCR could be missed. Our aim was, however, to 
study the association between BMI and BCR in an average population-based RP cohort. 
We conclude from our results that in this cohort, BMI does not have any prognostic 
value for risk of BCR. Whether BMI is associated with risk of recurrence in other 
treatment groups should be verified in future studies.  
In summary, BMI did not affect clinical or pathological characteristics of PC patients at 
time of diagnosis. Compared with non-obese men, pathological stage tended to be 
higher in obese men treated with RP. Clinical relevance of these findings with respect 
to risk of BCR, however, needs to be further elucidated, since BMI itself was not an 
independent predictor of BCR after RP.  
Acknowledgments   
DEG Kok is supported by a research grant from the World Cancer Research Fund 
(WCRF-NL and WCRF-UK). This project was funded in part by contract number 018827 
(Polygene) from the 6th Framework Program of the European Union.  
| C h a p t e r  5 a  
P a g e | 82  
Conflict of interest  
The authors declare that they have no conflict of interest. 
 
References 
 
1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, and Flegal KM. Prevalence of 
overweight and obesity in the United States, 1999-2004. JAMA 2006; 295(13): p. 1549-55. 
2. Branca F, Nikogosian H, and Lobstein T, eds. The challenge of obesity in the WHO European 
Region and the strategies for response. 2007. World Health Organization. ISBN 978 92 890 1388 
8. 
3. Isbarn H, Jeldres C, Budaus L, Salomon G, Schlomm T, Steuber T, et al. Effect of body mass index 
on histopathologic parameters: results of large European contemporary consecutive open radical 
prostatectomy series. Urology 2009; 73(3): p. 615-9. 
4. Paaskesen CE and Borre M. Body mass index and prognostic markers at radical prostatectomy. 
Scand J Urol Nephrol 2008; 42(3): p. 230-6. 
5. Pfitzenmaier J, Pritsch M, Haferkamp A, Jakobi H, Fritsch F, Gilfrich C, et al. Is the body mass index 
a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European 
study population? BJU Int 2009; 103(7): p. 877-82. 
6. Gallina A, Karakiewicz PI, Hutterer GC, Chun FK, Briganti A, Walz J, et al. Obesity does not 
predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in 
European men. Int J Cancer 2007; 121(4): p. 791-5. 
7. Chun FK, Briganti A, Graefen M, Erbersdobler A, Walz J, Schlomm T, et al. Body mass index does 
not improve the ability to predict biochemical recurrence after radical prostatectomy. Eur J 
Cancer 2007; 43(2): p. 375-82. 
8. van Roermund JG, Kok DE, Wildhagen MF, Kiemeney LA, Struik F, Sloot S, et al. Body mass index 
as a prognostic marker for biochemical recurrence in Dutch men treated with radical 
prostatectomy. BJU Int 2009; 104(3): p. 321-325. 
9. van Roermund JG, Hinnen KA, Battermann JJ, Witjes JA, Bosch JL, Kiemeney LA, et al. Body mass 
index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men 
treated with brachytherapy. BJU Int 2010; 105(1): p. 42-8. 
10. Gudmundsson J, Sulem P, Manolescu A, Amundadottir LT, Gudbjartsson D, Helgason A, et al. 
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. 
Nat Genet 2007; 39(5): p. 631-7. 
11. Website for nation-wide guidelines on oncology and palliative care from the Netherlands. Parts 
are also available in English. Available from: www.oncoline.nl. 
12. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC Cancer Staging Manual. 
6th ed. New York, Springer, 2002. 
13. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and 
recurrence rates as related to obesity and race in men with prostate cancer undergoing radical 
prostatectomy. J Clin Oncol 2004; 22(3): p. 439-45. 
14. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, et al. Impact of obesity on 
prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology 2005; 66(5): 
p. 1060-5. 
15. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, and Moul JW. Obese men have higher-grade and 
larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis 
2009; 12(3): p. 259-63. 
16. Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma 
hemodilution and PSA concentration among men with prostate cancer. JAMA 2007; 298(19): p. 
2275-80. 
17. Beebe-Dimmer JL, Faerber GJ, Morgenstern H, Werny D, Wojno K, Halstead-Nussloch B, et al. 
Body composition and serum prostate-specific antigen: review and findings from Flint Men's 
Health Study. Urology 2008; 71(4): p. 554-60. 
18. Freedland SJ, Platz EA, Presti JC, Jr., Aronson WJ, Amling CL, Kane CJ, et al. Obesity, serum 
prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol 
2006; 175(2): p. 500-4; discussion 504. 
B o d y  m a s s  i n d e x  a n d  b i o c h e m i c a l  r e c u r r e n c e | 
83 | P a g e  
19. Freedland SJ and Platz EA. Obesity and Prostate Cancer: Making Sense out of Apparently 
Conflicting Data. Epidemiol Rev 2007; 29: p. 88-97. 
20. Mistry T, Digby JE, Desai KM, and Randeva HS. Obesity and prostate cancer: a role for adipokines. 
Eur Urol 2007; 52(1): p. 46-53. 
21. Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, et al. Body size and risk of prostate 
cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol 
Biomarkers Prev 2008; 17(11): p. 3252-61. 
22. von Hafe P, Pina F, Perez A, Tavares M, and Barros H. Visceral fat accumulation as a risk factor for 
prostate cancer. Obes Res 2004; 12(12): p. 1930-5. 
23. van der Kooy K and Seidell JC. Techniques for the measurement of visceral fat: a practical guide. 
Int J Obes Relat Metab Disord 1993; 17(4): p. 187-96. 
  
 
 
 
Chapter 
Body mass index as a prognostic marker for biochemical 
recurrence in Dutch men treated with radical prostatectomy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joep GH van Roermund1, Dieuwertje EG Kok1, Mark F Wildhagen, Lambertus ALM 
Kiemeney, Femke Struik, Sarah Sloot, Inge M van Oort, Christina A Hulsbergen-van de 
Kaa, Geert JLH van Leenders, Chris H Bangma, and J Alfred Witjes 
 
 
Published in: British Journal of Urology International, 2009; 104(3): 321-325. 
1 Both authors contributed equally to this work 
 
 
 
 
Purpose To investigate whether body mass index (BMI) is a prognostic factor for biochemical recurrence 
(BCR) in Dutch men after radical prostatectomy (RP), as although epidemiological studies of obesity in 
relation to prostate cancer have provided conflicting results, recent studies from the USA suggest that a 
higher BMI is a risk factor for progression of prostate cancer. 
Subjects and methods Of the 1417 patients with prostate cancer who had RP at two University hospitals, 
1302 were included in the present study. BMI (kg/m2) classes were defined as normal (<25), overweight (25-
30) and obese (≥30). The median follow-up was 59 months and clinical data were obtained retrospectively 
from charts. BCR was defined as two consecutive prostate-specific antigen (PSA) levels of >0.1 ng/mL. 
Results In all, 600 patients were classified as having normal weight (43.9%), 665 as overweight (48.6%) and 
103 as obese (7.5%). Overall, 297 patients developed BCR after RP; the 10-year risk (95% confidence interval) 
of BCR was 31.9% (26.6-37.2%), 30.5% (25.8-35.2%) and 23.9% (14.9-32.9%) for patients in the three 
categories, respectively (P=0.836). Multivariable proportional hazard regression analyses of BMI and 
established prognostic factors for BCR did not change these results. 
Conclusion BMI appeared to have no prognostic value for BCR in Dutch patients with clinically localized 
prostate cancer and treated with RP. 
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Introduction 
Prostate cancer and obesity are among the most common health problems currently 
affecting European men. Obesity is now so common among the world’s population 
that it is beginning to replace undernutrition as the most significant contributor to ill 
health1. Moreover, obesity has enormous public health consequences because it not 
only increases the risk of several chronic diseases like diabetes, hypertension, coronary 
heart diseases and certain cancers, but it also imposes a large burden on healthcare 
use and costs. 
 
The relationship between obesity and prostate cancer is debatable, with some studies 
indicating that obesity is associated with a decreased risk of prostate cancer2, 3 and 
other studies suggesting an increased risk4, 5. However, recently two large American 
multi-institutional studies addressed a significantly higher biochemical recurrence 
(BCR) rate among obese men treated with radical prostatectomy (RP)6, 7. 
 
Almost all studies on obesity and the risk of death from prostate cancer or BCR are 
conducted in the USA; this might be important, because not only is the incidence of 
obesity much higher in the USA than in Europe, but the mean body mass index (BMI) 
of obese patients is also higher8. In addition, the USA population partly consists of 
African-Americans, who are more prone to be obese and have higher-grade prostate 
cancers. Therefore, the USA population has a distinct composition and characteristics 
compared to the European population. Thus, we analysed men who had RP for 
clinically localized prostate cancer at two university hospitals (Radboud University 
Medical Centre, Nijmegen and Erasmus MC, University Medical Center, Rotterdam) in 
the Netherlands to evaluate the relationship between obesity and risk of BCR. 
 
Subjects and methods 
The study population consisted of patients who had RP and for whom the medical 
records were reviewed retrospectively; 542 patients were treated at the Radboud 
University Medical Centre between 1992 and 2005, and 875 at the Erasmus University 
Medical Center between 1988 and 2007. Excluded were patients who had 
preoperative androgen deprivation or radiotherapy, and those with missing data for 
height or weight; in all, 49 patients were excluded. For analysis of the risk of BCR, 
patients with incomplete follow-up data, positive lymph nodes or PSA levels that did 
not reach a nadir of <0.1 ng/mL were also excluded (n=66). This resulted in a study 
population of 1302 patients. Preoperative height and weight data were collected 
retrospectively by reviewing anaesthesia records. The BMI was calculated as usual 
(kg/m2), and according to the WHO categories9, patients were stratified into three 
groups, i.e. normal weight (<25) overweight (25–30) and obese (≥30). 
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In general, patients were seen every 3 months during the first year, every 6 months 
during the second and third year, and yearly thereafter unless there was evidence of 
cancer recurrence, in which case more frequent follow-up visits were necessary. The 
serum PSA level was obtained before surgery and at every follow-up visit. BCR was 
defined as two subsequent PSA levels of >0.10 ng/mL or if a second treatment after RP 
was needed. The time to BCR was measured from the date of RP until the date of the 
first PSA level of >0.10 ng/mL. 
 
All RP specimens were fixed overnight, inked, embedded and processed according to 
well-established protocols10. Pathological staging and examination (seminal vesicle 
invasion, extracapsular extension, margin status and Gleason scores) were done by 
two specialized genitourinary pathologists (CAHK and GJL). The presence of tumour 
cells in the inked resection margin was considered a positive surgical margin. All stages 
were converted to the TNM staging criteria, using the 2002 American Joint Committee 
on Cancer classification. 
 
Associations between the predefined BMI subgroups and clinical or pathological 
characteristics were examined using chi-square tests for categorical characteristics and 
Mann-Whitney U-tests or Kruskal-Wallis tests for continuous characteristics. The risk of 
BCR was assessed with the Kaplan-Meier method, using the log rank-test to compare 
subgroups. A Cox proportional hazard model was used for multivariable analyses. 
Differences were considered to be statistically significant if P <0.05. 
 
Results 
Table 5b.1 summarizes the clinical and pathological characteristics of the study 
population stratified by preoperative BMI groups. The median (range) age of the 
patients at the time of RP was 63.1 (42.4-75.0) years, and the median BMI was 25.5 
kg/m2. In all, 600 patients were classified as having normal weight (43.9%), 665 as 
overweight (48.8%) and 103 as obese (7.5%). The median follow-up was 59.3 months 
and the median Gleason score was 6.  
 
Overall, 297 patients developed BCR after RP. The 10-year Kaplan-Meier risk (95% CI) 
of BRC was 30.5% (27.2-33.8%). Patients in the obese group had slightly lower 
recurrence rates than those in the normal weight group, but this was not statistically 
significant. The 10-year risk (95% CI) of BCR was 31.9% (26.6-37.2%), 30.5% (25.8-
35.2%) and 23.9% (14.9-32.9%) for patients in the normal, overweight and obese 
groups, respectively (P=0.836; Figure 5b.1). 
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Table 5b.1 Patients and pathological characteristics 
 Normal weight Overweight Obese P value 
Number of patients (%) 600 (43.9) 665 (48.6) 103 (7.5)   
Age (years) 63.0 (59.0-67.1) 63.3 (58.6-67.1) 62.1 (58.3-65.0) 0.127 
BMI (kg/m2) 23.5 (22.5-24.3) 26.9 (25.8-27.8) 31.4 (30.5-32.3)   
Pre-operative PSA level (ng/mL) 7.1 (4.8-11.1) 7.1 (4.6-11.8) 7.2 (4.6-10.2) 0.815 
Follow-up (months) 58.9 (23.7-100.4) 52.9 (18.0-98.2) 54.8 (21.5-102.8) 0.191 
Pathological stage      0.402 
    T2 404 (67.4) 419 (63.3) 68 (66.0)   
    T3 167 (27.9) 213 (32.3) 28 (27.2)   
   T4 28 (4.7) 30 (4.5) 7 (6.8)   
Pathological Gleason score      0.310 
    2-6 278 (56.2) 299 (52.7) 39 (47.6)   
    7 170 (34.3) 221 (39.0) 37 (45.1)   
    8-10 47 (9.5) 47 (8.3) 6 (7.3)   
Positive margins 208 (34.9) 256 (38.7) 42 (40.8) 0.276 
Seminal vesicle involvement 67 (11.2) 55 (8.3) 10 (9.8) 0.776 
Extracapsular extension 174 (29.5) 217 (33.3) 32 (31.7) 0.347 
Lymph node involvement 18 (3.0) 11 (1.7) 2 (2.0) 0.270 
Data presented as median (interquartile range) or number (%). Percentages may not add up to 100% 
because of missing values. Abbreviations: BMI body mass index, PSA prostate specific antigen. 
 
Using Cox proportional hazards regression models, prognostic factors for the risk of 
BCR were evaluated by using univariable and multivariable analyses (Table 5b.2). 
Univariable regression analysis showed no significant association between the risk of 
BCR and obesity in obese (P=0.78) and overweight patients (P=0.67) compared with 
normal-weight patients. Likewise, in multivariable regression analysis for the risk of 
BCR, BMI did not appear to have any independent prognostic value. 
 
Discussion 
Obesity is a growing problem in Western countries; in Europe, the prevalence of 
obesity has more than doubled during the last two decades. Obesity accounts for up to 
6% of direct health costs and >12% of indirect health costs of shortened lives, reduced 
productivity, and lowered incomes in Europe11. Simultaneously, since the introduction 
of PSA testing and the growing awareness of prostate cancer in men, the incidence and 
prevalence of localized prostate cancer has substantially increased and become a 
major health problem12.  
 
Several biological mechanisms have been proposed to explain the relationship 
between adiposity and the risk of prostate cancer. Adipose tissue is an active 
endocrine and metabolic organ. Beyond alterations in sex steroid hormones (increased 
serum concentrations of oestradiol and decreased serum concentrations of 
testosterone) it produces adipokines like leptin, IGF-1, interleukin-6 and vascular 
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endothelial growth factor. Alterations in sex steroid hormones and adipokines might 
contribute to the molecular basis of the association between obesity and prostate 
cancer. However, the exact role of obesity as related to the development of prostate 
cancer is not yet clear, although recent evidence suggests a particular role for obesity 
in prostate cancer progression. Mechanisms and the effect of obesity on prostate 
cancer have been reviewed in more detail elsewhere13, 14. 
Normal weight
Overweight
Obese
 
Figure 5b.1 Risk of biochemical recurrence following radical prostatectomy 
represented by Kaplan-Meier curves for normal weight, overweight and obese patients 
(P=0.836). 
 
Two large European historical cohort studies reported a positive relationship between 
BMI and risk of prostate cancer4, 5, while others found a protective influence of obesity 
on the development of prostate cancer3, 15. Most studies examined incident prostate 
cancer cases regardless of stage or grade. However, prostate cancer has a highly 
variable natural history, which can range from fast disease progression in months to a 
more indolent tumour in which survival can be measured in decades.  
 
Although the relationship between obesity and prostate cancer risk has been 
indistinct, recently more consistent results were published on the positive association 
between obesity and prostate cancer mortality16, 17. Recent reports, all from the USA, 
showed poorer cancer control after RP, with a significantly greater propensity for 
higher grade disease, positive margins, and nodal and seminal involvement than in 
non-obese patients; the results of these studies are summarized in Table 5b.36, 7, 18-20. 
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Table 5b.2 Univariable and multivariable Cox proportional hazard analyses 
 Hazard ratio (95% CI) 
Univariable  Multivariable 
Age (continuous) 1.03 (1.01–1.05)    
Preoperative PSA (continuous) 1.05 (1.04–1.07)    
Gleason score      
    ≤6 1  1 
    7 3.11 (2.28–4.25)  2.33 (1.68–3.22) 
    ≥8 7.72 (5.24–11.38)  3.90 (2.54–5.98) 
Pathological stage      
    T2 1  1 
    T3 (vs T2) 3.44 (2.69–4.40)  1.21 (0.87–1.70) 
    T4 (vs T2) 5.49 (3.75–8.02)  2.03 (1.23–3.36) 
Positive surgical margins, yes (vs no) 3.95 (3.12–5.00)    
Seminal vesicle invasion, yes (vs no) 5.46 (4.15–7.19)    
Extracapsular extension, yes (vs no) 3.50 (2.77–4.42)    
BMI, kg/m2 (categorical)      
    25 1  1 
    25–30 1.05 (0.83–1.34)  0.98 (0.74–1.29) 
    ≥30 0.94 (0.59–1.48)  0.72 (0.40–1.30) 
BMI (continuous) 1.00 (0.97–1.04)    
Year of surgery (continuous) 0.94 (0.91–0.97)    
Abbreviations: BMI body mass index, CI confidence interval, PSA prostate specific antigen. 
 
This suggests that obesity has a more prominent role in aggressiveness and 
progression rather than in the development of prostate cancer. These five studies from 
the USA reported a higher risk of BCR in obese than in non-obese patients within the 
first 5 years. Combining these studies, the risk of BCR within 5 years was 23.1% for the 
non-obese and 31.8% for the obese patients.  
 
The present study could not confirm this relationship, as the 5-year risk of BCR was 
23.9% for obese patients vs 20.7% in the normal-weight patients. There are several 
explanations for this difference. First, all five previous studies cited were in the USA; by 
contrast with these studies, in which 20-25% of men were obese, the present study 
had only 7% of obese patients in the study population. This is not surprising, when 
assessing the National Health and Nutrition Examination Survey; in 2004 the 
prevalence of obesity among American men was ≈32%21. According to the Netherlands 
Health Interview Survey the prevalence of obesity in Dutch men was only 9%22. The 
present study population had not only fewer obese patients, but more importantly, 
the obese patients in the study weighed less than those in the American studies listed 
in Table 5b.3. The higher degree and frequency of obesity might translate into ‘fatter’ 
fat cells, which might produce a greater quantity of adipokines23. This in their turn 
might result in a higher risk of BCR.  
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Table 5b.3 A comparison of American studies reporting a relationship between BCR and obesity 
Reference 6 7 18 19 20 
Number of patients 3162 1106 2131 5631a 526 
Mean follow-up (months) 31 46 23 54 54 
Mean BMI (kg/m2) NA 27.5 27 NA 27.8 
African American (%) 21.4 25.9 24.9 7.0 13.7 
Obese (%) 19.0 22.4 22.0 33.3 24.9 
Positive margins (%)      
    normal 29.3b 28.5 NA 11.1 15.0 
    obese 35.0 36.3 NA 18.0 18.6 
Positive nodes (%)      
    normal 3.0 b 1.8 NA 2.3 3.1 
    obese 3.8 0.4 NA 2.5 2.3 
Positive seminal vesicles (%)      
    normal 8.0 b 8.8 NA 2.8 7.8 
    obese 10.0 8.5 NA 4.0 13.8 
Gleason score ≥8 (%)      
    normal 44.3 b c 3.9 5.8 5.3 20.3 
    obese 52.4 c 8.1 5.1 6.8 19.2 
BCR at 5 years (%)      
    non-obese 32.5 32.0 22.0 10.0 18.3 
    obese 37.5 40.0 30.0 22.0 28.5 
Cox proportional hazard ratio (95% CI) for BMI  
≥30 vs <30 kg/m2 1.20 
(1.02-1.42) d 
- 1.31 
(1.00-1.71) d 
- - 
  P value 0.028 - 0.046 - - 
at diagnosis (continuous)  1.03 
(1.01-1.06) d 
1.20 
(1.02-1.41) e 
- 1.07 
(1.02-1.13) e 
  P value  0.014 0.028 - 0.001 
30–35 vs <25 kg/m2  1.19 
(0.86-1.64) d 
- - - 
  P value  0.296 - - - 
>35 vs <25 kg/m2  1.99 
(1.21-3.27) d 
1.69 
(1.01-2.84) e 
- - 
  P value  0.006 0.047 - - 
≥30 vs <25 kg/m2  - - 2.04 
(1.61-2.58) d 
2.35 
(1.43-3.86) df 
  - - 1.91 
(1.51-2.44) e 
 
  P value  - - <0.001 0.001 
Abbreviations: BCR biochemical recurrence, BMI body mass index, CI confidence interval, NA not available.  
a Patients in the normal weight and overweight cohorts were matched 1:1 to the cohort of obese patients on 
the basis of propensity scores; b Normal and overweight groups are combined; c Pathological Gleason score 
≥7;  d univariable; e multivariable; f at age 40 years. 
 
Second, by contrast with the Dutch population, the population of the USA includes 
African-American men. As an ethnic group, African-American men, who are also more 
obese, have a significantly higher incidence of prostate cancer and of mortality rates 
than white men24. For example, in the study of Amling et al.6 black race and BMI were 
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associated with higher BCR in the univariable analysis, but in multivariable analysis 
only black race remained significant. It is tempting to speculate that increased rates in 
African-American men might in part explain the differences in BCR after RP, especially 
because African-Americans are on average more obese and are more prone to have 
aggressive tumours. 
 
In the present study, obese men more often had (although not significantly) positive 
margins (40.8%) and T4 tumours (6.8%) than had men with a normal weight (34.9% 
and 4.7%, respectively). Nevertheless, the risk of BCR was not higher in the obese men. 
This might be related to the rather few obese patients in the present study. 
Interestingly, if there was BCR, the mean time to develop BCR was much shorter in the 
obese men, at 19.9 months, than in normal weight men, at 37.7 months. 
 
The limitations of the present study are, first, the use of BCR as a surrogate of cancer-
specific survival. This is important because it was reported previously that BCR can 
occur late in the postoperative course, and that the presence of BCR is not always a 
good predictor of prostate cancer-specific death25. A 10-year cohort study by Siddiqui 
et al.26 reported that despite worse pathological features at the time of RP in obese 
patients, the long-term cancer-specific survival remained the same regardless of BMI. 
Second, additional quantitative measures of obesity, such as waist-to-hip ratio 
(calculated as the ratio of waist circumference, at the level midway between the lower 
rib margin and iliac crest, over the hip circumference at the maximum circumference 
over the buttocks) and waist circumference were not available. In clinical practice and 
epidemiological studies, body fat is most commonly estimated using BMI. Abdominal 
fatness, which is more metabolic active, is best measured by the waist-to-hip ratio or 
waist circumference. This is particularly true in patients aged >75 years27; in the 
present study most patients were much younger. Third, the height and weight data 
used were recorded from the anaesthesia records, as reported by the patients at the 
time of surgery, and introduced the possibility of a bias. 
 
In conclusion, obese patients undergoing RP in two Dutch academic hospitals had no 
worse pathological characteristics, and had no significantly greater risk of developing 
BCR.  
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Purpose Selenium has been considered a chemopreventive agent for prostate cancer. The exact mechanisms 
of chemoprevention by selenium, however, are not fully understood. We conducted a randomized, placebo-
controlled intervention trial to examine the effects of a short-term intervention with selenium on gene 
expression profiles in non-malignant prostate tissue.  
Subjects and methods Twenty-three men scheduled for a prostate needle biopsy were randomly assigned to 
take 300 µg selenized yeast per day (n=12) or a placebo (non-selenized yeast, n=11) during a median 
intervention period of 35 (interquartile range: 31-35) days. Prostate biopsy specimens of 15 participants, 
collected from the transition zone before and after the intervention period, were available for whole-
genome microarray expression analyses (n=8 selenium, n=7 placebo). 
Results Pathway analyses revealed that the intervention with selenium resulted in a down-regulated 
expression of genes involved in signalling pathways related to inflammation. Furthermore, expression 
changes were observed for genes involved in cellular growth, proliferation and development. More 
specifically, expression of several epithelial markers was up-regulated, whereas expression of mesenchymal 
markers was down-regulated after the intervention with selenium. The latter finding implies a possible effect 
of selenium on the epithelial-to-mesenchymal transition.  
Conclusion Our data showed that selenium intake induced an anti-inflammatory gene expression profile and 
affected expression of genes implicated in epithelial-to-mesenchymal transition in non-malignant prostate 
tissue.  
| C h a p t e r  6  
P a g e | 96  
Introduction 
Prostate cancer is the most common cancer and an important cause of death among 
men in Western countries1, 2. Effective prevention strategies may be considered the 
optimal approach to reduce the incidence and mortality of prostate cancer. Selenium 
has been previously suggested as a likely chemopreventive agent3-5, although more 
recent observational and intervention studies did not consistently report a protective 
effect of selenium for prostate cancer6-8. The Nutritional Prevention of Cancer (NPC) 
trial showed that a daily intake of 200 μg selenium (as selenized yeast) reduced the 
incidence of prostate cancer by 52% as compared to the placebo group4. Contrary, 
results of the Selenium and Vitamin E Cancer Prevention (SELECT) trial, which aimed to 
determine whether selenium, vitamin E or a combination of both prevents the 
development of prostate cancer among the general population, demonstrated that 
selenium (200 μg per day) did not decrease the incidence of prostate cancer as 
compared to the placebo group7, 9. The provided form of selenium (L-
selenomethionine) and the relatively high serum selenium levels (~135 μg/L) at 
baseline might explain the null-findings of the SELECT trial7, 10, 11.  
 
In parallel with the inconsistency in observational studies and chemoprevention trials, 
the molecular mechanisms by which selenium might possibly lower prostate cancer 
risk have not been elucidated and warrant further research. It is known that 
supplementation with L-selenomethionine12 or selenized yeast13, 14 results in increased 
levels of selenium in the prostate. Furthermore, it has been shown that 
supplementation with 200 μg L-selenomethionine per day induces changes in the gene 
expression profile in prostate tissue15. Whether these changes in gene expression 
underlie a possible chemopreventive effect is not clear, because L-selenomethionine 
itself did not show preventive effects for prostate cancer in the SELECT trial7. Other 
forms of selenium, such as selenized yeast, have been proven to be effective in 
intervention trials3, 4, however, detailed information on the molecular effects in 
prostate tissue is lacking. The aim of the current study was therefore to obtain more 
insight into the molecular effects of selenium in the prostate by examining gene 
expression profiles in non-malignant prostate tissue before and after a short-term 
intervention with selenized yeast in a randomized, double-blind and placebo-
controlled intervention trial. 
 
Subjects and methods 
 
Subjects 
We recruited participants from the departments of Urology and Radiation Oncology of 
the Radboud University Medical Centre, an academic tertiary referral centre in the 
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Netherlands. Men scheduled for diagnostic prostate biopsies, and subsequent 
treatment with radical prostatectomy (RP) or radiotherapy (RT) for prostate cancer 
were invited for this study. Also, men scheduled for re-biopsies because of high-grade 
prostatic intraepithelial neoplasia (HGPIN) or suspicion of malignancies in previous 
biopsies were eligible for inclusion. 
 
Exclusion criteria were current use of dietary supplements providing more than the 
recommended daily allowance of 55 μg selenium per day16, any malignancy in the 
preceding five years (except for non-melanoma skin cancer), current hepatic or renal 
disease or inflammatory bowel disease, and neo-adjuvant therapies for prostate 
cancer. From June 2007 through October 2010, 281 men were assessed for their 
eligibility to participate in this study. Of these, 23 men were enrolled (Figure 6.1). 
Figure 6.1 Study flow chart  
Abbreviations: HGPIN high-grade prostatic intraepithelial neoplasia, RP radical prostatectomy,  
RT radiotherapy a Malignancy in the study biopsy. 
 
 
Screening 
Enrollment 
Assessed for eligibility 
n=281 
Enrolled 
n=23 
Selenium 
n=12 
RT 
n=5 
RP 
n=2 
Re-biopsy 
n=5 
Placebo 
n=11 
RT 
n=3 
RP 
n=4 
Re-biopsy 
n=4 
Excluded (n=258) 
    No prostate cancer / HGPIN (n=154)    
    No RP or re-biopsy (n=65)  
    Other exclusion criteria (n=37)    
    Refused to participate (n=2) 
Toenail selenium 
Before n=11 
Toenail selenium 
Before n=12 
Serum selenium 
Before n=11 
After n=10 
Microarray 
Before n=7 
After n=7 
Excluded (n=1) 
  No blood available 
Excluded (n=4) 
  Malignancya (n=2) 
  Inadequate RNA (n=1) 
  No biopsy (n=1) 
Serum selenium 
Before n=11 
After n=11 
Excluded (n=1) 
  No data available 
Microarray 
Before n=8 
After n=8 
Excluded (n=4) 
  Malignancya (n=4) 
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Design of the study  
Before start of the intervention, prostate tissue, blood samples and toenail clippings 
were collected and weight and height were measured. Body mass index (BMI) was 
calculated as weight (kg) divided by squared height (m2). Furthermore, participants 
filled out a baseline questionnaire on sociodemographic characteristics, medical 
history, medication use and dietary supplements.  
 
During the intervention period with an intended duration of five weeks, participants 
were asked to take daily supplements with selenium or placebo. At the end of the 
intervention period, prostate tissue and blood samples were collected for 22 
participants. Sample collection for one participant failed because of logistic reasons. All 
participants returned remaining blisters and their completed research diaries, in which 
details concerning the use of study supplements were registered. The institutional 
review board approved this study and all participants provided written informed 
consent. This trial has been registered at clinicaltrials.gov with identifier NCT00446901. 
 
Intervention  
Participants were randomly assigned using a permuted-block design (blocks of four 
participants) to take 300 μg selenized yeast per day (SelenoPrecise®, Pharma Nord, 
Vejle, Denmark) or a placebo (non-selenized yeast tablet, Pharma Nord, Vejle, 
Denmark). These tablets were previously used in the PRECISE Trial pilot studies17, 18. 
Compliance was assessed by checking research diaries, counting returned tablets and 
measuring serum selenium levels before and after intervention. The intervention 
period ranged from 9 days to 6 weeks, depending on the time between enrollment and 
final treatment or re-biopsy.  
 
Blood sampling 
Blood samples were collected before and after the intervention period. All samples 
were processed within two hours after withdrawal and analysed directly or stored for 
further analyses. For selenium analyses, blood was collected into 10-ml serum tubes 
(Becton Dickinson B.V., Breda, the Netherlands). Serum was collected after 
centrifugation and stored at -20°C until analyses.  
 
Selenium analyses  
Serum selenium levels were measured using an atomic absorption spectrometer 
(model 4100ZL, PerkinElmer, Groningen, the Netherlands) coupled with a graphite 
furnace and using Zeeman background correction19. The detection limit for the method 
was 0.10 μmol/L. For each analytical run, a series of standards (CertiPur® AAS 
standards, no. 1197960100, Merck Chemicals, Darmstadt, Germany) and a control 
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(Pathonorm-HighTM, SERO AS, Billingstad, Norway) were included. All samples were 
analysed in triplicate. Mean serum selenium levels were reported in μmol/L. During 
our study, serum selenium analyses in the study centre were discontinued and 
outsourced to an external laboratory (Algemeen Medisch Laboratorium, Antwerpen, 
Belgium). As a result, a few samples (n=3) were analysed using a different method, i.e. 
inductively coupled plasma mass spectrometry (ICP-MS). One participant for whom 
both serum samples (before and after the intervention) were analysed using ICP-MS 
was included in the analyses. Another participant, for whom only the sample collected 
after intervention was analysed using ICP-MS, was excluded.   
 
Baseline toenail selenium levels were assessed using Instrumental Neutron Activation 
Analyses (INAA)20 at the Reactor Institute of Delft University, Delft, the Netherlands. 
Briefly, the specimens were irradiated for 17 seconds in a thermal flux (3.2E+12 cm-2s-
1). After a decay of 3 seconds, γ-radiation of Se-77 was measured for 17 seconds. This 
measurement is repeated 6 times (cyclic NAA) with 3 seconds between each cycle. 
Levels of toenail selenium were reported in mg/kg. A certified bovine liver standard 
(Standard Reference Material 1577b, National Institute of Standards and Technology, 
Gaithersburg, USA) was analysed together with the toenail samples. For this standard, 
a mean selenium concentration (standard uncertainty) of 0.71 (0.04) mg/kg was 
observed against a mean certified value (standard deviation) of 0.73 (0.06) mg/kg.  
 
Collection of prostate tissue 
Prostate tissue was collected using an 18-gauge biopsy needle (Bard Biopsy Systems, 
Tempe, USA) during regular prostate needle biopsy series guided by transrectal 
ultrasound (TRUS) or during RP. A biopsy was taken from the superior, ventral region 
of the left lobe of the prostate, which is specified as the transition zone. The biopsy 
was embedded in Optimal Cutting Temperature (O.C.T.) Compound (Sakura Finetek 
Europe B.V., Zoeterwoude, the Netherlands) and frozen in liquid nitrogen. All samples 
were stored at -80°C.  
 
Histology 
The biopsies embedded in O.C.T. Compound were sectioned at -20°C. Representative 
sections of 5 μm were used for histological examinations; at least two sections were 
used for a Haematoxilin-Eosin (HE) staining, while three sections were stored at -80°C 
for additional immunohistochemical research. The remainder of the biopsy was 
sectioned at 20 μm. These sections were stored in a 12-ml polystyrene tube (Greiner 
Bio-One, Alphen aan den Rijn, the Netherlands) and used for RNA extraction. All HE-
stained slides were reviewed for malignancy, HGPIN and inflammation by an 
independent and experienced uropathologist (CHK).   
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RNA extraction 
Total RNA was extracted from the sectioned prostate biopsies using TRIzol Reagent 
according to the manufacturer’s instructions (Invitrogen, Breda, the Netherlands). 
Isolated RNA was purified using RNeasy Micro columns (Qiagen, Venlo, the 
Netherlands). RNA integrity (RNA 6000 Nanochips for the Agilent 2100 Bioanalyzer, 
Agilent Technologies) and total RNA yield (Nanodrop ND 1000, Nanodrop products, 
Wilmington, USA) were assessed for all samples. The mean RNA integrity (RIN) score 
was 8.2 (standard deviation: 0.66). Prostate biopsies with inadequate RNA yield (<20 
ng/µl, n=1) or histological evidence of adenocarcinoma (n=6) were excluded, leaving 
biopsies of 15 participants available for microarray analyses (n=8 selenium, n=7 
placebo). 
 
Microarray analyses 
A total of 30 RNA samples were processed for microarray analyses. Briefly, 100 ng of 
total RNA per sample was labeled using an Ambion WT Expression kit (Austin, TX, USA) 
and hybridized to Affymetrix GeneChip Human Gene 1.0 ST Arrays. Probe sets were 
redefined according to Dai et al.21 using the remapped chip description files (CDF) 
version 13.0.1 based on the Entrez Gene database. The signal intensities were 
expressed as Robust Multichip Average (RMA) expression values22, 23. Genes with RMA 
expression values >20 in at least 4 arrays were considered as expressed in prostate 
tissue and were selected for further analyses. Ratios of the log(base2) transformed 
intensity signals were used to compare the individual microarray data before and after 
the intervention. Changes in gene expression within the intervention groups were 
considered statistically significant if the p-value derived from a two-tailed, paired t test 
with Bayesian correction (Limma) was below 0.0524. Differentially changed genes 
between the intervention groups were identified using a one-way ANOVA with 
Bayesian correction (Limma p-value <0.05). Regulated pathways were identified 
through the use of IPA version 9.0 (Ingenuity® Systems, www.ingenuity.com). 
Canonical pathways with a p-value <0.01 in the Fisher’s exact test were considered as 
significant to the data. Gitools software was used to construct correlation matrices 
showing the Pearson correlation coefficients for the individual signal-log-ratios of 
selected genes within each of the intervention groups25. 
 
Statistical analyses  
Since levels of selenium after intervention, duration of intervention and a number of 
other participants’ characteristics were not normally distributed, data were 
summarized as median and interquartile ranges (IQR) or numbers and percentages. 
Baseline serum and toenail selenium levels were compared for the selenium group and 
the placebo group using the Mann-Whitney U test. Serum selenium levels after 
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intervention were compared to baseline values using the Wilcoxon Signed Rank test. 
All statistical tests were two-sided and p-values below 0.05 were considered as 
statistically significant. Statistical Package for Social Sciences (SPSS version 19, Chicago, 
Illinois) was used for all analyses unless otherwise stated.  
 
Results 
In total, 23 participants were enrolled in this study; 12 participants were randomized 
to the selenium group and 11 participants to the placebo group (Figure 6.1). Baseline 
characteristics of the participants are presented in Table 6.1. The median duration of 
the intervention period was 35 days (IQR: 31-35) and ranged from 9-42 days. Median 
compliance, as assessed by checking pill count and diaries, was 100% (range 94-100%).  
 
Table 6.1 Characteristics of the participants at baseline 
 All Placebo Selenium 
Sociodemographic    
Number of participants 23 11 12 
Age at start intervention (years) 67.5 (65.0-72.3) 69.5 (63.0-72.6) 67.1 (65.2-71.2) 
Body mass index (kg/m2) 26.2 (24.2-28.1) 26.2 (24.7-28.5) 26.4 (23.8-28.0) 
Smoking 
Current 
Former 
Never 
 
4 (17%) 
13 (57%) 
6 (26%) 
 
1 (9%) 
6 (55%) 
4 (36%) 
 
3 (25%) 
7 (67%) 
2 (8%) 
Use of dietary supplements (current) 7 (30%) 4 (36%) 3 (25%) 
Clinical     
Prediagnostic PSA levels (ng/mL) 8.0 (4.5-10.3) 7.7 (3.8-11.0) 9.4 (6.0-10.2) 
Diagnosis 
No evidence of malignancy 
HGPIN 
Prostate cancer 
 
1 (4%) 
5 (22%) 
17 (74%) 
 
- 
4 (36%) 
7 (64%) 
 
1 (8%) 
1 (8%) 
10 (83%) 
Gleason score at biopsya 
      <7 
      7 
      >7 
 
10 (44%) 
3 (13%) 
4 (17%) 
 
3 (27%) 
2 (18%) 
2 (18%) 
 
7 (58%) 
1 (8%) 
2 (17%) 
Type of treatment / clinical follow-up 
Re-biopsy  
Radical prostatectomy 
Radiotherapy 
 
9 (39%) 
6 (26%) 
8 (35%) 
 
4 (36%) 
4 (36%) 
3 (27%) 
 
5 (42%) 
2 (17%) 
5 (42%) 
Intervention    
Duration of intervention period (days) 35 (31-35) 35 (34-35) 33 (28-35) 
Time between collection of prostate tissue (days) 64 (35-98) 65 (36-98) 64 (33-96) 
Data presented as median (interquartile range) or numbers (%) Abbreviations: HGPIN high-grade prostatic 
intraepithelial neoplasia, PSA prostate specific antigen. a Only for patients with prostate cancer. 
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Table 6.2 Median selenium levels in toenail and serum at baseline and after 
intervention  
  Placebo (n=11) Selenium (n=12) 
Toenail selenium (mg/kg)   Baseline 0.45 (0.37-0.50) 0.43 (0.37-0.48) 
Serum selenium levels (μmol/L)   Baselinea 1.06 (0.92-1.18) 1.00 (0.92-1.08) 
    After interventiona,b 1.11 (0.95-1.25) 2.36 (1.74-2.98)c 
Data presented as median (interquartile range). a One participant from the selenium group was excluded 
because serum levels at baseline and after intervention were measured using two different analytical 
methods, b Ten participants in the placebo group, because sample collection after the intervention period 
failed for one participant, c Statistically significant if compared to baseline levels (p=0.004, Wilcoxon Signed 
Rank test). 
 
Levels of selenium 
Baseline levels of serum (p=0.562) or toenail (p=0.449) selenium did not differ 
between the two intervention groups (Table 6.2). As compared to baseline values, the 
levels of serum selenium after intervention were increased in the selenium group 
(median increase 1.44 µmol/L, IQR: 0.66-1.92, p=0.004), but not in the placebo group 
(median increase 0.02 µmol/L, IQR: -0.04-0.18, p=0.314). 
 
Microarray analyses 
Good quality RNA from prostate biopsies without evidence of malignancy was 
available before and after the intervention period for 15 participants, resulting in a 
total of 30 microarrays used in this study (Figure 6.1). After RMA normalization and 
filtering, 18,398 genes were considered expressed and were included in further 
analyses (Figure 6.2). Comparisons between the two intervention groups, based on a 
one-way ANOVA, showed that 2740 genes were differentially changed between the 
selenium and placebo group (ANOVA Limma p-value <0.05). Subsequent within-group 
comparisons of individual gene expression profiles before and after intervention 
revealed that of these genes, expression of 910 genes (522 down-regulated and 388 
up-regulated) changed in the selenium group (Supplementary table 6.A). In the 
placebo group expression changes were observed for 1368 genes, of which 660 were 
down-regulated and 708 up-regulated (Supplementary table 6.B).  
 
Pathway analyses 
In order to elucidate the roles of the differentially expressed genes, pathway analyses 
were conducted. As shown in Figure 6.2, expression changes in the selenium and 
placebo group were observed for genes involved in 49 and 77 pathways, respectively 
(Fisher’s exact p-value <0.01). The top-10 of the up- and down-regulated pathways is 
presented in Figure 6.3.  
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The intervention with selenium resulted in a down-regulated expression of genes 
involved in signaling pathways related to inflammation, cellular immune response and 
cellular growth, proliferation and development, while a number of metabolic pathways 
related to amino acid metabolism or carbohydrate metabolism were up-regulated. In 
the placebo group, opposite effects were observed; expression of genes involved in 
pathways related to inflammation was up-regulated, while metabolic pathways were 
down-regulated.  
Affymetrix  GeneChip 
Human Gene 1.0 ST Arrays
19 628 genes
RMA normalization
Filtering: RMA signal >20 in 
at least 4 arrays
18 398 genes
Between groups
ANOVA, p<0.05
2740 genes differentially 
changed
Within groups
Limma paired t test, 
p<0.05
Selenium
910 genes changed
(388 up- and 522 down-regulated)
Placebo
1368 genes changed
(708 up- and 660 down-regulated)
Ingenuity Pathway Analysis
Canonical pathways, p<0.01
Selenium
4 pathways up-regulated
45 pathways down-regulated
Placebo
61 pathways up-regulated
16 pathways down-regulated
 
 
Figure 6.2 Flow chart of gene selection in the microarray analyses   
Abbreviations: ANOVA analysis of variance, RMA robust multichip average. Up- or down-regulated pathways 
were defined as canonical pathways with a p-value <0.01 in the Fisher’s exact test. 
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Figure 6.3 The top-10 pathways, identified by Ingenuity Pathway Analysis, which are most 
significantly up- or down-regulated by the intervention with selenium or placebo. The numbers 
behind the pathways indicate the number of genes that belong to that pathway and the 
numbers behind the bars represent the number of differentially expressed genes within that 
pathway (these genes had a p-value <0.05 in the within group and between group comparisons). 
Pathways with a p-value >0.01 in the Fisher’s exact test were not listed in this figure. 
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One of the major pathways down-regulated by selenium was the integrin signalling. 
Further focus on integrin-related genes in the dataset revealed expression changes in 
other cell adhesion molecules, such as cadherins, selectins and members of the 
immunoglobulin superfamily as well. An overview of these cell adhesion molecules and 
their corresponding expression changes is visualized in Table 6.3. Specific cell adhesion 
molecules are suggested to be involved in the epithelial-to-mesenchymal transition 
(EMT), a process which is characterized by the transition of an epithelial phenotype 
towards a mesenchymal phenotype and is implicated in cancer progression. The 
intervention with selenium resulted in an up-regulation of E-cadherin expression and a 
down-regulation of N-cadherin (not statistically significant) and OB-cadherin 
expression. In line with these findings, we also found a down-regulated expression of 
other mesenchymal markers, such as vimentin and fibronectin, and an up-regulation of 
other epithelial markers (syndecan-1) after the intervention with selenium. An 
overview of the expression changes of several genes implicated in EMT is presented in 
Table 6.4.  
 
In order to explore the consistency of our findings, we correlated the expression 
changes (signal-log-ratios) of selected cell adhesion molecules and EMT-related genes 
amongst each other. The corresponding Pearson correlation matrix (Figure 6.4) 
showed that expression changes in epithelial markers were inversely correlated to the 
expression changes in mesenchymal markers and the majority of the cell adhesion 
molecules in the selenium group.  
.26, 27  
Discussion 
Our study demonstrated that a short-term intervention with selenium induced an anti-
inflammatory gene expression profile and affected expression of genes implicated in 
EMT in non-malignant prostate tissue.  
 
Inflammation 
Several pathways associated with cellular immune response signalling were down-
regulated by selenium, while these and other inflammatory pathways were up-
regulated in the placebo group. Possible explanations for the inflammatory gene 
expression profile observed in the placebo group are a progressive inflammatory or 
tumour environment in the prostate, or a persisting effect of the first series of prostate 
biopsies. For example, increased expression of BCL2 or PTGS2 (which encodes 
cyclooxygenase 2) is often associated with chronic inflammation in prostate tissue28, 29. 
In our study, both BCL2 and PTGS2 are strongly up-regulated in the placebo group, 
while there is a non-significant down-regulation of the expression of these genes in the 
selenium group, suggesting that in the latter group the inflammatory process is 
attenuated.  
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A wide range of previous studies described possible anti-inflammatory properties of 
selenium30, 31. A recent study showed that oral administration of selenium reduced 
prostatic inflammatory cell infiltration and interstitial fibrosis in a rat model for chronic 
bacterial prostatitis32. The exact mechanisms by which selenium might prevent against 
inflammation remain poorly understood. Traditionally, it has been suggested that 
antioxidant capacity of the selenoproteins, which attenuate oxidative stress and the 
formation of reactive oxygen species (ROS), play a pivotal role in the regulation of the 
anti-inflammatory effects33, 34. The nuclear factor kappaB (NFκB) pathway might play a 
central role in the effects of selenium and the selenoproteins on the immune system35. 
Selenium has been shown to inhibit activation of NFκB in various animal and human 
cell types,36-39 among which prostate cancer cells40. In our study, expression of NFκB or 
any of its major down-stream targets was not changed after the intervention with 
selenium. Expression of a number of NFκB-related genes (e.g. NFκB2, RELB, PTGS2), 
however, was increased in the placebo group. This finding suggests that during the 
intervention period certain stimuli, such as a progressive inflammatory or tumour 
environment or persisting effects of the prostate biopsies, activated the NFκB 
pathway. It seems that selenium was able to effectively prevent activation of this 
pathway. Previous studies demonstrated that the selenium-dependent glutathione 
peroxidases were responsible for blocking NFκB activation through inhibition of IκBα 
phosphorylation and degradation41. In our study, however, expression of the selenium-
dependent glutathione peroxidases was down-regulated (GPX3, GPX7) or unchanged 
after the intervention with selenium, although we cannot rule out the possibility that 
activity of these selenoproteins was increased. Others showed that NFκB activation 
can also be regulated by other selenoproteins, such as the thioredoxin reductases42. In 
our study, expression of the mitochondrial thioredoxin reductase 2 (TXNRD2) was 
significantly up-regulated after the intervention with selenium, while down-regulated 
in the placebo group.  
 
Epithelial-to-mesenchymal transition 
Besides the suggested induction of an anti-inflammatory gene expression profile, 
selenium also affected expression of genes involved in EMT. EMT is characterized by 
the transition of an epithelial phenotype towards a mesenchymal phenotype43. During 
EMT, the unique characteristics of epithelial cells are replaced by mesenchymal 
properties such as non-polarity and ability to migrate43. Some important molecular 
events that come along with the transition are loss of epithelial E-cadherin 
expression44 and aberrant expression of vimentin, fibronectin and mesenchymal N-
cadherin43. It is beyond the scope of this paper to describe the complete EMT process, 
however, excellent reviews have been published previously43, 45, 46. EMT plays an 
important role during embryogenesis and tissue repair or inflammation, however, it is 
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also considered as a critical process in cancer progression since the loss of cellular 
adhesion, the reorganization of the cytoskeleton and increased motility might result in 
tumour cell invasion and metastasis47.   
 
Several findings from our study suggest that selenium is able to prevent, inhibit or 
reverse the transition of the epithelial to the mesenchymal phenotype. First, 
expression of numerous well-established epithelial cell markers45 was increased (E-
cadherin, syndecan-1, desmoplakin), while expression of mesenchymal cell markers (N-
cadherin, vimentin, OB-cadherin, α-actin2) was decreased after the intervention with 
selenium. Second, expression of inducers of EMT (transforming growth factor-β, 
hepatocyte growth factor, fibroblast growth factor, type 1 collagen) was down-
regulated among the participants supplemented with selenium. Third, the canonical 
pathway related to actin cytoskeleton signalling, which is closely related to EMT46, was 
strongly down-regulated by selenium. Our microarray data did not provide compelling 
evidence that expression of transcriptional regulators of E-cadherin, such as SNAI1, 
SNAI2, ZEB1, ZEB2, and TWIST146, 48, was changed after the intervention with selenium, 
although this finding does not rule out a regulatory role of these factors.  
 
To the best of our knowledge, the role of selenium in the regulation of EMT has not 
been described in detail previously. One in-vitro study examined the effects of 
selenium (as sodium selenite) on features of EMT in human hepatoblastoma (C3a) cells 
treated with TGFβ1. The authors did not find changes in expression of vimentin or E-
cadherin, although expression of type 1 collagen (COL1A1) was reduced in response to 
sodium selenite49. Others showed that sodium selenite inhibits the expression of 
TGFβ1 in LPS-stimulated prostate cancer (PC3) cells50. Tsavachidou and colleagues 
examined gene expression profiles in distinct anatomical zones and cell-types of the 
prostate after a 3-6 week intervention with L-selenomethionine15. Results of their 
study indicated that genes related to the androgen receptor, tumour protein 53 (p53) 
and NFκB signalling pathways were differentially expressed between the patients 
supplemented with a daily dose of 200 µg L-selenomethionine or a placebo15. The 
authors did not explicitly report gene expression changes that could be linked to EMT. 
Prostate tissue, however, was only collected at a single time point, that is after the 
intervention period of 3-6 weeks15. In our study, we collected prostate tissue before 
and after the intervention period, which allowed us to compare changes in gene 
expression within individuals over time. This aspect can be considered as a major 
strength of our study, because variation due to inter-individual differences does not 
hinder the interpretation of our microarray data. Another strength of our study 
includes the ability to perform histological and gene expression analyses from one 
single prostate biopsy.  
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Potential limitations of our study are the limited number of participants and the 
collection of prostate tissue from the transition zone. We aimed to obtain non-
malignant tissue in order to study preventive effects of selenium and to avoid possible 
aberrant effects from tumour cells. The transition zone was chosen, because only 20% 
of the prostatic adenocarcinomas arise from this zone, in comparison to 68% from the 
peripheral zone51. Furthermore, the transition zone is easily accessible for tissue 
collection during TRUS-guided biopsies as well as surgical biopsies during RP. The 
transition zone and the peripheral zones have been shown to differ in gene expression 
profiles52, 53. Therefore, the observed effects of selenium in the transition zone may 
differ from the effects in the peripheral zone, which is considered the primary zone of 
interest for chemoprevention.  
 
Our finding that selenium is able to regulate expression of genes implicated in EMT 
might as such yield important therapeutic implications for prostate cancer, but also 
other EMT-related conditions such as organ fibrosis. However, it should be considered 
that EMT is involved in the progression of cancer, but is also initiated as a required 
response during tissue injury and inflammation45. Therefore, the relevance of our 
findings with respect to prostate cancer and other pathologies needs to be 
established. Furthermore, the underlying mechanisms need to be clarified and our 
data have to be validated. The latter also highlight the need for future studies focusing 
on the functional effects of selenium related to inflammation (e.g. inflammatory cell 
infiltration) and EMT (e.g. cellular migration or invasion). 
 
In conclusion, our data suggest that selenium induces an anti-inflammatory gene 
expression profile and might be able to interfere in the process of EMT in non-
malignant prostate tissue.  
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Supplementary Table 6.a 
Entrez ID Gene symbol Description Fold change p-value 
4057 LTF lactotransferrin -3.2 0.019 
11075 STMN2 stathmin-like 2 -2.2 0.033 
8549 LGR5 leucine-rich repeat-containing G protein-coupled receptor 5 -2.2 0.017 
8516 ITGA8 integrin, alpha 8 -2.0 0.007 
84189 SLITRK6 SLIT and NTRK-like family, member 6 -1.9 0.002 
389658 FAM150A family with sequence similarity 150, member A -1.9 0.026 
3624 INHBA inhibin, beta A -1.8 0.023 
81610 FAM83D family with sequence similarity 83, member D -1.8 0.012 
387758 FIBIN fin bud initiation factor homolog (zebrafish) -1.7 0.041 
10371 SEMA3A sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 3A -1.7 0.012 
343450 KCNT2 potassium channel, subfamily T, member 2 -1.7 0.006 
50507 NOX4 NADPH oxidase 4 -1.6 0.019 
9358 ITGBL1 integrin, beta-like 1 (with EGF-like repeat domains) -1.6 0.034 
3598 IL13RA2 interleukin 13 receptor, alpha 2 -1.6 0.017 
5139 PDE3A phosphodiesterase 3A, cGMP-inhibited -1.6 0.021 
157869 C8orf84 chromosome 8 open reading frame 84 -1.6 0.019 
57575 PCDH10 protocadherin 10 -1.6 0.009 
26002 MOXD1 monooxygenase, DBH-like 1 -1.6 0.013 
2487 FRZB frizzled-related protein -1.6 0.010 
4915 NTRK2 neurotrophic tyrosine kinase, receptor, type 2 -1.6 0.021 
10129 FRY furry homolog (Drosophila) -1.6 0.029 
27295 PDLIM3 PDZ and LIM domain 3 -1.6 0.009 
10631 POSTN periostin, osteoblast specific factor -1.6 0.050 
9369 NRXN3 neurexin 3 -1.6 0.026 
27129 HSPB7 heat shock 27kDa protein family, member 7 (cardiovascular) -1.6 0.008 
7111 TMOD1 tropomodulin 1 -1.5 0.008 
953 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 -1.5 0.001 
91624 NEXN nexilin (F actin binding protein) -1.5 0.003 
2823 GPM6A glycoprotein M6A -1.5 0.044 
8842 PROM1 prominin 1 -1.5 0.027 
5648 MASP1 mannan-binding lectin serine peptidase 1 (C4/C2 act. comp. of Ra-reactive factor) -1.5 0.003 
2669 GEM GTP binding protein overexpressed in skeletal muscle -1.5 0.005 
9729 KIAA0408 KIAA0408 -1.5 0.008 
11259 FILIP1L filamin A interacting protein 1-like -1.5 0.007 
254228 FAM26E family with sequence similarity 26, member E -1.5 0.003 
23213 SULF1 sulfatase 1 -1.5 0.015 
1490 CTGF connective tissue growth factor -1.5 0.016 
5350 PLN phospholamban -1.5 0.003 
79750 ZNF385D zinc finger protein 385D -1.5 0.025 
57188 ADAMTSL3 ADAMTS-like 3 -1.5 0.046 
7881 KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1 -1.5 0.000 
6401 SELE selectin E -1.5 0.026 
2273 FHL1 four and a half LIM domains 1 -1.5 0.014 
9595 CYTIP cytohesin 1 interacting protein -1.5 0.015 
58189 WFDC1 WAP four-disulfide core domain 1 -1.5 0.003 
161436 EML5 echinoderm microtubule associated protein like 5 1.5 0.042 
8349 HIST2H2BE histone cluster 2, H2be 1.5 0.027 
57512 GPR158 G protein-coupled receptor 158 1.5 0.037 
440905 LOC440905 hypothetical LOC440905 1.5 0.006 
3817 KLK2 kallikrein-related peptidase 2 1.5 0.043 
4824 NKX3-1 NK3 homeobox 1 1.5 0.016 
51109 RDH11 retinol dehydrogenase 11 (all-trans/9-cis/11-cis) 1.5 0.035 
84084 RAB6C RAB6C, member RAS oncogene family 1.5 0.021 
54566 EPB41L4B erythrocyte membrane protein band 4.1 like 4B 1.5 0.002 
131034 CPNE4 copine IV 1.5 0.031 
285175 UNC80 unc-80 homolog (C. elegans) 1.5 0.008 
55503 TRPV6 transient receptor potential cation channel, subfamily V, member 6 1.5 0.014 
57475 PLEKHH1 pleckstrin homology domain containing, family H (with MyTH4 domain) member 1 1.5 0.006 
54898 ELOVL2 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 1.5 0.028 
2786 GNG4 guanine nucleotide binding protein (G protein), gamma 4 1.5 0.020 
51280 GOLM1 golgi membrane protein 1 1.5 0.014 
440689 HIST2H2BF histone cluster 2, H2bf 1.5 0.001 
6695 SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 1.5 0.005 
11013 TMSB15A thymosin beta 15a 1.5 0.010 
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4986 OPRK1 opioid receptor, kappa 1 1.6 0.035 
6296 ACSM3 acyl-CoA synthetase medium-chain family member 3 1.6 0.033 
1803 DPP4 dipeptidyl-peptidase 4 1.6 0.013 
23657 SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 1.6 0.004 
85414 SLC45A3 solute carrier family 45, member 3 1.6 0.019 
6319 SCD stearoyl-CoA desaturase (delta-9-desaturase) 1.6 0.022 
3081 HGD homogentisate 1,2-dioxygenase 1.6 0.041 
2537 IFI6 interferon, alpha-inducible protein 6 1.6 0.011 
57126 CD177 CD177 molecule 1.6 0.023 
148823 C1orf150 chromosome 1 open reading frame 150 1.6 0.018 
80157 CWH43 cell wall biogenesis 43 C-terminal homolog (S. cerevisiae) 1.6 0.030 
6019 RLN2 relaxin 2 1.7 0.040 
957 ENTPD5 ectonucleoside triphosphate diphosphohydrolase 5 1.7 0.004 
79054 TRPM8 transient receptor potential cation channel, subfamily M, member 8 1.8 0.022 
10417 SPON2 spondin 2, extracellular matrix protein 1.8 0.012 
11012 KLK11 kallikrein-related peptidase 11 1.8 0.007 
283651 C15orf21 Dresden prostate cancer 2 1.8 0.023 
2346 FOLH1 folate hydrolase (prostate-specific membrane antigen) 1 1.8 0.027 
84419 C15orf48 chromosome 15 open reading frame 48 2.0 0.012 
3158 HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) 2.0 0.017 
Selection (fold change ≤-1.5 or ≥1.5) of genes which are up-regulated or down-regulated in the selenium group. The 
reported mean fold change and p-value represent expression changes within the selenium group and were calculated using 
the two-tailed, paired Limma t test (p-value <0.05). Furthermore, all genes were differentially changed between the 
selenium and placebo group (one-way ANOVA Limma p-value <0.05).   
 
Supplementary Table 6.b 
Entrez ID Gene symbol Description Fold change p-value 
6476 SI sucrase-isomaltase (alpha-glucosidase) -2.9 0.000 
23671 TMEFF2 transmembrane protein with EGF-like and two follistatin-like domains 2 -2.6 0.004 
6013 RLN1 relaxin 1 -2.6 0.044 
542767 PCOTH prostate collagen triple helix -2.4 0.001 
119694 OR51F2 olfactory receptor, family 51, subfamily F, member 2 -2.3 0.004 
440905 LOC440905 hypothetical LOC440905 -2.2 0.000 
7033 TFF3 trefoil factor 3 (intestinal) -2.2 0.003 
4224 MEP1A meprin A, alpha (PABA peptide hydrolase) -2.1 0.014 
1807 DPYS dihydropyrimidinase -2.0 0.000 
341883 LRRC9 leucine rich repeat containing 9 -2.0 0.003 
56667 MUC13 mucin 13, cell surface associated -2.0 0.050 
6019 RLN2 relaxin 2 -1.9 0.016 
54474 KRT20 keratin 20 -1.9 0.033 
54860 MS4A12 membrane-spanning 4-domains, subfamily A, member 12 -1.8 0.031 
50940 PDE11A phosphodiesterase 11A -1.8 0.003 
2044 EPHA5 EPH receptor A5 -1.8 0.001 
23310 NCAPD3 non-SMC condensin II complex, subunit D3 -1.8 0.032 
338596 ST8SIA6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 -1.8 0.009 
729171 ANKRD20B ankyrin repeat domain 20B -1.8 0.001 
157310 PEBP4 phosphatidylethanolamine-binding protein 4 -1.8 0.019 
54898 ELOVL2 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 2 -1.8 0.008 
6581 SLC22A3 solute carrier family 22 (extraneuronal monoamine transporter), member 3 -1.7 0.007 
33 ACADL acyl-CoA dehydrogenase, long chain -1.7 0.003 
1135 CHRNA2 cholinergic receptor, nicotinic, alpha 2 (neuronal) -1.7 0.032 
3899 AFF3 AF4/FMR2 family, member 3 -1.7 0.006 
55504 TNFRSF19 tumor necrosis factor receptor superfamily, member 19 -1.7 0.002 
4583 MUC2 mucin 2, oligomeric mucus/gel-forming -1.7 0.041 
493913 PAPPAS PAPPA antisense RNA (non-protein coding) -1.7 0.005 
4045 LSAMP limbic system-associated membrane protein -1.7 0.009 
11148 HHLA2 HERV-H LTR-associating 2 -1.7 0.013 
885 CCK cholecystokinin -1.7 0.004 
2980 GUCA2A guanylate cyclase activator 2A (guanylin) -1.7 0.005 
2168 FABP1 fatty acid binding protein 1, liver -1.6 0.004 
10223 GPA33 glycoprotein A33 (transmembrane) -1.6 0.016 
9576 SPAG6 sperm associated antigen 6 -1.6 0.005 
57554 LRRC7 leucine rich repeat containing 7 -1.6 0.028 
154091 SLC2A12 solute carrier family 2 (facilitated glucose transporter), member 12 -1.6 0.001 
1138 CHRNA5 cholinergic receptor, nicotinic, alpha 5 -1.6 0.012 
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353322 ANKRD37 ankyrin repeat domain 37 -1.6 0.001 
5558 PRIM2 primase, DNA, polypeptide 2 (58kDa) -1.6 0.018 
4285 MIPEP mitochondrial intermediate peptidase -1.6 0.002 
29091 STXBP6 syntaxin binding protein 6 (amisyn) -1.6 0.005 
6695 SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1 -1.6 0.006 
81796 SLCO5A1 solute carrier organic anion transporter family, member 5A1 -1.6 0.010 
9687 GREB1 growth regulation by estrogen in breast cancer 1 -1.6 0.006 
90288 C3orf25 chromosome 3 open reading frame 25 -1.6 0.008 
10739 RFPL2 ret finger protein-like 2 -1.6 0.029 
22843 PPM1E protein phosphatase, Mg2+/Mn2+ dependent, 1E -1.6 0.011 
1573 CYP2J2 cytochrome P450, family 2, subfamily J, polypeptide 2 -1.6 0.003 
375611 SLC26A5 solute carrier family 26, member 5 (prestin) -1.6 0.000 
220965 FAM13C family with sequence similarity 13, member C -1.6 0.012 
1015 CDH17 cadherin 17, LI cadherin (liver-intestine) -1.6 0.039 
1767 DNAH5 dynein, axonemal, heavy chain 5 -1.6 0.014 
57185 NIPAL3 NIPA-like domain containing 3 -1.5 0.049 
1047 CLGN calmegin -1.5 0.038 
4133 MAP2 microtubule-associated protein 2 -1.5 0.027 
84125 LRRIQ1 leucine-rich repeats and IQ motif containing 1 -1.5 0.002 
2651 GCNT2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) -1.5 0.028 
125981 ACER1 alkaline ceramidase 1 -1.5 0.013 
1491 CTH cystathionase (cystathionine gamma-lyase) -1.5 0.000 
10846 PDE10A phosphodiesterase 10A -1.5 0.020 
29968 PSAT1 phosphoserine aminotransferase 1 -1.5 0.007 
57715 SEMA4G sema domain, (Ig), transmembrane domain (TM) and short cytoplasmic domain, 4G -1.5 0.011 
39 ACAT2 acetyl-CoA acetyltransferase 2 -1.5 0.015 
79846 C7orf63 chromosome 7 open reading frame 63 -1.5 0.013 
81033 KCNH6 potassium voltage-gated channel, subfamily H (eag-related), member 6 -1.5 0.013 
11123 RCAN3 RCAN family member 3 -1.5 0.016 
11001 SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 -1.5 0.044 
64757 MOSC1 MOCO sulphurase C-terminal domain containing 1 -1.5 0.005 
2786 GNG4 guanine nucleotide binding protein (G protein), gamma 4 -1.5 0.037 
23566 LPAR3 lysophosphatidic acid receptor 3 -1.5 0.040 
84084 RAB6C RAB6C, member RAS oncogene family -1.5 0.028 
79748 LMAN1L lectin, mannose-binding, 1 like -1.5 0.017 
27284 SULT1B1 sulfotransferase family, cytosolic, 1B, member 1 -1.5 0.028 
79986 ZNF702P zinc finger protein 702, pseudogene -1.5 0.021 
2104 ESRRG estrogen-related receptor gamma -1.5 0.006 
23245 ASTN2 astrotactin 2 -1.5 0.002 
89944 GLB1L2 galactosidase, beta 1-like 2 -1.5 0.003 
54733 SLC35F2 solute carrier family 35, member F2 -1.5 0.022 
116328 C8orf34 chromosome 8 open reading frame 34 -1.5 0.000 
3977 LIFR leukemia inhibitory factor receptor alpha -1.5 0.006 
55964 SEPT3 septin 3 -1.5 0.033 
3638 INSIG1 insulin induced gene 1 -1.5 0.010 
10020 GNE glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase -1.5 0.003 
57181 SLC39A10 solute carrier family 39 (zinc transporter), member 10 -1.5 0.011 
56171 DNAH7 dynein, axonemal, heavy chain 7 -1.5 0.000 
202151 RANBP3L RAN binding protein 3-like -1.5 0.033 
4685 NCAM2 neural cell adhesion molecule 2 -1.5 0.010 
3781 KCNN2 potassium intermediate/small conductance calcium-activated channel, subfam N,2 -1.5 0.009 
220416 LRRC63 leucine rich repeat containing 63 -1.5 0.002 
728606 LOC728606 hypothetical LOC728606 -1.5 0.006 
4983 OPHN1 oligophrenin 1 -1.5 0.000 
128344 C1orf88 chromosome 1 open reading frame 88 -1.5 0.022 
4929 NR4A2 nuclear receptor subfamily 4, group A, member 2 1.5 0.007 
5920 RARRES3 retinoic acid receptor responder (tazarotene induced) 3 1.5 0.006 
714 C1QC complement component 1, q subcomponent, C chain 1.5 0.000 
3880 KRT19 keratin 19 1.5 0.006 
10261 IGSF6 immunoglobulin superfamily, member 6 1.5 0.003 
5328 PLAU plasminogen activator, urokinase 1.5 0.001 
4233 MET met proto-oncogene (hepatocyte growth factor receptor) 1.5 0.031 
25903 OLFML2B olfactomedin-like 2B 1.5 0.001 
3399 ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1.5 0.003 
4064 CD180 CD180 molecule 1.5 0.006 
8875 VNN2 vanin 2 1.5 0.026 
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27286 SRPX2 sushi-repeat-containing protein, X-linked 2 1.5 0.018 
5396 PRRX1 paired related homeobox 1 1.5 0.009 
3119 HLA-DQB1 major histocompatibility complex, class II, DQ beta 1 1.5 0.003 
79750 ZNF385D zinc finger protein 385D 1.5 0.035 
2122 MECOM MDS1 and EVI1 complex locus 1.5 0.000 
1075 CTSC cathepsin C 1.5 0.000 
963 CD53 CD53 molecule 1.5 0.003 
56938 ARNTL2 aryl hydrocarbon receptor nuclear translocator-like 2 1.5 0.006 
7474 WNT5A wingless-type MMTV integration site family, member 5A 1.5 0.003 
58475 MS4A7 membrane-spanning 4-domains, subfamily A, member 7 1.5 0.001 
633 BGN biglycan 1.5 0.006 
8870 IER3 immediate early response 3 1.5 0.000 
3772 KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15 1.5 0.004 
2335 FN1 fibronectin 1 1.5 0.015 
5270 SERPINE2 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 2 1.5 0.007 
3687 ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) 1.5 0.003 
54209 TREM2 triggering receptor expressed on myeloid cells 2 1.5 0.003 
27242 TNFRSF21 tumor necrosis factor receptor superfamily, member 21 1.5 0.001 
9332 CD163 CD163 molecule 1.5 0.011 
64231 MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 1.5 0.000 
1043 CD52 CD52 molecule 1.5 0.003 
56925 LXN latexin 1.5 0.002 
196 AHR aryl hydrocarbon receptor 1.5 0.001 
80896 NPL N-acetylneuraminate pyruvate lyase (dihydrodipicolinate synthase) 1.5 0.001 
1012 CDH13 cadherin 13, H-cadherin (heart) 1.5 0.016 
1999 ELF3 E74-like factor 3 (ets domain transcription factor, epithelial-specific ) 1.5 0.008 
2524 FUT2 fucosyltransferase 2 (secretor status included) 1.5 0.022 
3394 IRF8 interferon regulatory factor 8 1.6 0.001 
3397 ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 1.6 0.001 
7434 VIPR2 vasoactive intestinal peptide receptor 2 1.6 0.011 
7482 WNT2B wingless-type MMTV integration site family, member 2B 1.6 0.026 
1536 CYBB cytochrome b-245, beta polypeptide 1.6 0.002 
55107 ANO1 anoctamin 1, calcium activated chloride channel 1.6 0.004 
6337 SCNN1A sodium channel, nonvoltage-gated 1 alpha 1.6 0.002 
3689 ITGB2 integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) 1.6 0.000 
1959 EGR2 early growth response 2 1.6 0.000 
3726 JUNB jun B proto-oncogene 1.6 0.000 
10154 PLXNC1 plexin C1 1.6 0.000 
3934 LCN2 lipocalin 2 1.6 0.019 
9052 GPRC5A G protein-coupled receptor, family C, group 5, member A 1.6 0.009 
11006 LILRB4 leukocyte immunoglobulin-like receptor, subfamily B (with TM / ITIM domains), 4 1.6 0.001 
2207 FCER1G Fc fragment of IgE, high affinity I, receptor for ///  gamma polypeptide 1.6 0.003 
9120 SLC16A6 solute carrier family 16, member 6 (monocarboxylic acid transporter 7) 1.6 0.011 
388325 C17orf87 chromosome 17 open reading frame 87 1.6 0.001 
11010 GLIPR1 GLI pathogenesis-related 1 1.6 0.001 
3694 ITGB6 integrin, beta 6 1.6 0.001 
1462 VCAN versican 1.6 0.027 
6366 CCL21 chemokine (C-C motif) ligand 21 1.6 0.023 
51338 MS4A4A membrane-spanning 4-domains, subfamily A, member 4 1.6 0.001 
6423 SFRP2 secreted frizzled-related protein 2 1.6 0.001 
1846 DUSP4 dual specificity phosphatase 4 1.6 0.004 
7127 TNFAIP2 tumor necrosis factor, alpha-induced protein 2 1.6 0.005 
4688 NCF2 neutrophil cytosolic factor 2 1.7 0.002 
8832 CD84 CD84 molecule 1.7 0.000 
3075 CFH complement factor H 1.7 0.002 
11326 VSIG4 V-set and immunoglobulin domain containing 4 1.7 0.006 
241 ALOX5AP arachidonate 5-lipoxygenase-activating protein 1.7 0.004 
121506 ERP27 endoplasmic reticulum protein 27 1.7 0.007 
1520 CTSS cathepsin S 1.7 0.000 
7805 LAPTM5 lysosomal protein transmembrane 5 1.7 0.000 
4481 MSR1 macrophage scavenger receptor 1 1.7 0.006 
445 ASS1 argininosuccinate synthase 1 1.7 0.000 
9547 CXCL14 chemokine (C-X-C motif) ligand 14 1.7 0.004 
1958 EGR1 early growth response 1 1.7 0.001 
6347 CCL2 chemokine (C-C motif) ligand 2 1.8 0.041 
4582 MUC1 mucin 1, cell surface associated 1.8 0.004 
S e l e n i u m  a n d  p r o s t a t e  c a n c e r | 
119 | P a g e  
7052 TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase) 1.8 0.000 
7058 THBS2 thrombospondin 2 1.8 0.039 
9076 CLDN1 claudin 1 1.8 0.001 
1118 CHIT1 chitinase 1 (chitotriosidase) 1.8 0.005 
5918 RARRES1 retinoic acid receptor responder (tazarotene induced) 1 1.8 0.014 
6036 RNASE2 ribonuclease, RNase A family, 2 (liver, eosinophil-derived neurotoxin) 1.8 0.008 
2191 FAP fibroblast activation protein, alpha 1.8 0.020 
2359 FPR3 formyl peptide receptor 3 1.8 0.001 
51442 VGLL1 vestigial like 1 (Drosophila) 1.8 0.002 
2212 FCGR2A Fc fragment of IgG, low affinity IIa, receptor (CD32) 1.8 0.000 
968 CD68 CD68 molecule 1.8 0.000 
4023 LPL lipoprotein lipase 1.8 0.025 
5265 SERPINA1 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 1.8 0.007 
7057 THBS1 thrombospondin 1 1.9 0.000 
284340 CXCL17 chemokine (C-X-C motif) ligand 17 1.9 0.003 
1490 CTGF connective tissue growth factor 1.9 0.001 
6363 CCL19 chemokine (C-C motif) ligand 19 1.9 0.001 
10457 GPNMB glycoprotein (transmembrane) nmb 1.9 0.000 
346389 MACC1 metastasis associated in colon cancer 1 1.9 0.002 
1382 CRABP2 cellular retinoic acid binding protein 2 1.9 0.000 
3491 CYR61 cysteine-rich, angiogenic inducer, 61 2.0 0.001 
3855 KRT7 keratin 7 2.0 0.026 
1311 COMP cartilage oligomeric matrix protein 2.1 0.003 
22943 DKK1 dickkopf homolog 1 (Xenopus laevis) 2.1 0.000 
6523 SLC5A1 solute carrier family 5 (sodium/glucose cotransporter), member 1 2.1 0.002 
4318 MMP9 matrix metallopeptidase 9 (92kDa gelatinase, 92kDa type IV collagenase) 2.2 0.007 
5743 PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin synthase/ cyclooxygenase) 2.2 0.003 
2568 GABRP gamma-aminobutyric acid (GABA) A receptor, pi 2.2 0.000 
5054 SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), 1 2.3 0.000 
4069 LYZ lysozyme 2.3 0.002 
266977 GPR110 G protein-coupled receptor 110 2.4 0.001 
1356 CP ceruloplasmin (ferroxidase) 2.5 0.024 
4316 MMP7 matrix metallopeptidase 7 (matrilysin, uterine) 2.5 0.039 
6590 SLPI secretory leukocyte peptidase inhibitor 3.0 0.000 
1116 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) 3.1 0.003 
Selection (fold change ≤-1.5 or ≥1.5) of genes which are up-regulated or down-regulated in the placebo group. The reported 
mean fold change and p-value represent expression changes within the placebo group and were calculated using the two-tailed, 
paired Limma t test (p-value <0.05). Furthermore, all genes were differentially changed between the selenium and placebo group 
(one-way ANOVA Limma p-value <0.05). 
  
 
Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The overall aim of this thesis was to obtain insight into nutritional and clinical aspects relevant to different 
stages of prostate cancer. In the following paragraphs, the main findings presented in this thesis will be 
summarized. Next, implications and future perspectives, which might be of relevance to the researcher, 
(future) patient or urologist will be discussed.  
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Table 7.1 Overview of the studies presented in this thesis  
Chapter Design  
of the study 
Population Exposure Outcome Main findings 
 2 Descriptive 
study 
(retrospective) 
Patients 
diagnosed with 
PCA (n=956) 
- Perceived 
causes of 
their PCA 
Established causes 
of PCA were not 
commonly 
perceived, not even 
among patients with 
these risk factors 
 3 Population-
based cohort 
study 
General male 
population 
(n=2,118)  
Serum levels of 
triglycerides 
and total, HDL 
and LDL 
cholesterol  
PCA incidence 
(43 cases) 
Higher LDL and HDL 
cholesterol 
increased the risk of 
aggressive PCA and 
non-aggressive PCA, 
respectively 
 4 Population-
based cohort 
study 
Patients with 
cancer identified 
through the 
population-based 
cancer registry 
(n=551,553) 
Type of cancer 
(versus the 
general 
population) 
PCA incidence 
(9,243 cases) 
Cancer survivors had 
an increased PCA 
risk in the first year 
following their first 
cancer diagnosis 
 5a Population-
based cohort 
study 
Patients with PCA 
and treated with 
RP identified 
through the 
population-based 
cancer registry 
(n=493) 
BMI Risk of 
biochemical 
recurrence 
after RP  
(142 cases) 
BMI was not a 
predictor of 
biochemical 
recurrence after RP  
 5b Hospital-based 
cohort study 
Patients with PCA 
and treated with 
RP identified 
from two 
academic 
hospitals 
(n=1,302) 
BMI Risk of 
biochemical 
recurrence 
after RP 
(297 cases) 
BMI was not a 
predictor of 
biochemical 
recurrence after RP 
 6 Randomized, 
placebo-
controlled 
intervention 
trial 
Patients with a 
suspicion or 
diagnosis of PCA 
and scheduled 
for prostate 
biopsies (n=23) 
300 ug 
selenized yeast 
or placebo 
during a 5-
week 
intervention 
period 
Changes in 
gene 
expression 
profiles in 
non-
malignant 
prostate 
tissue (n=15) 
Selenium affected 
expression of genes 
implicated in 
inflammation and 
EMT in the prostate 
Abbreviations:  BMI body mass index, EMT epithelial-to-mesenchymal transition, HDL high-density 
lipoprotein, LDL low-density lipoprotein, PCA prostate cancer, RP radical prostatectomy. 
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7.1  Outline 
 
The aim of this thesis was to evaluate nutritional, lifestyle and clinical factors involved 
in different stages of prostate cancer. Reflecting on this main aim, I focused on a 
number of specific research objectives, which were also described in Chapter 1; 
 
1. Identification of leads for research on potential risk factors  
2. Evaluation of risk factors for incident prostate cancer  
3. Evaluation of factors that might influence risk of recurrent disease  
4. Studying the molecular mechanisms of chemoprevention  
 
In order to address these research objectives, this thesis described a relatively broad 
spectrum of studies, ranging from a descriptive, qualitative study to a randomized 
clinical trial with molecular endpoints. An overview of the design of these studies is 
presented in Table 7.1.  
 
In the following paragraphs, the main findings will be briefly summarized and I will 
reflect on the scientific implications and future perspectives of each of the research 
objectives. Relevance of the findings from the point of view of the (future) patient and 
urologist will be discussed in paragraph 7.3 and 7.4.  
 
 
7.2  Implications for researchers  
 
Methods for evaluation of scientific quality are widely described1, 2 and frequently 
applied in systematic literature reviews or meta-analyses. Therefore, these issues will 
not be discussed in detail in this chapter. Instead, I will focus on the questions: “How 
can we develop studies that provide useful answers to our research questions? What 
have we learned from our studies and how can we implement this knowledge or 
experience to improve future studies?”  
 
7.2.1 Identification of leads for research on potential risk factors  
 
The identification of new risk factors for prostate cancer is important in order to 
understand the aetiology, to identify high-risk groups for early detection and to 
develop effective prevention strategies. Chapter 2 described the results from an 
explorative study in which patients with prostate cancer were asked about perceived 
causes of their disease. Results of this study showed that the majority of the patients 
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was not able to mention any cause that might have contributed to the development of 
their prostate cancer. Patients who did report perceived causes often referred to 
heredity, specific environmental factors, nutrition or physical activity, and stress. 
Although we were not able to identify outstanding leads for research on new risk 
factors, this study was valuable from the perspective that possible gaps were identified 
in the perception and knowledge of both patients and scientists.  
 
The odd one out 
At the time of writing this discussion, the paper described in Chapter 2 was submitted 
to eight different peer-reviewed journals in the field of oncology or urology. Only one 
journal has sent this paper for peer-review, all others directly indicated that the paper 
was outside the scope of the journal. There might be a few possible underlying reasons 
for the repeated rejections. First, the topic of the paper was indeed outside the scope 
of all the approached journals or other papers had priority for these journals. Second, 
the quality of the paper was believed to be poor. Third, the objective or design of the 
study was perceived as inadequate. Or fourth, a qualitative paper with mainly quotes 
rather than numbers or graphs is rather exceptional in this field. As a number of 
independent editors explicitly stated that the paper was clear and well-written, I tend 
to assume that quality was not the main reason, although we are of course willing to 
accept other opinions. Also, the topic of the paper seems to be adequate as prostate 
cancer is a rather common topic in the fields of oncology and urology. Therefore, it 
was likely the approach, the design and the nature of our paper that were critically 
perceived. Since I still think that the results of our study are interesting in a way that 
they reflect the reasoning and perceptions of the patients, we critically reconsidered 
its limitations and looked for improvements. A few methodological aspects and 
implications will be discussed below. 
 
How to find a needle in a haystack? 
In this study, over 65 unique, possible causes of prostate cancer were identified. All of 
these causes were reported by experts in the field; namely the patients who more or 
less know what happened during their lives, who experienced all important events by 
themselves and who might be aware of the different aspects that preceded their 
prostate cancer development. However, out of all these answers, how should we 
exactly find the interesting and promising leads for future research? Is the use of felt-
tip pens a possible cause of prostate cancer, or is the Chernobyl disaster a more likely 
candidate?  
 
Ideally, we would like to observe a ‘pattern’ in the answers of the patients. If several 
patients would have mentioned the use of felt-tip pens as a possible cause of their 
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prostate cancer, this would have been an interesting lead, apart from a low prior in the 
sense of biological plausibility. Nevertheless, the fact that only one patient mentioned 
felt-tip pens does not necessarily mean that this is not a possible risk factor for 
prostate cancer. In our study, we found some general causes or broad categories, such 
as stress and heredity, which were reported by several patients. Majority of the 
causes, however, referred to highly-specific factors reported by individual patients. 
Therefore, the most efficient and adequate approach to analyse these data seemed to 
be a combination of a systematic strategy and common sense.  
 
First, we intended to group the reported causes in categories. Based on the available 
literature, we then aimed to judge whether these categories are likely risk factors for 
prostate cancer or not. Finally, we tried to provide insight into the reasoning and 
perceptions of the patients by citing and emphasizing various specific causes within 
each category. Although we realize that this approach may not be the most 
conventional strategy to find new and outstanding risk factors, it helped us to reveal 
unprompted beliefs of cancer causation, to identify common misperceptions, and to 
recognize gaps in the available literature. 
 
The question has partly determined the answer 
Various studies have already evaluated perceptions about causes of prostate cancer3-5 
and also other forms of cancer6-8. Most of these studies asked their participants or 
patients the question: “Do you know what causes cancer?” In our study, we used a 
similar question, however, we just added a personal touch by asking: “Do you known 
what may have been the cause of your cancer?” There is a substantial difference in the 
interpretation of both questions. The first question determines knowledge, while the 
second question refers to a personal situation. If we asked our patients: “Do you know 
what causes prostate cancer?” we assume that various patients would have reported 
age, heredity and black race, because these are established risk factors for prostate 
cancer3. In our study, however, we did not ask the patients about their knowledge, but 
about their personal situation. This might explain why relatively few patients reported 
causes related to established risk factors for prostate cancer; our patients were merely 
white men who possibly did not perceive themselves as old or did not have a positive 
family history. However, we cannot rule out the possibility that lack of knowledge also 
contributed to the relatively low response rate.  
 
A few other studies from the United States and Australia examined perceived causes of 
prostate cancer among patients recently diagnosed with this disease4, 5, 9. In these 
studies it was demonstrated that patients with prostate cancer were least likely (42%) 
to report perceived causes, as compared to other cancer patients (48-75%), which was 
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explained by the authors by the lack of scientific evidence available for factors involved 
in prostate carcinogenesis5. Although we were not directly able to provide useful data 
on the knowledge of our patients, we clearly demonstrated that the vast majority of 
the patients was not able to identify any cause of their disease and that some 
overestimations and misconceptions persist about factors that are unlikely to influence 
prostate cancer risk. 
 
Furthermore, the established risk factors for prostate cancer were not commonly 
perceived, not even among patients with these risk factors, which suggests that there 
might be a key role for effective cancer education and prevention programmes. In 
order to provide detailed insight into the reasoning of the patients, we suggest 
combining data on knowledge and perception of cancer causes. A suggestion for future 
studies is therefore to include the following questions: “Do you know what causes 
prostate cancer?”, “Can you report which of these causes might have contributed to 
the development of your prostate cancer?”, and “Are there any other possible factors 
that might have contributed to the development of your prostate cancer?” By using this 
approach it will be possible to determine either the knowledge about general risk 
factors, as well as the perception of individual risk factors.  
 
In conclusion 
Cancer is a multifactorial disease with a complex aetiology. The identification and 
confirmation of new risk factors for cancer is complicated by the lack of a standardized 
approach, the limitations and challenges of most study designs, and the possible 
interactions between risk factors and biological factors. Asking patients about 
perceived causes of their cancer might help to identify leads for aetiological research. 
Combining information on patients’ perceptions and knowledge will improve insight 
into reasoning of the patients and at the same time indicate whether effective 
education and prevention programs are required.  
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7.2.2 Evaluation of risk factors for incident prostate cancer  
 
Two potential risk factors for incident prostate cancer were evaluated in this thesis. In 
Chapter 3, the association between blood lipid levels and prostate cancer incidence 
was studied. Results showed that higher serum levels of total cholesterol and LDL 
cholesterol were associated with an increased risk of prostate cancer. Furthermore, 
higher levels of LDL cholesterol were also associated with an increased risk of 
aggressive prostate cancer, while higher levels of HDL cholesterol were associated with 
an increased risk of non-aggressive disease. Based on these findings, we confirm that 
blood lipid levels might be considered as a possible risk factor for prostate cancer, 
although the potential underlying mechanisms should be examined in more detail in 
future studies.  
 
The risk of prostate cancer as a second primary cancer was examined in Chapter 4. We 
showed that cancer survivors had an increased risk of being diagnosed with prostate 
cancer as compared to the general Dutch population. For most of the specific first 
cancer sites, the increased prostate cancer risk was limited to the first year of follow-
up, which implies a main effect of active screening or incidental detection. 
 
The incidence of prostate cancer depends on screening 
Incident prostate cancer, registered by the Dutch population-based cancer registry, is 
used as an endpoint in both studies described in Chapter 3 and 4. Incident prostate 
cancer is defined as a registered diagnosis of prostate cancer after start of a study or 
exposure measurement. A possible limitation of incident prostate cancer as an 
endpoint is that active screening influences the incidence rates, especially in studies 
with disease-related exposures. PSA tests are widely used to detect prostate cancer. 
Although the specificity of this method for prostate cancer is debatable10, 11, active 
searching and screening for prostate cancer will lead to more detected cases of 
prostate cancer; i.e. higher incidence rates. A substantial number of the detected 
prostate cancers might lack clinical relevance, because most insignificant tumours will 
never cause symptoms or increase morbidity, but may lead to overtreatment and 
related complications12, 13. This observation also explains why PSA testing is not 
implemented as a population-wide screening method for prostate cancer and why the 
intensive screening policies for the general population in the USA have been recently 
tempered14, 15.  
 
Nevertheless, men who were previously diagnosed with any disease or experienced 
health problems might, because of anxiety or medical indications, tend to apply for 
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PSA testing or other screening or diagnostic methods relatively frequently. As a 
consequence, the prostate cancer incidence might be higher in these men as 
compared to the general, healthy population. With respect to scientific studies, this 
does not necessarily affect study outcomes as long as the likelihood of detecting 
prostate cancer is the same for all study participants. However, if only specific 
subgroups are far more likely to undergo screening, which in theory could be the 
patients with an unfavourable blood lipid profile, or previously diagnosed urological 
cancers in our studies, this might influence the risk estimates for prostate cancer.   
 
Besides, the diagnosis of mainly non-aggressive, or insignificant prostate tumours 
detected by screening might hinder the generalizability and clinical relevance of the 
study findings. An example of this issue is also provided by the Reduction by 
Dutasteride of Prostate Cancer Events (REDUCE) trial (see also Chapter 1). The 
extensive REDUCE trial aimed to evaluate the effects of dutasteride on prostate cancer 
incidence in high-risk men16, 17. As expected due to the high-risk profile, but also due to 
the protocol-directed biopsies for all participants at the end of the study, the incidence 
of prostate cancer was extremely high (25%)17, even compared to men with a 
comparable prostate cancer risk (8-10%)18, 19. Because of the intervention with 
dutasteride, the prostate cancer incidence decreased from 25% to 20%17. Given the 
much lower expected incidence rates for the general population, the relevance of this 
risk reduction remains debatable19. In parallel, caution should be paid to the possible 
effects of a detection bias in our studies. Although our patients were not intensively 
screened for prostate cancer, there might be a tendency to relatively frequent PSA 
testing among some specific subgroups. Ideally, future studies should take into 
account the frequency and reasons for PSA testing, for instance by linking incidence 
data to electronic patient files with laboratory applications and results.  
 
It is time to shift the focus from association to causation 
Our studies provided useful insight into the associations between exposures and 
incidence of prostate cancer. The outcomes of the studies can be interpreted in terms 
of chance or risk: “does the studied exposure influence the risk of getting prostate 
cancer?” However, information about risk usually does not explain the underlying 
mechanisms. Therefore, the next step is to gain insight into the causality. It is 
important to determine whether there is a biological, clinical or technical explanation 
for the suggested association. The risk of getting prostate cancer after a previous 
cancer diagnosis can, for instance, be higher because both cancers share specific 
aetiological factors such as a common genetic background. Another option is that 
treatment for the first cancer results in an increased or decreased risk of prostate 
cancer. Third, patients with a previous cancer might opt for PSA screening more often 
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as compared to a general population. Also reverse causality should be considered in 
our studies. Reverse causality refers to the phenomenon that the outcome influenced 
the exposure. Our study suggests that higher levels of serum cholesterol increased the 
risk of getting prostate cancer. However, we cannot exclude the possibility that the 
opposite happened; i.e. that the preclinical prostate tumour affected blood lipid levels. 
This issue of reverse causality might be partly solved by excluding the incident prostate 
cancer cases diagnosed during the first years of follow-up. However, because prostate 
cancer is often a slow-growing and indolent cancer, reverse causality cannot be fully 
excluded.  
 
Adding another level of evidence might provide more insight into the issues described 
above. An option is to continue with mechanistic-oriented research. Experiments with 
cell lines or animal models could for example elucidate whether high levels of 
cholesterol will increase the synthesis of androgens from cholesterol, whereas clinical 
studies are needed to confirm the suggested association between availability of 
cholesterol and androgen synthesis in malignant prostate tissue20. Another level of 
evidence might be provided by the randomized trials. This applies in particular to the 
studies with high-risk patients or modifiable exposures, such as the blood lipid levels 
which can be altered by diet and lifestyle changes or statin use. Nevertheless, the 
advantages of these approaches in contrast to the observational studies should not be 
overestimated, because the limited generalizability of most mechanistic studies and 
the ethical considerations of the randomized trials should be kept in mind.  
 
In conclusion 
Within the scope of the previously described research aim, we evaluated two possible 
risk factors for incident prostate cancer. As in other epidemiological studies, we cannot 
provide much information about the causality of the suggested association, which 
highlights the relevance of future studies. These studies should focus in particular on 
confirmation and validation of the findings and examination of aetiological 
mechanisms.  
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7.2.3 Evaluation of factors that might influence risk of recurrent 
disease  
 
For this research objective, we focussed on the evaluation of body mass index (BMI). In 
Chapter 5a and Chapter 5b, BMI was examined as a risk factor for biochemical 
recurrence following radical prostatectomy among patients with prostate cancer 
identified from the population-based cancer registry and two academic referral 
hospitals, respectively. BMI was not an independent predictor of biochemical 
recurrence in these two studies.  
 
Differentiation can make the difference 
BMI is often used to classify overweight (BMI 25.0-30.0 kg/m2) and obesity (BMI ≥30 
kg/m2)21. However, it has been extensively reviewed by others that the use of these 
categories has some limitations, because BMI in itself does not reflect body 
composition and does not differentiate between visceral and subcutaneous fat22-24. 
Other measures of overweight and body fat distribution might therefore provide 
additional information. There are some indications that waist circumference or the 
amount of visceral or periprostatic fat might predict prostate cancer risk25, 26 or 
aggressiveness27. Evidence for an effect on biochemical recurrence following radical 
prostatectomy or brachytherapy is scarce28. Therefore, it is suggested to include 
measures of fat distribution in future studies focussing on overweight and the risk of 
prostate cancer recurrence. As imaging techniques, such as magnetic resonance 
imaging (MRI), are nowadays often used for diagnosis and staging purposes29, it might 
be worthwhile to implement a standard protocol for the assessment of the amount of 
different types of fat on these images in clinical practice.  
 
Body size early in life warrants special attention 
Another relevant issue regarding the exposure in our studies is the timing of exposure 
measurement. Weight and height were collected retrospectively from questionnaires 
which were distributed among the prostate cancer patients, or from the clinical charts. 
In the questionnaire, patients reported average weight during adult life. In most cases, 
clinical data from the charts were recorded during an anaesthetic intake for the radical 
prostatectomy, which indicates that the patients were already diagnosed with prostate 
cancer at time of exposure measurement. From a clinical perspective, insight into the 
association between BMI at time of diagnosis and risk of biochemical recurrence can 
be useful for treatment-related considerations. From a biological perspective, 
however, rather than focussing on BMI at diagnosis, it might be interesting to evaluate 
whether overweight or obesity earlier in life predisposes towards more aggressive 
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prostate cancer or an increased risk of recurrence. Some cohort studies showed that a 
higher BMI at young age (18-29 years) was associated with either a decreased30, 31 or 
an increased32 risk of developing prostate cancer later in life33. Possible explanations 
for these findings might refer to hormonal conditions31, the ability to control 
homeostasis due to prolonged exposure, or specific lifestyle habits which explain some 
residual confounding. Although published results are conflicting and the exact 
mechanisms are not elucidated, these findings at least suggest that body size early in 
life might influence prostate carcinogenesis. To what extent this finding can be 
extrapolated to the risk of prostate cancer recurrence is not yet clear. For our study 
described in chapter 5a, we had self-reported data on weight at age 18. However, we 
did not include this variable in our univariable or multivariable proportional hazards 
regression models, as these data were only available for part of the patients who 
completed the questionnaires (n=399/504) and data on height at age 18 was not 
available for any of the patients. It might be interesting to include measures on weight 
and height during childhood, adolescence and adult life in future studies. Ideally, 
future comprehensive, prospective cohort studies should start at birth or even during 
pregnancy in order to follow body size at regular time points during life. Already a few 
of these extensive (sub)cohorts starting at relatively young age were initiated in the 
Netherlands (e.g. the PRIDE study34). Another option is to look into the possibility to 
link the patient data to registries of the Well Baby Clinics (0-4 years) and the 
Community Health Services (GGD, 4-19 years), who record weight and height during 
childhood and adolescence. As most of these registries use digital files since 2009, this 
approach is probably not effective until the current generation reaches the age of fifty 
and becomes at risk for prostate cancer. 
 
Biochemical recurrence as endpoint; does it really matter? 
As described above, we were interested in the effects of BMI on prostate cancer 
recurrence following radical prostatectomy. As radical prostatectomy is considered as 
a radical and curative treatment during which the entire prostate is removed, PSA 
levels should ideally become undetectable within six weeks following surgery35. Rising 
PSA levels, after an undetectable PSA, are often indicated as biochemical recurrence. 
In clinical practice, the regular follow-up of PSA levels and determination of 
biochemical recurrence can be used to consider options for secondary therapies. The 
use of biochemical recurrence as an endpoint in scientific studies, however, is 
characterized by some limitations. First, the cut-off levels to define rising PSA levels are 
not uniformly implemented. Over fifty different criteria were described to define 
biochemical recurrence following radical prostatectomy35. Also in our studies, two 
different approaches were used, which is due to the differences in registry strategies 
by the population-based cancer registry and the academic centres. In chapter 5a, we 
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defined biochemical recurrence as two consecutive PSA levels ≥0.2 ng/mL, while in 
chapter 5b we have chosen for two consecutive PSA levels ≥0.10 ng/mL. Although such 
subtle differences in definitions for biochemical recurrence does not necessarily 
influence the results of a study36, it hinders comparisons between studies. Therefore, I 
suggest that, if biochemical recurrence is used as an endpoint, a consensus about a 
uniform definition should be accepted. As suggested by others, a cut-off point 
between ≥0.2 ng/mL and ≥0.4 ng/mL seems to be most relevant with respect to clinical 
outcome35, 37. 
 
Second, although biochemical recurrence might reflect disease recurrence, it has been 
argued that it does not necessarily predict prognosis or prostate cancer-specific 
mortality38, 39. Alternative approaches would be to include ‘more clinically relevant’ 
endpoints such as prostate-cancer specific mortality. Potential disadvantages of this 
approach are the requirement of a relatively long follow-up, and the possible 
interference of secondary therapies, which can make it rather complicated to deduce 
the direct association between exposure and outcome. Already a few prospective 
studies showed suggestive associations for BMI and prostate-cancer specific mortality 
following various types of treatment40. Another option is to verify disease recurrence 
using additional methods. According to the guidelines of the European Association of 
Urology it is recommended to follow patients for at least ten years after treatment41. 
In case of rising PSA levels (≥20 ng/mL) or complaints of bone pain, prostate biopsies 
and MRI/CT or bone scans are indicated to verify disease recurrence and presence of 
metastases. Combining the information regarding rising PSA levels (biochemical 
recurrence), a palpable nodule, and presence of metastases detected by biopsy or 
imaging techniques (clinical recurrence) might improve the clinical relevance of future 
studies. 
 
Mechanistic research is needed to understand the role of adiposity in prostate 
carcinogenesis 
In the previous paragraphs, we already discussed topics related to the exposure and 
endpoint of our current studies. Optimization and extension of the observational 
studies will hopefully contribute to new insights and compelling evidence. However, it 
does not add an extra level of evidence. It is now time to move forward and to have a 
look from a different perspective. One approach is to focus on the tissues of interest 
itself: adipose tissue and prostate tissue. Especially for patients treated with radical 
prostatectomy, it is relatively easy to collect small samples of subcutaneous fat and 
pre-peritoneal fat or periprostatic fat42. Also small prostate needle biopsies can be 
easily collected during surgery. By collecting these tissues from all patients who 
provide written informed consent, a biobank of surgical samples can be initiated. 
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Combined with routinely collected information about weight, height (anaesthetic 
records) and body fat distribution (from a staging MRI), this biobank can be a starting 
point for mechanistic research on the association between body size, metabolic health 
and prostate carcinogenesis. 
 
As adipose tissue behaves like a metabolically-active organ43, it might be interesting to 
study the secretory profile of the adipose tissue surrounding the prostate. Circulating 
levels of several adipokines have already been associated with the development and 
progression of prostate cancer44, 45. For colorectal cancer, a recent study showed that 
the expression of inflammatory adipokines in the visceral adipose tissue was higher in 
patients as compared to healthy controls46. These findings carefully suggest that the 
inflammatory adipokines might facilitate the development of cancer, possibly by 
maintaining a microenvironment which is favourable to the tumour cells. In parallel, 
adipose tissue surrounding the prostate might influence prostate carcinogenesis. Van 
Roermund and colleagues showed that the periprostatic fat content as measured by CT 
did correlate with prostate cancer aggressiveness in patients treated with radiotherapy 
or brachytherapy27. Furthermore, levels of the proinflammatory adipokine interleukin 
6 (IL-6) secreted by the periprostatic adipose tissue were correlated with increasing 
tumour grade in the prostate47. From these studies, however, it cannot be concluded 
whether the characteristics of the adipose tissue influenced prostate cancer 
aggressiveness or vice versa. Therefore, it would be interesting to study the role of the 
adipokines in the development and progression of prostate cancer in more detail. A 
possible starting point can be to isolate and culture periprostatic adipose tissue from a 
wide range of subjects. Exposure of prostate (cancer) cells to the conditioned culture 
medium of the periprostatic adipose tissue might explain how the secreted adipokines 
modulates proliferation of the prostate cancer cells.  
 
Mechanistic studies with prostate tissue, rather than adipose tissue, offer the 
opportunity to link body size to molecular signatures in the prostate. A recent study by 
Sharad and colleagues described the gene expression profiles in tumour (relative to 
normal) cells of patients with a high (mean ± SD; 27.6±1.67 kg/m2) or normal BMI 
(mean ± SD; 21.9±2.20 kg/m2)48. Although the authors did not extensively describe 
comparisons of high versus normal BMI, they showed that processes related to lipid 
metabolism and cholesterol homeostasis were altered in tumour cells of patients with 
a high BMI48. A next step would be to compare the prostatic gene expression profiles 
for patients with normal weight, overweight and obesity, or even correlate the gene 
expression profiles to a metabolic signature including BMI, fat distribution, the levels 
of circulating adipokines and characteristics of adipose tissue surrounding the 
prostate. 
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In conclusion 
In the previous paragraphs, some methodological aspects of our studies were discussed 
and at the same time suggestions or improvements for future research were provided. 
Ideally, future studies focussing on the effects of overweight and obesity on the risk of 
disease recurrence or progression should innovate by extending and collecting a broad 
spectrum of data. By using the current methodologies in clinical practice in an efficient 
way, these ‘new’ types of studies will not necessarily lead to complicated logistics or 
financial limitations. Diagnostic MRI or CT images can be used for measurements of fat 
distribution or periprostatic fat content, samples from adipose tissue and prostate 
tissue can be collected during radical prostatectomy and routinely collected data on 
disease recurrence or progression can be used to define clinically relevant endpoints. 
Hopefully, such new approaches will not only clarify whether or not, but also how and 
why, the presence of (abundant) adipose tissue is associated with prostate cancer 
development, recurrence and progression. 
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7.2.4 Studying the molecular mechanisms of chemoprevention  
 
In order to study the molecular mechanism underlying the possible chemopreventive 
effect of selenium, we examined changes in gene expression profiles in non-malignant 
prostate tissue in a randomized, placebo-controlled trial with selenized yeast. Results 
of this study showed that selenium induced an anti-inflammatory gene expression 
profile in the prostate. Furthermore, our data showed that supplementation with 
selenized yeast affected expression of genes implicated in the process of epithelial-to-
mesenchymal transition (EMT).   
 
The use of transcriptomics is a powerful tool to identify potential mechanisms 
As described above, the aim of our study presented in Chapter 6 was to examine the 
molecular mechanism underlying a possible chemopreventive effect of selenium. By 
using whole-genome microarrays, we were able to examine the expression of over 
19,000 annotated genes in one prostate needle biopsy simultaneously. The use of this, 
so called, ‘transcriptomics’ approach provided complete and comprehensive insights 
into the overall effects of selenium on gene expression profiles in the prostate. The 
main advantage of this approach is that we were not limited to a group of a priori 
selected genes which might be involved in cancer prevention according to previous 
literature or common hypotheses. Although these experiments are sometimes called 
‘fishing expeditions’, the whole-genome microarrays as such provide good 
opportunities for the development of new, pioneering ideas about molecular 
mechanisms. There are also a few methodological limitations considering the use of 
whole-genome microarrays. Meaningful genes might be missed due to the enormous 
amount of data, while biologically irrelevant processes could be overestimated as a 
consequence of prior knowledge or overrepresentation in the available literature.  
 
Since statistical testing for the identification of differentially expressed genes is 
performed for more than 19,000 genes simultaneously, there is a plausible chance of 
finding false-positives49. The use of q values, which is based on false discovery rates 
(FDR)50 and takes into account multiple-testing, is therefore often indicated in 
microarray analyses. However, the use of q values is complicated in human dietary 
intervention studies with relatively few participants and small effects as extensively 
described by others in our group51. We did not select genes based on q values in our 
studies for the reasons described earlier51. Instead, rather than highlighting expression 
changes of individual genes, we focussed on the identification of biological pathways 
that were differentially regulated within and between the experimental groups. 
Furthermore, the expression changes were highly consistent among the patients in the 
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two experimental groups, implicating that the observed effects were robust and truly 
reflect the effects of the intervention.  
 
Another possible difficulty related to the microarray experiments is the biological 
interpretation. As an example, the effects of selenium on the inflammatory processes 
will be discussed. Based on the observation that pathways involved in inflammation 
were down-regulated after the intervention with selenium, it was hypothesized that 
selenium induces an anti-inflammatory effect. From a biological point of view, one 
could argue that a down-regulation of inflammatory pathways is beneficial (less 
inflammation) or harmful (inadequate response to inflammation). Since it is well-
studied that a down-regulation of inflammatory pathways is associated with less 
inflammation in many conditions and tissues (e.g. references52, 53), we have no reason 
to assume that the anti-inflammatory effect of selenium is harmful. However, this 
example illustrates the difficulties related to the ‘two-way reasoning’. A possibility to 
improve the biological interpretability of the microarray data is again to add multiple 
levels of evidence. The microarray data we have used only reflect gene expression. 
Ideally, adding data related to, for instance, histology, protein expression, microRNA 
expression, and DNA methylation might result in a better understanding of the exact 
mechanisms and thereby improve clinical relevance. 
 
Studying differences in gene expression changes gets the most out of your 
microarray experiment 
Our intervention study is relatively unique in a way that we have collected prostate 
tissue at two time points, that is before and after the intervention period, and that we 
have included a placebo group. There have been a few studies which examined the 
effects of a dietary or lifestyle intervention on whole-genome gene expression profiles 
in the prostate54-58. Some have used a ‘preoperative’ model which means that after the 
intervention, prostate tissue was collected during surgery57. By using the preoperative 
model, it is only possible to compare experimental groups after intervention. Our ‘two-
biopsy’ model, however, also allowed comparisons within a person and thereby 
reflects changes in gene expression over time. Other studies, which did also use a ‘two-
biopsy’ model, did not include a placebo or control group54, 56. The use of a placebo or 
control group is crucial for the identification of effects that are independent of the 
intervention. By including a placebo group, we were able to identify the effects of the 
repeated biopsy, although we cannot fully exclude the possibility that the composition 
of the placebo pills or a progressive inflammatory or tumour environment contributed 
to the gene expression changes in the placebo group as well. There is one limitation of 
the ‘two-biopsy’ model in comparison to the ‘preoperative’ model. Since the biopsies 
were routinely collected during ultrasound-guided prostate needle biopsies, there was 
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limited amount of tissue available. In theory, this problem can be solved by extending 
the number of collected biopsies and thereby increasing the amount of tissue. The 
burden of these additional biopsies should be balanced against the well-being of the 
patients, because most patients already provide eight to ten prostate biopsies for 
diagnostic purposes. Future studies should therefore carefully consider whether the 
‘two-biopsy’ model, the ‘preoperative’ model or a combination of both will be most 
accurate to answer their research questions.  
 
Deficiency might explain efficiency 
The inconsistent findings from previous intervention studies focussing on the effects of 
selenium on prostate cancer incidence may be, amongst other reasons, explained by 
the baseline selenium status of the participants. In the Nutritional Prevention of 
Cancer (NPC) trial, mainly the participants with relatively low selenium status at 
baseline (plasma selenium <123.2 µg/L) seem to benefit from the daily intervention 
with 200 µg selenized yeast59. The median baseline serum selenium levels of the 
participants of the Selenium and Vitamin E Cancer Prevention (SELECT) Trial, which did 
not confirm a protective effect of selenium on prostate cancer risk, were relatively 
high at 135 µg/L60. After the daily intervention with 200 µg L-selenomethionine, serum 
selenium levels of the SELECT participants even increased to 252 µg/L60, which might 
exceed an optimal selenium status. Based on experimental studies in dogs, and a 
number of observational studies in humans, a U-shaped dose response curve for 
selenium status and several health outcomes was suggested61-63. This U-shaped dose 
response curve indicates that men with low selenium status might benefit from 
selenium supplementation, while men with a higher status might experience adverse 
effects of an additional selenium intake.  
 
What are the implications of this U-shaped dose response curve for the findings of our 
study? Since the selenium intake in most European countries is relatively low as 
compared to the United States62, it was expected that the selenium status of our 
patients was low in comparison to participants of the NPC trial and the SELECT trial. As 
shown in Figure 7.1, median serum levels of selenium of our patients were 78 µg/L and 
increased to 185 µg/L after a five week intervention with 300 µg selenized yeast per 
day. While overlaying the U-shaped dose response curve with these data, it indeed 
seemed that our patients started at a ‘low status’ and ended with an ‘optimal to high 
selenium status’. Based on these data and the results of our study, we hypothesize 
that our patients may benefit from a prolonged intervention with selenium. However, 
we do not have any data on prostate cancer risk and other health outcomes or 
occurrence of long-term adverse effects. Some60, 64-66, but not all67 previous studies 
suggested that serum selenium levels above 120-150 µg/L may already be associated 
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with adverse effects such as an increased risk of type 2 diabetes. It seems that the 
optimal range of selenium intake and status is narrow and strongly depend on various 
factors such as baseline status, genotype68-70, and metabolic capacity62. At this 
moment, the exact role of all these factors is unclear and there is insufficient evidence 
to justify recommendations for supplemental selenium intake.  
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Figure 7.1 The U-shaped dose response curve for selenium status and health outcomes 
illustrated by the risk of prostate cancer. Based on figures presented by Chiang et al.61 
and Fairweather-Tait et al.62. To convert µg/L to µmol/L multiply by 0.0127. 
 
The beauty of the yeast 
The different forms of selenium used in the NPC trial and the SELECT trial might also 
explain the conflicting findings of these studies. The NPC trial has used selenized yeast. 
Selenized yeast is produced by growing yeast in a selenium-enriched medium, which 
result in the binding of selenium compounds to yeast components, such as cell wall 
proteins71, 72. Although the exact composition might vary by batch and manufacturer, 
selenized yeast normally contains a mixture of selenium compounds, with the organic 
selenomethionine being the most abundant form (~70%)72, 73. Based on the advice of a 
panel of selenium experts, there is consciously chosen for the use of L-
selenomethionine within in the SELECT trial74. The preference of L-selenomethionine 
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over selenized yeast was based on the suggested batch-to-batch variation in selenized 
yeast, and the ability to link possible health effects to one well-defined selenium 
compound60, 74. Because we aimed to explore the mechanisms underlying the 
chemopreventive effect as observed in the NPC trial, we have chosen for the use of 
selenized yeast in our study. Our selenized yeast tablets (SelenoPrecise, Pharma Nord, 
Vejle, Denmark) were also used in other intervention trials75 and were characterized by 
their stable batch-to-batch quality profile. As long as the exact selenium compound 
which might be responsible for potential chemopreventive properties has not been 
identified, the use of selenized yeast, because of its variety in active selenium 
compounds, seems to provide best opportunities to study the chemopreventive effects 
of selenium.  
 
The design of the SELECT trial was too efficient 
As described previously, the transition to a mesenchymal phenotype is considered as a 
critical process in cancer progression, because the loss of cellular adhesion, the 
reorganization of the cytoskeleton and increased motility might result in invasion and 
metastasis. Our study suggested that selenium affects expression of genes implicated 
in the process of epithelial-to-mesenchymal transition (EMT). Although this hypothesis 
needs to be confirmed in future studies, this finding might implicate that selenium 
prevents the progression rather than the development of prostate cancer. This 
suggestion might also explain the contradicting findings of the NPC trial and the SELECT 
trial. The recruitment and the blinded intervention of the NPC trial took place between 
1983 and 199676. At that time, the use of PSA testing was just introduced. Since 
prostate cancer was a secondary endpoint in the NPC trial, there were no standardized 
prostate cancer detection methods, such as PSA tests or digital rectal examinations 
(DRE), implemented in the study protocol76, 77. Plasma PSA levels were available for 
75% of the male participants, however, these analyses were performed retrospectively 
from samples stored for research purposes. Therefore, the diagnosis of prostate 
cancer during the study was mainly based on pathology reports that were available for 
patients who visited their urologist on their own initiative77. In conclusion, men 
participating in the NPC trial were representative for a general, non-screened 
population and the detection of prostate cancer was part of normal clinical practice. In 
contrast, the SELECT trial has, in parallel with the current trends in the USA, more 
intensively screened its participants for the diagnosis of prostate cancer. Participants 
visited their study centre every 6 months and although PSA tests and DREs were not 
mandatory except for the baseline measures60, the majority of the participants 
underwent one or more PSA tests (~85%) or DREs (~72%) during the first years of the 
study60. The biopsy rates of both trials also illustrate the differences in the probability 
to detect prostate cancer (NPC trial 3-7%59 and SELECT trial 12%60). In theory, prostate 
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cancers might be diagnosed not at all or at a later stage in the NPC trial as compared to 
the SELECT trial. This hypothesis is supported by the observation that 24% of the 
prostate cancers were advanced (stage T3-T4) in the NPC trial59, whereas in the SELECT 
trial almost exclusively (99.4%) localized (stage T1-T2) tumours were found60. If 
selenium indeed influences the progression of prostate cancer, there was no 
opportunity to express its effects in the SELECT trial where all cancers were already 
detected and strictly controlled or treated in an early stage. Primary analyses within 
the NPC trial showed that the preventive effects of selenium were most pronounced 
for advanced prostate cancer (relative risk compared to placebo; RR 0.27, p=0.03) 
compared to localized cancer (relative risk compared to placebo; RR 0.42, p=0.02)77. 
This finding, however, was not described in subsequent analyses after additional 
follow-up59. Previous observational studies already suggested that a high selenium 
status was associated with a decreased risk of advanced, but not localized prostate 
cancer78, 79. After years of ambiguity, the results of our study might provide a possible 
explanation for the specific effects of selenium on prostate cancer progression rather 
than development.  
 
Taking together all the evidence described above, combined with the findings from our 
intervention study described in Chapter 6, it might be worthwhile to shift the focus 
from prostate cancer as one general disease to the recognition of more specific 
defined subclasses of clinically relevant prostate cancer. Not only selenium, but also a 
variety of other factors such as BMI80, 81, statins82, and blood lipid levels83, 84, seem to 
have an effect on advanced, high-grade or aggressive forms of prostate cancer in 
particular. Apparently, prostate cancer is a disease with two, or maybe more, faces 
with respect to aetiology, treatment, and prognosis and it should be considered as 
such in future studies.   
 
In conclusion  
In theory, adequate chemopreventive strategies might help to lower the incidence and 
mortality of prostate cancer. Extensive research on biological mechanisms and the 
long-term effects on cancer biology and other health outcomes, however, is required 
before any chemopreventive strategy can be implemented. Selenium has been 
considered a chemopreventive candidate for prostate cancer. Although the exact 
biological mechanisms remain to be elucidated, previous studies suggest that the 
effects of selenium depend on baseline selenium status, provided form of selenium and 
the stage of the disease. So far, there is insufficient evidence to justify 
recommendations for supplemental selenium intake. Future studies should specifically 
focus on the (preventive) role of selenium in prostate cancer progression in high-risk 
populations, rather than in the general population.  
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7.3  Implications for (future) patients 
 
Prostate cancer is a very common disease among elderly men. Although prostate 
cancer is relatively well-studied, various aspects of this disease remain poorly 
understood. The aim of the research described in this thesis was to obtain insight into 
factors that might be involved in the development and recurrence of prostate cancer. 
Furthermore, factors that might play a role in the prevention of prostate cancer were 
studied. Insight into these factors is important for researchers and health professionals 
in order to optimize diagnostic methods and to develop new and effective treatment 
or prevention strategies. For men, patients, their family and friends, knowledge on 
these factors also has important implications and might help to answer questions such 
as: “What can I do to lower my prostate cancer risk and how can I prevent the 
progression or recurrence of the disease?”    
 
What can I do to lower my prostate cancer risk? 
In theory, lowering prostate cancer risk can be achieved by avoidance of factors (risk 
factors) that increase the risk of getting cancer or exposure to factors (preventive 
factors) that protect against the disease. Only a few risk factors for prostate cancer 
have been clearly identified; age, a positive family history, black race and some genetic 
variants. All of these risk factors are non-modifiable, i.e. that they cannot be avoided. 
So far, there is no strong and consistent evidence that any modifiable factors, apart 
from a suggestive role for blood lipid levels, influence the risk of prostate cancer. The 
study described in Chapter 3 confirmed that high levels of cholesterol might increase 
the risk of prostate cancer. As levels of cholesterol can be altered by adapting a 
healthy lifestyle or by the use of cholesterol-lowering drugs; this factor can be 
considered as a modifiable risk factor. Although larger studies presented similar 
findings84-87, it should be realized that relatively few patients were included in our 
study. At this moment, it is not clear whether actively lowering cholesterol levels by 
adapting a healthy lifestyle will indeed result in a lower prostate cancer risk. 
Nevertheless, adapting a healthy lifestyle is recommended since a balanced diet, 
adequate levels of physical activity and maintenance of a healthy weight may not only 
lower prostate cancer risk, but also reduce the burden of many other diseases.  
 
There is no consensus about the effectiveness and safety of active prevention 
strategies for prostate cancer. Many pharmacological, dietary and lifestyle 
interventions have been investigated during the past years, however, at this moment 
there is insufficient evidence to recommend any of these strategies. More and more 
people are using dietary supplements on their own initiative. Data from a national 
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survey in the Netherlands indicated that in the period 2007-2010 up to 36% of all men 
aged 51-69 years took dietary supplements88. The widespread use of dietary 
supplements might be facilitated by the fact that they are easily available in 
supermarkets, drugstores and internet shops, and that some of them have been 
associated with beneficial health effects. There might be indeed a few promising 
candidates for prostate cancer prevention. However, although dietary supplements 
seem to be relatively innocent, recent studies suggested that a prolonged intake of 
some specific supplements might result in serious adverse effects and even an 
increased risk of getting prostate cancer89. Therefore, the use of dietary supplements is 
not recommended for the prevention of prostate cancer until the safety, long-term 
effects and biological mechanisms are carefully evaluated.   
 
Unfortunately, it seems that there is not much that can be done to lower the risk of 
getting prostate cancer at the moment. Although the beneficial effects with respect to 
prostate cancer are not proven, the general recommendations provided by the World 
Cancer Research Fund90 might be a good starting point to adapt a healthy lifestyle; 
maintain a healthy body weight and be physically active, consume mainly plant-based 
foods and limit the consumption of energy-dense foods, red meat, processed meat, 
salt and alcoholic drinks. Furthermore, it might be worthwhile to recognize possible 
symptoms related to prostatic disorders in an early stage, and to be aware of the non-
modifiable risk factors for prostate cancer such as a positive family history. It should be 
noted that active screening with PSA tests without having symptoms or medical 
indications is not indicated, because the burden of the diagnostic tests might not 
balance the benefits of finding tumours in the general population14, 15. 
 
How can I prevent the progression or recurrence of the disease?  
For patients who are already diagnosed with prostate cancer, the question how to 
lower risk of progression or recurrence might be extremely important. Compared to 
incident (newly diagnosed) prostate cancer, there are relatively few studies which 
addressed modifiable factors that might influence the course of the disease in prostate 
cancer patients. Overweight is the main modifiable risk factor studied in relation to risk 
of prostate cancer recurrence. In our studies described in Chapter 5, we did not find 
any evidence that overweight influences the course of the disease after surgery for 
prostate cancer. However, we did follow the patients only for a period of five years 
and the study population was limited to patients treated with surgery for prostate 
cancer. The findings might therefore not apply to other (overweight) patients with 
prostate cancer. Overweight is associated with complications during surgery, increased 
risk of recurrence and more aggressive prostate cancers in other studies40, 91, 92. 
Therefore, there are some indications that maintaining or adapting a healthy weight 
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after the diagnosis is beneficial and might possibly help to prevent adverse side-
effects, and improve prostate cancer outcome, in addition to other possible beneficial 
effects.  
 
A few dietary and lifestyle interventions are evaluated in patients diagnosed with 
prostate cancer. For some of these strategies, it is suggested that they have beneficial 
effects because they influence levels of PSA93, or disease progression94. However, the 
findings of these studies need to be confirmed and validated and the long-term effects 
on prostate cancer outcome, safety, quality of life and feasibility need to be examined. 
At this moment, there is insufficient evidence to recommend any of the specific dietary 
and lifestyle programs, and therefore patients mainly adhere to the advices of their 
physicians, or follow their own intuition. The World Cancer Research Fund 
recommends also patients already diagnosed with cancer to follow the general 
guidelines as described above. Of special importance are the recommendations 
regarding avoidance of self-prescribed supplement use, because of the unexplored 
effects of these supplements on cancer growth, and the possibility that specific dietary 
supplements might interfere with some cancer therapies95-97.  
 
In conclusion 
There is an unfortunate lack of information about modifiable risk factors for prostate 
cancer. This implies that there is hardly anything what patients can do to lower their 
risk of getting prostate cancer or to prevent progression or recurrence of this disease. 
In line with this, there is insufficient evidence to implement recommendations for the 
prevention of prostate cancer development, progression or recurrence. The 
recommendations for the general population as well as cancer patients refer to 
adapting a lifestyle with a balanced diet, adequate levels of physical activity and a 
healthy weight. The use of self-prescribed dietary supplements for the prevention of 
prostate cancer is explicitly discouraged.  
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7.4  Implications for the urologist 
 
Above anyone else, the urologist recognizes the increasing incidence, and thereby the 
clinical and social burden, of prostate cancer. Although a major progress has been 
made in the past decades, there is a strong need for better understanding of prostate 
cancer aetiology and for the identification of targets for effective prevention or 
treatment strategies. The aim of this thesis was to evaluate potential risk factors for 
incident and recurrent prostate cancer and to study the molecular mechanisms 
possibly involved in the aetiology of prostate cancer. From this perspective, a few 
implications, which might be of relevance in clinical practice, will be discussed below.  
 
Incident prostate cancer 
There is a growing body of evidence that high levels of serum cholesterol are 
associated with an increased risk of aggressive prostate cancer84-87, 98. In theory, the 
identification of patients with an unfavourable blood lipid profile at high-risk of 
developing aggressive prostate cancer might provide implications for early detection 
and targeted prevention or treatment strategies. One of the suggested prevention 
strategies in these high-risk patients is the use of statins83, 85, 99. However, before such 
clinical prevention strategies can be implemented, the long-term effects on cancer 
biology and other health outcomes should be carefully determined. Furthermore, 
there is not yet an indication to screen men for unfavourable blood lipid profiles, as 
the benefits of early prostate cancer detection in these men are not established.  
 
In the first year after their diagnosis, patients diagnosed with a previous cancer (and 
previous urological cancers in particular) seem to have an increased risk of prostate 
cancer. Nevertheless, this finding does not necessarily indicate that these patients are 
more likely to develop prostate cancer; it might also mean that prostate cancers are 
detected more frequently, possibly as a consequence of active screening or early 
detection. As there is no data on long-term effects and cancer-specific mortality, it is 
not possible to advice or dissuade active screening for prostate cancer in cancer 
survivors. In order to elucidate the role of screening and detection in cancer patients, 
however, it might be extremely useful to register the reasons for PSA testing (e.g. 
anxiety, complaints, regular checks), whether the diagnosis of prostate cancer was 
incidental, and the method used for the prostate cancer diagnosis (e.g. imaging 
techniques, biopsy, surgical specimens) for research purposes in the medical files.  
 
Recurrent prostate cancer 
Overweight and obesity are the main modifiable risk factors studied in relation to risk 
of prostate cancer recurrence. Contrary to most studies performed in the United 
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States, our studies did not provide evidence that overweight or obesity influence the 
risk of biochemical recurrence following radical prostatectomy. Based on our findings, 
there is no strong indication, apart from technical issues or other co-morbidities, to 
refuse overweight and obese patients for radical prostatectomy. Overweight, however, 
is associated with complications during and after surgery, increased risk of recurrence 
and more aggressive prostate cancers in other studies40, 91, 92. Therefore, patients may 
be advised to maintain or adapt a healthy weight, which might help to prevent side-
effects, and improve prostate cancer outcome, in addition to other possible beneficial 
effects. 
 
Chemoprevention 
There has been considerable interest in the role of nutrition and lifestyle factors in 
prostate cancer prevention. Men at risk for prostate cancer might find information on 
suggested candidates for prostate cancer prevention as a consequence of the easy 
access to health information on the internet100. The ‘innocent character’ of dietary 
supplements might persuade these men start taking specific dietary supplements 
focussing on prostate health. So far, there is no consensus about the effectiveness and 
safety of dietary supplements for prostate cancer prevention in the general 
population. In contrast, it is suggested that a prolonged intake of some dietary 
supplements (e.g. a high dose of vitamin E as α-tocopherol) might result in an 
increased prostate cancer risk89. The use of dietary supplements for the prevention of 
prostate cancer should be discouraged until the safety, long-term effects and biological 
mechanisms are carefully evaluated. Also patients already diagnosed with prostate 
cancer should be advised to avoid the use of self-prescribed dietary supplements. 
Although some dietary and lifestyle interventions are suggested as appropriate 
candidates for the prevention of prostate cancer progression, the unexplored effects 
on cancer biology and the possible interference with cancer therapies95-97 should be 
carefully determined.  
 
In conclusion 
Patients suspected for or diagnosed with prostate cancer may be advised to adapt a 
lifestyle with a balanced diet, adequate levels of physical activity and maintenance of a 
healthy weight. The use of self-prescribed dietary supplements is explicitly discouraged.  
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7.5  Future research agenda  
 
The results of this thesis show that specific nutritional and clinical factors might 
influence risk of prostate cancer or have an effect on gene expression in the prostate. 
A future challenge is the confirmation and ‘translation’ of these findings into the 
development and implementation of effective treatment or prevention strategies for 
prostate cancer.  
 
Suggested research agenda 
- The current knowledge and perception of risk factors among cancer patients 
and the general population should be taken into account while developing 
effective cancer education and awareness programs. 
- It should be determined whether men with unfavourable blood lipid profiles 
might benefit from screening and early detection of prostate cancer. 
- The effects of lowering (either by lifestyle or pharmaceutical interventions) 
circulating levels of cholesterol in high-risk men need to be established with 
respect to prostate cancer risk, cancer biology and other long-term health 
outcomes.  
- The mechanisms underlying the suggested effects of high levels of circulating 
cholesterol on (aggressive) prostate cancer risk warrant clarification.  
- Detailed insight into prognosis and cancer characteristics of screen-detected 
prostate cancers among cancer survivors is warranted.   
- Given the increasing number of patients with overweight and obesity, the 
effect of body mass index (BMI) on risk of biochemical recurrence needs to be 
monitored over time. Weight and BMI earlier in life should be taken into 
account whenever possible.   
- It might be interesting to explore the potential interaction between gene 
expression profiles in the prostate and the ‘metabolic signature’ of the patient 
(including body mass index, fat distribution, levels of circulating adipokines 
and characteristics of the adipose tissue surrounding the prostate).  
- The hypothesis that selenium might prevent against the development of 
advanced prostate cancer needs to be tested. 
- Potential effects of selenium on functional processes (e.g. cellular invasion 
and migration) related to the epithelial-to-mesenchymal transition need to be 
determined.  
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Prostaatkanker is de meest voorkomende kanker bij mannen in Nederland. Er is weinig 
bekend over de oorzaken van prostaatkanker. Tot op heden zijn slechts een paar 
risicofactoren voor prostaatkanker vastgesteld, namelijk hogere leeftijd, zwart ras en 
bepaalde genetische factoren. Helaas geldt voor al deze risicofactoren dat ze niet te 
beïnvloeden zijn. Hierdoor zijn er weinig tot geen opties voor preventie (ofwel het 
voorkómen) van prostaatkanker. Voor de ontwikkeling van effectieve preventie-
programma’s, maar ook voor het opsporen van mannen met een hoog risico en het 
optimaliseren van behandelmethoden, is het van groot belang dat er meer inzicht 
wordt verkregen in risicofactoren voor prostaatkanker in verschillende stadia van de 
ziekte.  
 
Het doel van dit proefschrift is het bestuderen van factoren die een rol kunnen spelen 
bij het ontstaan of de terugkeer van prostaatkanker. Dit proefschrift richt zich hiervoor 
in het bijzonder op factoren die te maken hebben met voeding, leefstijl en bepaalde 
medische condities. 
 
Allereerst is een inventarisatie gemaakt van factoren die interessant kunnen zijn om te 
bestuderen in relatie tot prostaatkanker (hoofdstuk 2). Hiervoor hebben we 956 
mannen met prostaatkanker met behulp van een vragenlijst gevraagd om mogelijke 
oorzaken voor hun ziekte te noemen. Uit dit onderzoek bleek dat de grote 
meerderheid (85%) van deze patiënten niet in staat was om een mogelijke oorzaak te 
noemen. De patiënten die wel een verklaring hadden, noemden zeer diverse oorzaken 
variërend van fietsen tot het gebruik van viltstiften en van sterilisatie tot de Tsjernobyl-
ramp. Over het algemeen wijten relatief veel patiënten hun prostaatkanker aan 
factoren gerelateerd aan erfelijkheid, specifieke omgevingsfactoren, voeding of leefstijl 
en stress. Opvallend is dat er vaak oorzaken (zoals alcohol-inname) werden genoemd 
die zeer waarschijnlijk geen rol spelen bij het ontstaan van prostaatkanker. De eerder 
genoemde ‘bewezen’ risicofactoren voor prostaatkanker werden daarentegen niet 
regelmatig genoemd, zelfs niet door patiënten die tot de risicogroepen behoren. 
Concluderend kan dus gesteld worden dat veel patiënten zich niet bewust zijn van 
mogelijke oorzaken van hun prostaatkanker. In hoeverre dit te wijten is aan een 
gebrek aan kennis, of doordat er simpelweg weinig eenduidige risicofactoren voor 
prostaatkanker zijn, is niet bekend. Wel is duidelijk dat er verkeerde opvattingen 
bestaan over risicofactoren voor prostaatkanker en dat ‘bewezen’ risicofactoren niet 
goed herkend worden.  
 
In navolging van eerdere onderzoeken zijn de volgende twee hoofdstukken gericht op 
specifieke factoren die mogelijk een rol kunnen spelen bij het ontstaan van 
prostaatkanker. In de studie beschreven in hoofdstuk 3 is bestudeerd of cholesterol-
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concentraties in het bloed verband houden met het risico om prostaatkanker te 
ontwikkelen. Voor dit onderzoek zijn de gegevens onderzocht van 2.118 mannen die 
allen afkomstig zijn uit de regio Nijmegen en deelnemen aan de Nijmegen Biomedische 
Studie. Bij aanvang van de studie is bloed afgenomen en zijn de 
cholesterolconcentraties gemeten. Vervolgens zijn deze mannen gedurende een 
langere periode (gemiddeld ruim 6,5 jaar) gevolgd. Na afloop van deze periode bleek 
dat 43 mannen prostaatkanker hadden gekregen. De resultaten van dit onderzoek 
laten zien dat mannen met een hoge cholesterolconcentratie in het bloed een hoger 
risico hebben om prostaatkanker te ontwikkelen. Dit verhoogde risico geldt 
voornamelijk voor de agressieve vormen van prostaatkanker.  
 
Door middel van een onderzoek met een vergelijkbare opzet is vervolgens het risico op 
prostaatkanker bepaald voor mannen die al eerder een andere soort kanker hebben 
gehad (hoofdstuk 4). Aanleiding voor dit onderzoek is de hypothese dat het 
vóórkomen van prostaatkanker mogelijk geassocieerd is met andere kankersoorten 
door gemeenschappelijke risicofactoren, door blootstelling aan eerdere 
kankerbehandelingen, ofwel doordat er intensiever gezocht wordt naar andere 
tumoren als iemand al kanker heeft. Voor dit onderzoek heeft de Nederlandse 
Kankerregistratie de gegevens beschikbaar gesteld van 551.553 mannen die in de 
periode 1989-2008 voor de eerste keer met kanker zijn gediagnosticeerd. Bij 9.243 van 
deze mannen is vervolgens prostaatkanker gevonden. Het bleek dat met name in het 
eerste jaar na een eerdere kankerdiagnose het risico op prostaatkanker verhoogd was. 
Waarschijnlijk is dit te wijten aan een toegenomen alertheid bij patiënt of arts en 
intensieve medische controles, waardoor veel prostaattumoren opgespoord werden. 
Op de langere termijn was er voor de meeste kankerpatiënten echter geen verhoogd 
risico op prostaatkanker. Alleen voor mannen die eerder huidkanker hadden, lijkt er na 
tien jaar nog steeds een iets verhoogd risico op prostaatkanker te zijn, terwijl mannen 
met een kanker aan hoofd of hals dan juist een verlaagd risico op prostaatkanker 
hadden. Tot slot is met dit onderzoek ook aangetoond dat prostaatkanker iets minder 
vaak voorkomt bij mannen die eerder een bestraling in het bekkengebied hebben 
ondergaan.  
 
Overgewicht wordt ook regelmatig in verband gebracht met prostaatkanker. Omdat 
overgewicht in eerdere studies voornamelijk geassocieerd is met prostaatkanker in 
een laat stadium of terugkeer van de ziekte na een behandeling, zijn de hoofdstukken 
5a en 5b specifiek gericht op de vraag of het hebben van overgewicht een risicofactor 
is voor de terugkeer van de tumor na een operatie voor prostaatkanker. Hiervoor zijn 
de gegevens bekeken van patiënten met prostaatkanker die een operatie hebben 
ondergaan waarbij de prostaat in zijn geheel is verwijderd. Na de operatie is er bij deze 
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patiënten, volgens de standaard richtlijnen in de betreffende ziekenhuizen, regelmatig 
bloed afgenomen. In het bloed is de concentratie van het prostaat-specifiek antigeen 
(PSA) bepaald; dit is een eiwit dat in hoge concentraties kán duiden op de 
aanwezigheid van prostaatkanker. In het geval van stijgende PSA concentraties na de 
prostaatoperatie wordt er gesproken van terugkeer van de ziekte, ook wel recidief 
genoemd. Wij hebben niet kunnen aantonen dat het hebben van overgewicht de kans 
op een dergelijk recidief beïnvloedt.  
 
Hoofdstuk 6 van dit proefschrift is gewijd aan de mogelijkheden voor preventie, ofwel 
het voorkómen van prostaatkanker. Selenium is een voedingsstof die in het verleden 
regelmatig in verband is gebracht met de preventie van prostaatkanker. Er is echter 
maar weinig bekend over de biologische mechanismen en de daadwerkelijke effecten 
van selenium in de prostaat. Dit onderzoek is uitgevoerd om te bestuderen welk effect 
selenium heeft op de activiteit van de genen, ofwel de genexpressie, in de prostaat. 
Wij hebben hiervoor aan 23 mannen gevraagd om gedurende een periode van vijf 
weken dagelijks een voedingssupplement met 300 µg selenium of een placebo in te 
nemen. Bij aanvang en na afloop van de studie is bij deze mannen een klein stukje 
prostaatweefsel (prostaatbiopt) afgenomen. Na controle van dit weefsel bleken de 
biopten van 15 deelnemers geschikt om te analyseren op een zogenoemde microarray. 
Met behulp van een dergelijke microarray waren we in staat om de expressie van meer 
dan 19.000 genen in de prostaat tegelijkertijd te meten. De resultaten van deze 
metingen suggereren dat genen die betrokken zijn bij ontstekingsreacties 
(inflammatie) verminderd tot expressie komen na inname van selenium. Dit zou 
kunnen duiden op een mogelijk ontstekingsremmend effect van selenium. Ook voor 
genen die betrokken kunnen zijn bij de ontwikkeling van agressieve vormen van 
prostaatkanker waren veranderingen in genexpressie waarneembaar na inname van 
selenium. In hoeverre deze bevindingen relevant zijn met betrekking tot de preventie 
van prostaatkanker, en welke biologische mechanismen er verantwoordelijk zijn voor 
deze effecten zal bestudeerd worden in vervolgonderzoeken. 
 
Tot slot zijn de belangrijkste bevindingen van dit proefschrift kort samengevat in 
hoofdstuk 7. In dit hoofdstuk zijn ook verschillende aspecten genoemd die belangrijk 
zijn voor de interpretatie van de resultaten én zijn speerpunten voor toekomstig 
onderzoek beschreven.  
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Concluderend kan gesteld worden dat zowel bij de patiënt als de onderzoekers, vrij 
weinig bekend is over factoren die betrokken zijn bij de ontwikkeling van 
prostaatkanker in verschillende stadia van de ziekte. Op basis van de resultaten van dit 
proefschrift wordt bevestigd dat een hoge cholesterolconcentratie waarschijnlijk een 
risicofactor is voor (agressieve) prostaatkanker. Op de vraag óf en waarom het hebben 
van een eerdere kanker het daaropvolgende risico op prostaatkanker beïnvloedt, is 
nog geen eenduidig antwoord te geven, al lijkt het erop dat de meeste 
kankerpatiënten zich op lange termijn geen extra zorgen hoeven te maken. Op basis 
van onze resultaten is er geen overtuigend bewijs om aan te nemen dat overgewicht 
het risico op de terugkeer van prostaatkanker na een prostaatoperatie beïnvloedt. 
Echter, gezien het sterk stijgende aantal patiënten met overgewicht is het wellicht 
interessant om deze vraagstelling ook vanuit een meer mechanistisch oogpunt te 
bestuderen. Wat betreft de preventie van prostaatkanker kunnen we concluderen dat 
selenium een aantal duidelijke effecten heeft op de genexpressie in de prostaat. In 
hoeverre deze veranderingen in genexpressie daadwerkelijk kunnen bijdragen aan de 
preventie van prostaatkanker, in het bijzonder bij mannen met een verhoogd risico op 
prostaatkanker, moet blijken uit toekomstig onderzoek.  
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toeval’ onder jouw hoede terecht kwam. Ik bewonder je manier van werken, je 
gedrevenheid en je wetenschappelijke visie. Ondanks een aantal tegenslagen in ons 
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overbrengt. Je aanstekelijke enthousiasme, tezamen met de kritische en zorgvuldige 
reacties op mijn vragen of teksten heb ik als zeer plezierig ervaren.  
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en het mogelijk maken van het onderzoek. Uiteraard wil ik ook alle deelnemers aan de 
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warme ontvangst, geduld, interesse én zorg voor de patiënten zijn absoluut goud 
waard! Voor een groot aantal projecten heb ik samen mogen werken met Joep van 
Roermund. Beste Joep, je was altijd betrokken, bereikbaar en bereid om mijn vragen te 
beantwoorden, hartelijk dank hiervoor!  
 
Regelmatig heb ik gedurende de afgelopen jaren experimenten uitgevoerd op het 
laboratorium Experimentele Urologie. Prof. Schalken, dank dat ik gebruik mocht 
maken van uw faciliteiten. In het bijzonder wil ik Gerald Verhaegh bedanken voor zijn 
onuitputtelijke kennis op het gebied van prostaatkanker en voor het uitvoeren van de 
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St Radboud was ik regelmatig te vinden om prostaatcoupes te laten beoordelen. Dr. 
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gedetailleerde opmerkingen in de manuscripten bijzonder gewaardeerd. Saskia, het 
was leuk om met je samen te werken. Bedankt dat ik met al mijn vragen steeds weer 
bij je terecht kon. 
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Binnen de NMG-groep van Wageningen Universiteit wil ik graag iedereen bedanken 
voor de nuttige inzichten en leuke gesprekken. Michael Müller, bedankt voor de 
interesse in mijn onderzoek. Het was fijn dat ik mee 'mocht' draaien binnen deze jonge 
en actieve groep. Guido, Philip en Mark, jullie hulp en praktische tips bij de microarray 
analyses heb ik bijzonder gewaardeerd. Susan, Diederik en Vera, 'partners in crime' op 
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vrolijkheid . Ik wens je veel succes met de laatste loodjes. Vera, het was leuk om jou 
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dankbaar dat je regelmatig in Nijmegen wilde bijspringen.  
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de prettige werksfeer. ‘Ervaringsdeskundigen’ Mariëlle en Ondine, het was fijn om de 
kunst van het ‘aio-zijn’ een beetje bij jullie af te kijken. Olga, ik vind het heel erg 
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dagelijkse gesprekjes. Nicolien en Gertrude, ondanks dat we elkaar op ‘werkgebied’ 
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hebben. Leuk dat je nu weer terug bent! Akke, wat was het leuk en leerzaam om 
samen met jou over van alles en nog wat te discussiëren. Je gaat ongetwijfeld een 
fantastische carrière tegemoet. Renate, Fränzel en Meeke, ik ben trots dat ik samen 
met jullie deel uit mag maken van een inspirerende onderzoeksgroep en ik kijk erg uit 
naar onze toekomstige samenwerking. Dames van het secretariaat, Karen, Jacqueline 
en Gabriëlle bedankt voor jullie praktische hulp, vrolijkheid en persoonlijke interesse 
(en voor alle dropjes!). Karen, wat was het leuk om ervaringen (als moeder van een 
peuter ) te kunnen uitwisselen. Ik hoop dat we hier ook de komende jaren nog mee 
verder zullen gaan. 
 
Anita Bruggink-Hoopman wil ik graag heel erg bedanken voor haar inzet bij de werving 
van deelnemers tijdens mijn zwangerschapsverlof. Het was fijn om het onderzoek met 
een gerust gevoel over te kunnen dragen. Linda Rieswijk, als student heb je een zeer 
waardevolle bijdrage geleverd aan de werving van de deelnemers. Dankzij jou kon het 
onderzoek ook gewoon doorgaan toen ik in Newcastle was. Dear prof. Mathers, thank 
you very much for the opportunity to work in your laboratory. I highly appreciated 
your warm welcome and the inspiring environment of your research group in 
Newcastle.  
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het allereerste begin hebben we een kamer en daarmee ook lief en leed gedeeld. 
Tijdens onze dagelijkse wandelingetje (al dan niet met dikke buiken) hadden we altijd 
zoveel te bespreken en te lachen. Het was bijzonder om jouw paranimf te mogen zijn 
en ik ben erg blij dat je ook mij bij wilt staan. Ik vind het zo leuk dat je nu een nieuwe 
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Merian, het is alweer ruim 13 jaar geleden dat we samen de biologielessen volgden. 
Ondanks dat we elkaar soms tijden niet spreken of zien, voelt elk afspraakje weer net 
zo vertrouwd en gezellig als toen. Ik hoop dat we in de toekomst nog veel mooie 
momenten, ook samen met Laurens en Emmy, zullen beleven. Ik vind het erg bijzonder 
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oprecht en geïnteresseerd. Bram, mijn ‘kleine’ broertje. Ik ben heel erg trots op jou. Ik 
vind het zo gezellig dat je soms zomaar even langskomt om te kletsen of met je 
nichtjes te spelen. Liefste pap en mam, bedankt dat jullie er altijd voor ons zijn. Het is 
altijd weer fijn om thuis te komen. Jullie onvoorwaardelijke vertrouwen, steun en 
liefde hebben ervoor gezorgd dat ik zonder zorgen mijn dromen kon waarmaken en ik 
nu zoveel plezier beleef aan mijn werk. 
 
Maarten, mijn lieve Maart, je bent een kanjer! Wat ben ik trots dat we ouders zijn van 
twee prachtige dames. Sophie en Madelief, mijn twee mooie, lieve meiden, jullie 
maken ons geluk compleet!    
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